

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2012269907 B2**

(54) Title  
**Vaccine composition comprising an inactivated chikungunya virus strain**

(51) International Patent Classification(s)  
**C07K 14/18** (2006.01) **A61K 39/12** (2006.01)

(21) Application No: **2012269907** (22) Date of Filing: **2012.06.18**

(87) WIPO No: **WO12/172574**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>2067/CHE/2011</b>	<b>2011.06.17</b>	<b>IN</b>

(43) Publication Date: **2012.12.20**

(44) Accepted Journal Date: **2017.05.18**

(71) Applicant(s)  
**Bharat Biotech International Limited**

(72) Inventor(s)  
**Ella, Krishna Murthy;Kandaswamy, Sumathy**

(74) Agent / Attorney  
**FB Rice, Level 23 44 Market Street, Sydney, NSW, 2000, AU**

(56) Related Art  
**WO 2008/026225 A2**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2012/172574 A1**

(43) International Publication Date  
20 December 2012 (20.12.2012)

(51) International Patent Classification:

A61K 39/12 (2006.01) C07K 14/18 (2006.01)

(21) International Application Number:

PCT/IN2012/000432

(22) International Filing Date:

18 June 2012 (18.06.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2067/CHE/2011 17 June 2011 (17.06.2011) IN

(71) Applicant (for all designated States except US): **BHARAT BIOTECH INTERNATIONAL LIMITED** [IN/IN]; Genome Valley, Turkapally, Shameerpet, Hyderabad 500078 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ELLA, Krishna Murthy** [IN/IN]; Bharat Biotech International Limited, Genome Valley, Turkapally, Shameerpet, Hyderabad 500078 (IN). **KANDASWAMY, Sumathy** [IN/IN]; Bharat Biotech International Limited, Genome Valley, Turkapally, Shameerpet, Hyderabad 500078 (IN).

(74) Agent: **HASAN, Afzal**; Hasan And Singh, Flat No. 1-A, C. O. D. Apartment, Hitech City Main Road (Near ING Vysya Bank), Cyberabad Post, Madhapur, Hyderabad 500081 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: VACCINE COMPOSITION COMPRISING AN INACTIVATED CHIKUNGUNYA VIRUS STRAIN

(57) Abstract: A vaccine composition for prophylaxis and treatment of Chikungunya virus infections is disclosed which is capable of conferring immunity against any genotypic variants of the Chikungunya virus. More particularly the invention discloses particular nucleotide sequences and their translated proteins thereof, which may be expressed as Virus Like Particles which for use as a vaccine antigens against Chikungunya virus infections. The compositions disclosed in this invention are also protective against any genotypic variants of the Chikungunya virus which may be propagated by any suitable vector of the disease including Aedis albopictus and Aedis aegypti



WO 2012/172574 A1

**VACCINE COMPOSITION COMPRISING AN INACTIVATED  
CHIKUNGUNYA VIRUS STRAIN**

**FIELD OF THE INVENTION**

The invention relates to stable immunogenic compositions for prophylaxis and treatment  
5 against any infections caused by Chikungunya Virus. The present invention particularly  
relates to compositions of Chikungunya virus (henceforth termed as CHIKV) strains and  
use of the subunit antigens of the virus thereof, for prophylaxis, therapeutic treatment and  
diagnosis of Chikungunya infections in humans. More particularly, the invention relates to  
10 stable immunogenic vaccine compositions for prophylaxis and treatment against any  
genotypes or antigenic variants or mutants of Chikungunya virus conferring an antibody  
titer sufficient for the seroprotection for any genotypic variant or mutant for the  
Chikungunya virus. The invention also relates to vaccine compositions for immunization  
against Chikungunya virus in combination with other bacterial and viral infections selected  
15 from the following list that include but is not limited to vaccines for Japanese encephalitis  
virus, dengue vaccines, West Nile virus vaccine and Chandipura virus vaccine and rabies  
vaccines. Combinations with other viral vaccines are also within the scope of the  
invention.

**BACKGROUND OF THE INVENTION**

20 Chikungunya virus (CHIKV) is an alphavirus of the family *Togaviridae*. It is a positive  
strand RNA virus that causes a generally non-fatal infection characterized by high fever and  
sudden onset of polyarthralgia. Hemorrhagic and neurological manifestations including  
seizures, lymphadenopathy, fulminant hepatitis and conjunctivitis not hitherto associated  
25 with CHIKV infections were reported since the re-surgent infection in 2005 (Sourisseau et  
al., 2007; Kannan et al., 2007). Phylogenetic analyses based on the partial E1 structural  
glycoprotein sequences have identified three CHIKV lineages, the West African, Asian and  
the East, Central and South African (ECSA) (Powers et al., 2000). Asian lineage circulated  
in India and Southeast Asia until it was replaced by the ECSA genotype, which emerged  
30 during the 2005–2006 outbreak in the Indian Ocean islands (Yergolkar et al., 2006). Sub-  
lineages of ECSA strains that had established locally were spread by travellers from endemic  
areas to Africa, Asia and Europe and caused local outbreaks (Powers and Logue, 2007).

Nearly 1.39 million suspected cases of Chikungunya virus infection occurred in India in 2006. (National Vector Borne Disease Control Programme (NVBDCP), 2007) which was caused by the ECSA strain carrying the E1-226A (Arankalle et al., 2007). The E1-A226V adaptive mutation that increases transmissibility by *Aedes albopictus* is responsible for the wide geographical spread of the virus since then (de Lamballerie et al., 2008). Host immune pressure and resultant site specific mutations in the human leukocyte antigen (HLA) class-I restricting elements of CHIKV genome are implicated in the explosive Chikungunya virus outbreaks since 2005 (Tong et al., 2010). Prior art known in the field do not include any vaccine candidate derived from the ECSA strain. Bharat Biotech International Limited has earlier developed (disclosed in WO 2008/026225) the 2006 ECSA strain with E1-226A and its use in the development of potential vaccines against Chikungunya virus infections.

Chikungunya virus strains of the urban (epidemic) transmission cycles show a higher evolutionary rate than that of the enzootic (sylvatic) cycle, and the difference in the evolutionary dynamics between the two transmission cycles are influenced by several factors that determine virus-host interactions such as vector diversity and abundance, vector larval habitats and herd immunity in the population (Volk et al., 2010). Arboviruses like Chikungunya interacts with both the arthropod and the vertebrate hosts, and the selection pressure on the envelope glycoproteins are driven by preferences for vector adaptation and by vertebrate host immune defense mechanisms. Viral evolution tends to select for mutations in the antigenic determinants involved in neutralization as well as those residues involved in vector/host adaptation.

The vaccines under development such as that disclosed in WO 2008030220 and in Akahata et al. 2010 make use of the West African genotype and the E1-A226V isolates. Another CHIKV vaccine development is a DNA vaccine (Mallilankaraman et al., 2011) which is different in scope from that disclosed in this invention. An earlier prototype vaccine which is a live attenuated vaccine used the Asian genotype of the virus (Edelman et al., 2001). DNA vaccines have not been successful in human prophylactic vaccination so far, and live attenuated CHIKV vaccine caused side effects in human subjects (Edelman et al., 2001) who received the vaccine. The CHIKV strain used in the earlier vaccine development (WO 2008/026225) was the 2006 ECSA strain with E1-226A. The strains isolated in 2009-2010



from India as disclosed in this invention belong to a distinct sub-lineage within the ECSA lineage and carry novel mutations in the E2 and E1 envelope glycoproteins. One of the mutations in the E1 glycoprotein in all the isolates reported in the study maps to a region that determines host vector specificity and is under significant positive selection for enhanced adaptation to *Adis. aegypti*, which is the most abundant mosquito vector in the region and indeed in the tropical countries where prevalence of Chikungunya virus infection is now endemic. Other novel mutations hitherto unreported are also disclosed. Thus it is desirable to make a vaccine composition which would confer immunity to the newly developed and distinct sublineages of the ECSA strain of the Chikungunya virus which would also confer immune protection to the other mutated strains of the ECSA strain propagated by the vector *Aedis aegypti*. Inventors in this application after prolonged research disclose such an effective vaccine in this application including other additional advantages over the earlier vaccine (WO 2008/026225) such as new methods of inactivation of the virus and improved formulations with novel adjuvants that enhance the immunogenicity of the inactivated viral vaccine and the recombinant subunit vaccines and virosomes which are also included herein this invention.

#### **DISCLOSURE OF THE INVENTION**

- 20 The present invention provides a stable vaccine composition that is capable to prevent as well as provide treatment from infections caused by Chikungunya virus. The said vaccine composition is applicable to any genotypic variants of the Chikungunya virus for prophylaxis and treatment thereof.
- 25 The invention provides for a stable vaccine composition that is capable to prevent as well as provide treatment from infections caused by Chikungunya virus propagated by any suitable vector which includes prevention and treatment of Chikungunya infections propagated by the vectors *Aedis albopictus* and *Aedis aegypti* which happens to be the most commonly adaptable vectors of the Chikungunya virus.

The invention provides for a stable vaccine composition which is effective against any genotypic variants of the Chikungunya virus particularly of the ECSA strain and its particular distinct and unique sublineages as applicable thereof.

5

The invention provides for a stable vaccine composition wherein the antigenic component of the vaccine includes the whole inactivated virion or the subunit antigens of the recombinant CHIKV viral strains that can be expressed as Virus Like particles (henceforth termed as VLPs) in combination of suitable pharmaceutically acceptable carriers, stabilizers, and adjuvants.

10

The invention provides a method for preparation of a stable vaccine composition that is capable to elicit an immune response sufficient to prevent as well as provide treatment from infections caused by any genotypic mutants or variants of Chikungunya virus including inactivation of the CHIKV virus and mixing with adjuvants in appropriate amounts.

15

The invention provides antibodies so generated against the Chikungunya virus strains or its subunit antigens useful for diagnosis of Chikungunya virus infections in humans.

20

The invention relates to provide major antigenic determinants of the Chikungunya virus which are suitable as effective vaccine candidates and nucleotide and protein sequences disclosed thereof.

The invention includes combined vaccine compositions which are effective for prophylaxis and treatment of infections caused by Chikungunya virus and other other bacterial and viral infections selected from the following list that includes but is not limited to vaccines for Japanese encephalitis virus vaccines, dengue vaccines, West Nile virus vaccine and Chandipura virus vaccine and rabies vaccines.

30

**SUMMARY OF THE INVENTION**

According to one aspect of the invention, the invention includes vaccine compositions which specifically contain the whole inactivated virion or the subunit antigens of the CHIKV virus strains. The compositions of the present invention more particularly relate to vaccine capable of eliciting protective antibody and strong T cell responses against Chikungunya virus infection.

Another aspect of the invention is to provide a vaccine composition, comprising one or more Chikungunya virus antigens, wherein the Chikungunya virus antigens are derived from one or more Chikungunya virus isolates selected from TN01610, TN015110, TN06210, TN06310, TN06410, and AP109 comprising a nucleotide sequence as provided in any one of SEQ ID NO. 1 to SEQ ID NO. 6 and SEQ ID NO. 15 to SEQ ID NO. 20.

Another aspect of the invention is to provide inactivated recombinant CHIKV vaccines along with appropriate adjuvants that offer high protective efficacy.

Yet another aspect of the invention of the present invention more particularly relate to vaccine capable of eliciting protective antibody and strong T cell responses against Chikungunya virus infections.

One another aspect of the invention relate to methods of preparing and using Chikungunya virus (CHIKV) antigens of defined sequences expressed as recombinant proteins, virus like particles and as virosomes which are used to elicit protective immune response. The potency of such subunit vaccines are comparable to that elicited by the vaccine consisting of whole inactivated virion of CHIKV that are inactivated with reagents under conditions that confer high immunogenicity to the vaccine.

Another aspect of the invention relates to methods of inactivation of the virus which comprises heat, gamma irradiation, ultraviolet light or chemically inactivated whole virion of Chikungunya virus isolates in a stable formulation. A combination of two or more inactivating agents has also been used with similar effect. The virus isolates disclosed in the invention are used in vaccine development, and all the methods are applicable to any genotypes or genotypic variants/serotypes/strains/mutants of Chikungunya virus.

One another aspect of the invention is to provide vaccine compositions against Chikungunya virus that elicit strong immunological response when administered parenterally, preferably intradermally, intramuscularly or sub-cutaneously in mammals preferably in humans, and are effective when administered mucosally and by other routes such as oral routes.

Yet another aspect of the invention is to provide antibodies against Chikungunya virus or the subunit antigens thereof to be used for treatment and diagnosis of Chikungunya virus infections in mammals, preferably humans.

Another aspect of the invention is to provide a method of eliciting a protective immune response in a human individual against Chikungunya virus infection comprising administering the vaccine composition as described herein to a human.

Another aspect of the invention is to provide use of the vaccine composition as described herein in the preparation of a vaccine formulation for eliciting a protective immune response in a human individual against Chikungunya virus infection.

Another aspect of the invention is to provide use of one or more Chikungunya virus isolates comprising a structural polyprotein gene sequence as provided in any one of SEQ ID NO. 1 to SEQ ID NO. 6 in the preparation of an immunodiagnostic agent for detection of Chikungunya virus infection in a human.

One another aspect of the invention is to provide a composition for eliciting protective antibody and strong T cell responses either singly or in combination with other vaccines included within the scope of the invention. The other vaccines in combination are but not  
5 limited to vaccines for Japanese encephalitis virus vaccines, dengue vaccines, West Nile virus vaccine and Chandipura virus vaccine and rabies vaccines.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of  
10 these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application.

Throughout this specification the word "comprise", or variations such as "comprises" or  
15 "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

20

### **Figure 1:**

Immunogenicity of CHIKV whole virion antigen inactivated by several inactivation methods were tested for potency. The details of inactivation procedures are provided in Example 2. Potency of the 15 µg of the inactivated viral vaccine was tested in three  
25 intramuscular injections in 4-6 week old Balb/c mice (8 nos per group) at intervals of 0, 7 and 21 days and bled 7 days after the last dose administration. Only a single dose of the live virus was administered for comparison. The potency of the vaccine preparations were tested by estimating the titer of neutralizing antibodies by PRNT<sub>50</sub>.

**Figure 2:**

Immunogenicity of the CHIKV vaccine preparation with and without adjuvants was tested in three intramuscular injections in 4-6 week old Balb/c mice (8 nos per group) at intervals of 0, 7 and 21 days and bled 7 days after the last dose administration. The composition of the adjuvanted vaccine formulations are provided in Example 5. The potency of the vaccine preparations were tested by estimating the titer of neutralizing antibodies by PRNT<sub>50</sub>.

10 **DETAILED DESCRIPTION OF THE INVENTION**

No detailed study on evolution of CHIKV serotypes due to sequence diversity has been reported. We report for the first time the adaptive evolution of ECSA strains of CHIKV to *Ae. aegypti* as found in the 2009-2010 virus isolates from India. Incidentally, *Ae. aegypti* is the most prevalent vector in India and indeed in several tropical countries. Despite unique mutations in isolates reported in the current invention, the virus strains cross neutralize the Asian genotypes and various ECSA sub-lineages of CHIKV indicating that they are good candidates for vaccine development. Using virus strains or antigens derived from such strains thereof, that are better adapted to the most prevalent vector in the region is important for vaccine development rather than using strains of West African or Asian genotype which are not so widely prevalent now than the ECSA genotype. Even among the ECSA genotype, using candidates such as LR2006 isolates from Reunion Island that carry E1-A226V mutation which is an adaptive mutation to increase transmissibility in *Ae. albopictus* is less advantageous as *Ae. albopictus* vector in India is prevalent widely only along the West coast of India such as in the states of Kerala and South coastal Karnataka, whereas the mosquito vector that is most abundant in the rest of the country is *Ae. aegypti*. The virus strains isolated and reported in this invention are unique in that they show adaptive evolution to *Ae. aegypti* and at the same time also infect *Ae. albopictus*. Apart from the unique mutations that increase adaptation to *Aedes aegypti*, the advantage of the invention is that the virus isolates cross neutralize the Asian genotypes and various ECSA variant strains and hence are good candidate vaccines. Hence, a subunit vaccine derived from the virus antigens or recombinant antigens of these isolates are good vaccine candidates as well, as the recombinant vaccine antisera also cross neutralizes the different genotypes and genotypic variants.

Hence, using the Indian virus strains that show unique adaptation to *Ae. aegypti* and also infects *Ae. albopictus* is advantageous than using the West African, Asian or ECSA E1-226A and other variant strains as *Ae. aegypti* is the most widely prevalent vector in the India which has the highest incidence of CHIKV infection in the world.

The Chikungunya virus isolates within the scope of the invention are those that belong to the ECSA (East, Central and South African) genotype whose structural polypeptide sequence comprises of the capsid, E3, E2, 6K and E1 (C-E3-E2-6K-E1) proteins. The

isolates obtained from the Indian epidemic of 2009-2010 are unique in the sequence reported so far. The structural polyprotein sequence comprising the C-E3-E2-6K-E1 proteins have been deposited in the public sequence repository (GenBank) on 27th April 2010 and have been assigned the accession numbers HM159385 to HM159390. The sequences were published in March 2012 after the date of filing the provisional patent. The unique nucleotide sequences reported in this invention are SEQ ID NO.1 (isolate TN01610), SEQ ID NO.2 (isolate TN15110) SEQ ID NO.3 (isolate TN06210), SEQ ID NO. 4 (TN06310), SEQ ID NO. 5 (TN06410) and SEQ ID NO.6 (AP0109), whose corresponding protein sequences when translated are SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11, SEQ ID NO.12 and SEQ ID NO.13 respectively. The CHIKV strain CHIKV/03/06 has structural polyprotein of SEQ ID NO.7 and was isolated during the 2006 Indian epidemic, the corresponding protein sequence is SEQ ID NO.14. The names of the virus isolates are provided in the brackets. The full length genomic RNA sequences of the above mentioned virus isolates of the current invention are provided in SEQ ID NO.15 to SEQ ID NO.20.

The sequence of the isolates disclosed in the invention have unique genetic signatures such as the combination of T1766C (E2-V264A) + A3058G (E1-K211E) + 3104C (E1-226A) in the structural polyprotein sequence in addition to other amino acid changes when compared to the S27 African prototype (Gen Bank Acc No. AF369024). The position of nucleotide substitution in the structural polyprotein and the corresponding amino acid change in the individual proteins within the polyprotein is indicated in brackets. Other unique mutations that are being reported are Capsid-A232V in TN06310, E3-D40N in TN15110, E2-K47N in TN06210, E2-G55R in TN01610 and AP0109, E2-K66E in TN064110, E1-P58L in AP0109, and E1-G195R in TN15110 and TN06310. Codon by codon analyses by maximum likelihood estimates of 'ω' (the ratio of non-synonymous to synonymous substitutions) of the ECSA strains show that the amino acid mutation E1-K211E in the isolates reported in the invention (of SEQ ID NO. 8 to SEQ ID NO.13) is under significant positive selection (posterior probability of  $\geq 0.97$ ;  $p < 0.05$ ) and is suggestive of adaptive mutation to increase infectivity in the *Aedes* mosquito vectors, particularly in *Aedes aegypti*. The amino acid residue E1-211E is conserved in the Asian genotypes of CHIKV which are circulated by *Ae.aegypti*. Additional mutations disclosed in this invention such as the three



novel mutations E2-K47N, E2-G55R and E2-K66E also cluster in the same region of the E2 protein that are reported to increase the infectivity of the Sindbis virus in *Aedes aegypti*. The E2 aa 52 – 82 region is exposed at the top of the spike, which is the point of contact with cellular receptors. Codon by codon maximum likelihood estimates of 'ω' by SLAC  
5 (Single Likelihood Ancestor Counting), eFEL (Fixed Effects Likelihood), iFEL (internal Fixed Effects Likelihood) and REL (Random Effects Likelihood) identified amino acid sites across the capsid and the structural glycoproteins under significant purifying selection. Among the amino acid sites that were negatively selected, the E2-199Y residue was selected as the genetic loci under most significant purifying selection by all the four  
10 likelihood estimates (posterior probability >0.99 by REL,  $p < 0.01$  by iFEL,  $p = 0.001$  by SLAC and  $p = 0.00$  by eFEL). E2-199Y is an important residue in Chikungunya virus determining virus fitness in mosquitoes.

Viral evolution tends to select for mutations in the antigenic determinants involved in  
15 neutralization as well as those residues involved in vector/host adaptation. Because of its high immunological specificity, the serum neutralization test is often the gold standard against which the specificity of the other serological techniques is evaluated. The antisera raised against the virus isolates reported in the invention neutralized the virus isolates of Asian and ECSA lineages and several variant strains of ECSA genotype including the E1-  
20 A226V ECSA variant strain, indicating that they are good vaccine candidates as they have broad neutralizing activity.

The properties of Chikungunya virus particles as an immunogen, adaptation and propagation of the virus in host cell lines to a high titer, determination of the identity of the virus by RT-  
25 PCR, methods of purification and inactivation of the virus, preparation of stable vaccine formulation in a pharmaceutically acceptable carrier suitable for administration in humans, the viral assays and tests for vaccine potency in animal models are also within the scope of the invention. The virus particles obtained from infected patients or isolated from the vectors of the virus where the virus resides, are adapted in cell lines and propagated *in vitro*  
30 in cell culture in several passages.

The use of the CHIKV strains in the development of an inactivated whole virion vaccine is one aspect of the invention. The Chikungunya virus strains were infected in mammalian cell lines for production of the virions. The mammalian cells include but are not limited to Vero cells (ATCC CCL-81), MRC-5 or any other cell line suitable for vaccine production for

5 human use.

The whole virions obtained from cell culture were inactivated with different inactivating agents. The optimum time, temperature and use of stabilizers such as sugars like sucrose, lactose, trehalose and other sugars and sugar combinations, and the addition of sugar alcohols such as mannitol or sorbitol either alone or in combination with different sugars, addition of human serum albumin either alone or in combination with sugars, amino acids and sugar alcohols during the inactivation process are within the scope of the invention. The virus was rendered non-infectious by inactivating either by heat, gamma irradiation or ultra violet light or by chemical means with formalin and beta-propiolactone (BPL) among others under conditions that retained high immunogenicity of the vaccine preparation. The conditions of virus inactivation were optimized and are presented in Example 2. Chemical inactivating agents are selected from the following list which includes but is not limited to: formalin, beta-propiolactone, glutaraldehyde, N-acetyleneimine, binary ethyleneimine, tertiary ethyleneimine, ascorbic acid, caprylic acid, psolarens, detergents including non-ionic detergents etc. is added to a virus suspension to inactivate the virus. The concentration of the sugars, sugar alcohols, human serum albumin and amino acids either when used alone or in various combinations were in the concentration range of 0.01% to 20%, preferably 0.1% to 10% and most preferably 0.1% to 5%. Time and temperature of inactivation in the presence of the stabilizers were optimized from 2-8°C to 37°C for varying period of time such as 30 min to 20 days. Such vaccine formulations were highly immunogenic and elicited protective neutralizing antibodies.

The structural glycoproteins C-E3-E2-6K-E1 of the Chikungunya virus are the major antigenic determinants. Hence, the structural glycoproteins are excellent vaccine candidates for subunit vaccine for prophylaxis of CHIKV infections. The sequence of the structural proteins as defined in SEQ ID NO.8 to SEQ ID NO. 14. The recombinant non-structural proteins are also immunogenic and are good candidate vaccines. The eukaryotic expression system of choice includes mammalian cells, baculovirus in insect cells, and yeast cells of

any species, most preferably *Pichia pastoris* or *Saccharomyces cerevisiae*. Genes encoding the subunit antigens were also expressed in prokaryotic cells such as *E.coli* using any of the suitable prokaryotic expression vectors. *Pichia pastoris* as recombinant expression host is advantageous at industrial scale as it is cost effective for large scale manufacture compared to other eukaryotic expression systems. Recombinant proteins derived from *Pichia pastoris* have been successfully commercialized and have been found safe for human use. The structural proteins such as C-E3-E2-6K-E1 of the sequences disclosed in this application are capable of assembling into 'virus like particles' (VLPs). Alternatively, the VLPs contain only the E3-E2-6K-E1 or E2-6K-E1 or only E2-E1 proteins and are immunogenic and elicited protective immune response when administered in animals. The subunit antigens comprising E3-E2-6K-E1 or E2-6K-E1 are also capable of assembling into virosomes as CHIKV is an enveloped virus. Virosomes comprising E3-E2-6K-E1 or E2-6K-E1 or only E2-E1 are also immunogenic. The liposomes and virosomes can contain different combination of lipid soluble substances which include but are not limited to cholecalciferol, cholesterol, phospholipids etc. and the viral envelope proteins. The methods for virosomes preparation such as solubilization of the virus particles with detergents or with short chain phospholipids and reconstitution of the envelope proteins after removal of the chaotropic agents and the non-envelope proteins and RNA that are applicable to any enveloped virus are also applicable to CHIKV.

20

Purification of the virus was achieved by physical or chemical means and preferably by a combination of both. Physical methods utilize the physical properties of the virus such as density, size, mass, sedimentation coefficient etc. and include any of the following techniques but are not limited to: ultracentrifugation, density gradient centrifugation, ultrafiltration etc. Purification through chemical means employs methods such as adsorption/desorption through chemical or physiochemical reactions such as ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, gel filtration chromatography, hydroxyapatite matrix, salting with inorganic salts one such example being ammonium sulphate, and by the use of proprietary Himax<sup>TM</sup> technology, organic salts and organic compounds such as polyethylene glycol. Purification of the virus or the recombinant virus antigens was achieved by either one or a combination of two or more of the above mentioned methods.

30

The antigenic compositions of the above mentioned CHIKV candidate vaccines, such as the inactivated whole virion vaccines or the recombinant vaccines were formulated in pharmaceutically acceptable carrier for immunization in mammals, preferably humans. The Chikungunya virus vaccine formulation was adjuvanted and adjuvants were selected from the following list, which includes but is not limited to: alum; calcium phosphate; inulin of any polymorphic form, preferably gamma inulin; adjuvants containing inulin in combination with other organic and inorganic compounds such as aluminum hydroxide, aluminum phosphate, aluminum sulphate phosphate and calcium phosphate; liposomes, chitosan and complex carbobhydrates such as dextran, dextrans, starch, inulin, mannans and glucomannans, galactomannans, beta-glucans, heparin, cellulose, pectins and pectinates, lectins and any other carbohydrates either synthetic or derived from any source, any biodegradable and biocompatible polymers, such as poly lactide and poly(lactide co-glycolides; PLG) or PLGA; any emulsions including but not limited to oil in water emulsions one such example being ASO3, other squalene based adjuvants such as MF59 etc., any water in oil emulsion; liposomes prepared with cholecalciferol as one of the ingredients along with other lipid soluble compounds; liposomes of other compositions; RIBI adjuvant systems, saponins including but not limited to QS-21, QuilA, tomatine, ISCOMs, ISCOMATRIX etc, lipopeptides, glycopeptides, lipopolysaccharides, muramyl dipeptides and any peptide based adjuvants, oligonucleotides, any TLR ligands as adjuvants, any cytokine, vitamins and non-toxic bacterial toxins etc. The most compatible and cost effective adjuvant was selected in the final vaccine formulation after testing for immunogenicity which was enhanced by the addition of adjuvants. In addition to the above, any other organic and inorganic substances that have good immunopotentiating activity can also be used as adjuvants either singly or in combinations to enhance the immunogenicity of Chikungunya virus vaccines. In addition to the inactivated whole virion vaccine, the aforementioned adjuvants or adjuvant combinations are also effective with recombinant Chikungunya virus vaccine using recombinant subunit antigens either when presented as virosome, virus like particles (VLPs) or when expressed, purified and formulated as individual recombinant proteins. The use of suitable adjuvants in the vaccine formulations reduces the amount of antigen required and helps in the manufacture of low-cost vaccines thus conferring economic advantage.

The buffer used in the formulations is phosphate or phosphate-citrate buffer or any other pharmaceutically acceptable buffer. The vaccines optionally contain preservative(s), stabilizer(s) etc. The excipients were selected from a list that includes but is not limited to reducing and non-reducing sugars, sugar alcohols such sorbitol and mannitol, glycerol, amino acids, human serum albumin, inulin, thiomerosol and a choice of adjuvant from the  
5      aforementioned list of adjuvants. The excipients are added in the range of 0.01% to 20% for the liquid formulation and upto 60% of the total solids for a lyophilized formulation. The vaccine formulations were also presented as emulsions, either as water in oil emulsion or as oil in water emulsion. Such emulsions of vaccine antigens contain preservatives and  
10     stabilizers and other adjuvants. Such a stable formulation of the immunogen either in a liquid or in a lyophilized form and after reconstitution in a pharmaceutically acceptable buffer or water is suitable for administration parenterally in human host and is also formulated for mucosal administration. The vaccine formulations were highly immunogenic and neutralized homologous and heterologous CHIKV strains.

15

For potency testing of the vaccine, the vaccine formulations were tested in Balb/c mice and rabbits. The resultant serum is assayed by *in vitro* neutralization tests and the antibody titer is determined by ELISA. Seroconversion was observed in the animals immunized with the vaccine formulations described in the present invention. Efficacy of the recombinant  
20     vaccine in offering a protective immune response was comparable with the whole virion vaccine and the titers of the neutralizing antibody responses were determined by either serum neutralization test (SNT), plaque reduction neutralization test (PRNT<sub>50</sub>) and ELISA among other methods. Passive immunization of the vaccine antibody offered good protection against virus infection indicating therapeutic use of CHIKV antibodies. The  
25     presence of virus in infected patients samples were accurately determined using CHIKV antibodies. Chikungunya virus vaccine obtained by the methods included in the scope of the current invention elicits strong neutralizing antibodies in combination with other vaccines. The vaccines that can be included in the combination are selected from the following list that includes but is not limited to vaccines for Japanese encephalitis virus, Dengue vaccines,  
30     West Nile virus vaccine and Chandipura virus vaccine and rabies vaccines. Combinations with other viral vaccines are also within the scope of the invention. As known to those skilled in the art, a bivalent or polyvalent vaccine can be prepared by mixing vaccines

produced from two or more CHIKV strains, and is mixed in a suitable ratio based on the antigen content. Such mixing provides a vaccine preparation having a broad antigenic spectrum for protection against the infection.

5 According to the present invention, the methods and compositions of CHIKV strains of the current invention is applicable to any CHIKV strain. The vaccines of this invention offered good immune protection against plural strains of CHIKV in addition to the virus strains used in production of the vaccine. The CHIKV isolates reported in the study have broad neutralizing activity as they cross neutralize different genotypes /genotypic variants / strains  
10 of CHIKV and are ideal vaccine candidates for development of whole inactivated virion vaccine or recombinant vaccines comprising the antigens derived from these virus isolates. The methods disclosed in the invention are applicable to any genotype/genotypic variants/serotype/strain of Chikungunya virus and as demonstrated offer good cross protection against multiple genotypes/genotypic variants of the virus.

15

The invention is further described in the following examples. It should be noted that features, integers, characteristics, ranges, compounds, and/or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless  
20 incompatible therewith and should be considered within the scope of the invention.

#### **Example 1: Isolation of virus strains**

The virus strains were isolated from blood samples collected from febrile patients with their  
25 informed consent during an epidemic outbreak in India in 2009-2010. The blood samples were collected during the acute phase of Chikungunya virus infection when patients reported high fever, acute polyarthralgia and painful swelling in joints and rashes. The patients' sera samples were transported on dry ice to the laboratory. About 0.05 ml of the serum was used for infection of Vero cells (ATCC No. CCL-81) in 25<sup>2</sup>cm flask in medium  
30 containing DMEM (Dulbecco's Modified Eagle Medium; Sigma- Aldrich Catalog # D5523) containing 1% fetal bovine serum (FBS). The flasks were incubated at 34<sup>0</sup>C to 37<sup>0</sup>C. The virus was harvested 48 hours after infection. Scaled up cultures of the virus were

made in cell stacks or in cell factories or in bioreactors in liquid culture All the blood samples were negative for Dengue infection by specific IgM ELISA (National Institute of Virology, Pune). The infectious titer of the virus increased more than 10 fold after the virus particles were passaged once in suckling mice brain or after passage in mosquito cell lines  
5 such as C6/36 cells, and also after repeated passage of the virus in cell culture *in vitro*.

### Example 2: Purification and inactivation of CHIKV virus

The two virus isolates TN01610 and TN15110 were purified from the infected Vero cell  
10 monolayers from scaled up cultures by initial ultrafiltration to remove cellular debris, and by filtration and concentration through a 300 kD membrane followed by purification by ion exchange and gel filtration column chromatography. Heat inactivation of the virus was carried out at different temperatures ranging from 45°C to 60°C for 30 min to 4 hrs and optimally at 56°C for 30 min. Inactivation by ultraviolet (UV) light was done at 254 nm for  
15 varying period of time from 30 – 120 min on ice, and optimally for 40 min. Chikungunya virus was inactivated effectively by formalin at ratios upto 1:3000 for formalin:virus at 2°C -8°C upto 7 days, and with beta propiolactone at 1:1000 to 1:2500 (beta propiolactone:virus) for upto 7 days at 2°C -8°C. In both the cases, the time of inactivation was reduced to 24-48 hrs when carried out at ambient temperatures of +20 - 25°C. Formalin  
20 and beta propiolactone were removed by dialysis. During inactivation, use of additives such as glycine, mannitol, sorbitol and sugars and sugar combinations increased the stability of the vaccine preparation. The sugars used may be selected from sucrose, lactose, trehalose, maltose at varying concentrations from 0.5% to 5%. Inactivation of the virus by gamma irradiation was carried out by exposure of the virus samples to a dose of 10 kGy (Kilo Gray)  
25 to 25 kGy from a <sup>60</sup>Co source (Ms.Gamma Agro-Medical Processings Pvt.Ltd. Hyderabad) and optimally to 20 kGy. Complete inactivation of the virus samples by all of the above methods were confirmed by three serial passages in Vero cells for absence of virus cytopathic effect, and additionally by the absence of growth abnormalities and death when inoculated by intracerebral route in the brain of 2-day old mice. The inactivated virus  
30 antigens were tested for potency as candidate vaccines..

**Example 3: Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) and Sequencing:**

Viral RNA was isolated using Absolutely RNA Miniprep kit (Stratagene, La Jolla, CA) from infected Vero cells (ATCC CCL-81), after a single passage. RT-PCR was carried out using the AccuScript High Fidelity 1<sup>st</sup> Strand cDNA Synthesis Kit (Stratagene) as per the kit protocols, and the 3,747 bp structural polyprotein gene was amplified with the PfuUltra High-Fidelity DNA polymerase (Stratagene). PCR primers were designed based on the consensus sequence of the S27-African prototype (AF369024) and the Indian 2006 isolate (HM159384), and used to amplify overlapping sequences of the structural polyprotein gene. PCR reaction consisted of initial denaturation at 95°C for 1 min, followed by 32 thermal cycling steps at 94°C for 40 sec, annealing at 52–65°C (depending on the primer sets) for 30 sec and extension at 70°C for 3 min, followed by final extension at 70°C for 10min. PCR products were purified by QIAquick gel extraction kit (QIAGEN, Hilden, Germany) after separation on 1% agarose gel and used for DNA sequencing. Nucleotide sequencing of CHIKV structural polyprotein gene gel purified PCR products were sequenced on both strands of DNA by BigDye terminator v3.1 reaction (Applied Biosystems, Foster City, CA) and the sequence data was analyzed using Sequencher v4.7 (GeneCodes, Ann Arbor, MI). The sequences were deposited in GenBank on 27<sup>th</sup> April 2010 before filing the provisional patent and published by GenBank on 02 March 2012. The unique nucleotide sequences reported in this invention are SEQ ID NO.1 (isolate TN01610), SEQ ID NO.2 (isolate TN15110) SEQ ID NO.3 (isolate TN06210), SEQ ID NO. 4 (TN06310), SEQ ID NO.5 (TN06410) and SEQ ID NO.6 (AP0109), whose corresponding protein sequences when translated are SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11, SEQ ID NO.12 and SEQ ID NO.13 respectively. The CHIKV strain CHIKV/03/06 has structural polyprotein gene of sequence SEQ ID NO.7 and was isolated during the 2006 Indian epidemic and its corresponding protein sequence is SEQ ID NO.14. The names of the virus isolates are provided in the brackets. For complete genomic RNA sequences, the sequencing reactions were performed using sequencing by synthesis (SBS) technology on the Illumina GAIIx (Genotypic Technology Pvt. Ltd. Bangalore). The complete nucleotide sequences (in the form of cDNA) of the virus genomic RNA of the above mentioned virus strains are provided in SEQ ID NO.15 to SEQ ID NO.20. Mutations identified with



reference to strain S27-African prototype (AF369024) were mapped to the individual structural proteins and are presented in Table 1.

**TABLE I.** Unique mutations in the Chikungunya virus structural genes reported in this study.

Amino acid position		Nucleotide change in polypeptide	strain S27-African prototype	CHIKV/03/06	TN01610	TN151100	TN06210	TN06310	TN06410	AP0109
Poly-peptide	Protein									
232	C-232	c695t	A	.	.	.	.	V	.	.
301	E3-40	g901a	D	.	.	N	.	.	.	.
372	E2-47	a1116t	K	.	.	.	N	.	.	.
380	E2-55	g1138a	G	.	R	.	.	.	.	R
391	E2-66	a1171g	K	.	.	.	.	.	E	.
589	E2-264	t1766c	V	.	A	A	A	A	A	.
867	E1-58	c2600t	P	.	.	.	.	.	.	L
1004	E1-195	g3010c	G	.	.	R	.	R	.	.
1020	E1-211	a3058g	K	.	E	E	E	E	E	E

Unique mutations identified in the capsid, E1, E2 and the E3 structural glycoproteins in the 2009-2010 CHIKV isolates from the States of Tamil Nadu and Andhra Pradesh.

“.” Amino acids identical to the reference strain S27-African prototype (AF369024). The GenBank accession numbers of the isolates from Tamil Nadu are HM159385 (TN01610), HM159386 (TN15110), HM159387 (TN06210), HM159388 (TN06310), HM159389 (TN06410), and from Hyderabad, Andhra Pradesh are HM159384 (CHIKV/03/06) and HM159390 (AP0109).

#### Example 4: Phylogenetic Analyses and Inference of Selection Pressure

The sequences reported in this study and those retrieved from GenBank were screened for recombination by the Genetic Algorithm Recombination Detection (GARD) (Kosakovsky Pond et al. 2006) prior to phylogenetic analysis. Evolutionary analyses were performed in MEGA5 (Tamura et al. 2007) using Kimura-2 parameter model of nucleotide substitution with 1000 bootstrap replicates. Multiple sequence alignment was performed using ClustalW2.0.3. The ECSA structural polyprotein sequences from 2005-2010 retrieved from GenBank and those reported in the study were used in the inference of selection pressure on the ECSA lineage. About 52 unique sequences were short listed by HyPhy (Pond et al. 2005) from 58 sequences retrieved from GenBank for the analyses. Codon-based Maximum Likelihood estimates of  $\omega$  or the dN/dS (the ratio of non-synonymous to synonymous substitutions) were inferred by Random Effects Likelihood (REL), Fixed Effects Likelihood (eFEL) and selection along the internal branches of phylogeny was tested using Internal Fixed Effects Likelihood (iFEL) method in HyPhy. In the likelihood methods, positive selection was inferred as significant if the  $p$  value of the likelihood ratio test (LRT) was less than 0.05 or when the Bayes factor was equal to or larger than 100 for a site. Statistical testing of positive selection operating on the entire protein was inferred by Single Likelihood Ancestor Counting (SLAC) method in HyPhy. Inference of  $\omega$  by empirical Bayesian method using LRT (Likelihood Ratio Test) with the MEC (Mechanistic Empirical Combination) model for positive selection, and M8a model for purifying and neutral selection was carried out using Selecton v2.2 (Stern et al. 2007). The amino acid sites of CHIKV structural proteins under significant positive and purifying selection is provided in accompanying Table II.

**TABLE II.** Amino acid sites of CHIKV structural proteins under significant positive and purifying selection

Method	Codon no. in structural polyprotein	Positively selected amino acid	Negatively selected amino acid	$p$ -value	Posterior probability	Bayes factor†
REL	523	E2-198R			0.87	111.55
	<b>524</b>		<b>E2-199Y</b>		0.999	505.10
	645	E2-320T			0.86	100.71
	711	E2-386A			0.87	108.86

	<b>1020</b>	<b>E1-211K</b>			0.97	532.15
	<b>1035</b>	<b>E1-226A</b>			0.98	773.33
	1078	E1-269V			0.86	100.10
	1113	E1-304 P			0.88	120.58
iFEL	28		C-28I	0.034		
	273		E3-12N	0.008		
	326		E2-1S	0.036		
	397		E2-72N	0.008		
	524		<b>E2-199Y</b>	<b>0.003</b>		
	834		E1-25S	0.036		
	909		E1-100N	0.005		
	916		E1-107H	0.016		
	<b>1020</b>	<b>E1-211K</b>		0.040		
	<b>1035</b>	<b>E1-226A</b>		0.006		
	1120		E1-311D	0.042		
	1245		E1-436F	0.009		

The amino acids under positive selection in the capsid (C) and in the E1, E2 and E3 glycoproteins in the 2009-2010 Indian CHIKV isolates were inferred by Random Effects Likelihood (REL) and by Internal Fixed Effects Likelihood (iFEL) methods using the HyPhy 5 package. The amino acid sites under significant positive and purifying selection in the E1 and E2 proteins respectively (Bayes factor >500, posterior probability  $\geq 0.97$  and  $p < 0.05$ ) are indicated in boldface. †Bayes factor is statistical estimation of posterior odds/prior odds for positive selection (dN>dS) at the site.

#### 10 Example 5: Cloning and Expression of the Structural Polyprotein Sequences

The virus isolates reported in this patent was used as the source for cloning and expression of all viral antigens. The complete open reading frame of the Chikungunya virus structural polyprotein encoded by the SEQ ID NO.1 was amplified by RT-PCR of the viral genomic 15 RNA using the primers CHKVCPFP as the forward primer and CHKVE1RP as the reverse

primer to obtain a ~ 3747 bp PCR fragment. The sequence of the PCR primers used for PCR amplification is:

**CHKVCPFP:**

55' ACAGAATTCATATGGAGTTCATCCCAACCCAAAC 3'

**CHKVE1RP:**

5' AATTGGATCCGCGGCCGCTTAGTGCCTGCTGAACGACACGC 3'

The PCR fragment was digested with NdeI and BamHI and cloned into the NdeI and BamHI sites of the prokaryotic expression vector, pET-11B and the recombinant plasmid containing the insert was transformed in *E.coli* DH5a. The recombinant plasmid DNA isolated from DH5a was used to transform the *E.coli* strain BL21(DE3). The PCR gene fragment was digested with EcoRI and NotI, gel purified by standard protocols and cloned into EcoRI and NotI sites of the yeast expression vector pPIC3.5K (Invitrogen Corporation, Carlsbad, USA) and transformed in *E.coli* DH5a. Recombinant plasmid DNA isolated from *E.coli* clone was linearized with BglII and was transformed into *Pichia Pastoris* GS115 as per the protocol from manufacturers (Invitrogen). The gene has been cloned into the *AOX1* locus and expressed under the *AOX1* promoter by methanol induction. The cloning, screening, isolation of the recombinant *Pichia* strains and induction of the cloned gene with methanol were carried out as per the User's manual "A Manual of Methods for Expression of Recombinant Proteins in *Pichia pastoris*" Version M Jan 2002, of *Pichia* Expression Kit, Catalog # K1710-01, Invitrogen Corporation, Carlsbad, USA).

**Example 6: *In vivo* potency testing of the vaccine formulations:**

25

The inactivated virus sample in vaccine formulations was tested with different adjuvants for potency. The adjuvants tested (at concentrations per single human dose) include a) aluminum hydroxide (0.5mg aluminum content) b) aluminum phosphate (0.5 mg aluminum content) c) gamma inulin (10 mg), d) algamulin (a combination of aluminum hydroxide and gamma inulin) at 10 mg, e) cholecalciferol in oil at 0.75 mg per dose, f) an oil in water emulsion OWEM1, containing 4.3% squalene, 0.5% tween-80, and 0.5% Span-85 (Sigma Aldrich product # S7135) in 10 mM phosphate-citrate buffer, f) oil in water emulsion OWEM2

containing 9.5mg squalene, 1 mg tween-80, 1 mg Span-85, 11 mg alpha tocopherol in phosphate-citrate buffer, g) an oil in water emulsion OWEM3 containing at the same concentration of excipients as in OWEM2 except that alpha tocopherol is replaced with 1-10 mg cholecalciferol. The formulated and adjuvanted vaccine preparations were injected intramuscularly in mice and booster doses were administered on day 7 and day 21 after administration of the first dose. Blood was collected at 28 days after the first dose was administered. Pooled sera from each test group were complement inactivated at 56°C for about 30 min. All the formulations contained 15 µg viral antigen in 40 mM phosphate buffer, pH 6.8 – 7.2 containing 150 mM NaCl. Sera samples were used for estimation of neutralizing antibodies and for the estimation antibody titer by ELISA. Vaccinated animals offered complete protection against viremia with a virus challenge dose of 10<sup>4.5</sup> pfu/ml when monitored over a period of 72 hours after intravenous/intraperitoneal administration of the challenge virus. In another experiment, passive immunization with rabbit antisera with PRNT<sub>50</sub> titer of 640 when administered intravenously in 4-6 week old Balb/c mice offered complete protection against viremia when challenged with 10<sup>4.5</sup> pfu/ml of the challenge virus. For serotype analyses, antisera against CHIKV/03/06 neutralized heterotypic virus isolates of the Asian genotype (GenBank Acc No. EF027140, isolated in Kolkata in 1963), ECSA, (E1-A226V, E1-211K, GenBank Acc No. FJ000069, isolated in Kerala in 2007) and ECSA (E1-226A, E1-K211E, GenBank Acc No. HM159386, obtained from Tamil Nadu in 2010 with neutralizing antibody titer ≥ 40 indicating heterotypic protection against genotypic variants, and also indicating that no distinct serotypes have evolved.

#### **Example 7: Plaque Reduction Neutralization Assay**

One day prior to the assay 6-well plates were seeded with 2.5 x 10<sup>3</sup> Vero cells (ATCC CCL-81) per well and the plates were incubated at 37°C in a 5% CO<sub>2</sub> incubator. To 4-fold dilutions of the sera samples in MEM containing 2% fetal bovine serum, equal volume of the standardized virus (10<sup>5</sup> pfu/ml) was added and incubated at 37°C with 5% CO<sub>2</sub> for 90 min. The cells were washed twice with 1 x PBS pH 7.4 (10 mM phosphate with 150 mM NaCl) and 0.3 ml of each dilution of the serum-virus mixture was added to the corresponding well and incubated for 90 min at 37°C in a 5% CO<sub>2</sub> incubator. Each assay was carried out in triplicates. The cells were overlaid with 2 ml of 0.85% methyl cellulose in MEM containing 10% fetal bovine serum, 1% penicillin-streptomycin and 1% L-

glutamine. The plates were incubated at 37°C in a 5% CO<sub>2</sub> incubator for 5 days. At the end of incubation, the plaques were fixed with 10% formalin, washed with 1 x PBS, pH 7.4 and were visualized with 0.1% crystal violet. The highest dilution of serum causing 50% reduction in plaques formed by the control virus sample was estimated as the PRNT<sub>50</sub> titer.

- 5 PRNT<sub>50</sub> assays were carried out to test the potency of the vaccine preparations by various inactivation methods, as well as for adjuvanted CHIKV vaccines and vaccine combination with JEV vaccine..

#### **Example 8: Vaccine combinations**

- 10 A combination of CHIKV vaccine inactivated by beta-propiolactone was tested in combination with formalin inactivated vaccine for Japanese encephalitis virus (JEV). 15 µg of CHIKV vaccine antigen formulated in alum (0.5mg aluminum/ dose) was tested in combination with inactivated JE (JEV) virus vaccine containing 6 µg of Japanese encephalitis virus whole virion antigen also formulated in alum. The vaccine combination
- 15 was injected in 8 nos of Balb/c mice with appropriate controls that included either of the antigens alone, and also control animals that received equivalent amount of alum. The animals were boosted at 7 and at 21 days after the first immunization. Blood was collected at 7 days after the last booster injection. Pooled sera from each group were complement inactivated at 56°C for about 30 min. The sera samples were used for estimation of
- 20 neutralizing antibody by PRNT<sub>50</sub> for both CHIKV and JEV. The buffer used in all the formulations was 40 mM phosphate buffer, pH 6.8 – 7.2 containing 150 mM NaCl. All the methods disclosed above are applicable to any genotype/genotypic variants/serotypes and strains of Chikungunya virus.

25

30

**References:**

1. Kannan M, Rajendran R, Sunish IP, Balasubramaniam R, Arunachalam N, Paramsivan R, Tewari SC, Samuel PP, Tyagi BK. 2007. A study on Chikungunya outbreak during 2007 in Kerala, south India. *Indian J Med Res* 129:311-315
- 5 2. Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O. 2007.
- 10 3. Powers AM, Brault AC, Tesh RB, Weaver SC. 2000. Re-emergence of Chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. *J Gen Virol* 81:471-479.
- 15 4. Yergolkar PN, Tandale BV, Arankalle VA, Sathe PS, Sudeep AB, Gandhe SS, Gokhle MD, Jacob GP, Hundekar SL, Mishra AC. 2006. Chikungunya outbreaks caused by African genotype, India. *Emerg Infect Dis* 12:1580-1583.
- 20 5. Powers AM, Logue CH. 2007. Changing patterns of Chikungunya virus: re-emergence of a zoonotic arbovirus. *J Gen Virol* 88:2363-2377.
6. Arankalle VA, Shrivastava S, Cherian S, Gunjekar RS, Walimbe, AM, Jadhav, SM, Sudeep AB, Mishra AC. 2007. Genetic divergence of Chikungunya viruses in India (1963-2006) with
- 25 special reference to the 2005-2006 explosive epidemic. *J Gen Virol* 88:1967-1976.
7. de Lamballerie X, Leroy E, Charrel RN, Tsetsarkin K, Higgs S, Gould EA. 2008. Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come? *Virol J* 5:33.
- 30 8. Tong JC, Simarmata D, Lin RT, Rénia L, Ng LF. 2010. HLA Class I restriction as a possible driving force for Chikungunya evolution. *PLoS One* 5:e9291.
9. Volk SM, Chen R, Tsetsarkin KA, Adams AP, Garcia TI, Sall AA, Nasar F, Schuh AJ, Holmes EC, Higgs S, Maharaj PD, Brault AC, Weaver SC. 2010. Genome-scale phylogenetic
- 35 analyses of Chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. *J Virol* 84:6497-6504.
10. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ. 2010. A virus-like particle vaccine for epidemic
- 40 Chikungunya virus protects nonhuman primates against infection. *Nat Med*. 2010; 16(3):334-8.
11. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J, Vijayachari P, Sundaram SG, Muruganandam N, Sarangan G, Srikanth P, Khan AS, Lewis MG, Kim JJ, Sardesai NY, Muthumani K, Weiner DB. 2011: A DNA

vaccine against Chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis.; 5(1):e928.

12. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. 2001:  
5 Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218.  
Am J Trop Med Hyg. 2000; 62(6):681-5.

10

15

20

25

30



**We claim:**


1. A vaccine composition, comprising one or more Chikungunya virus antigens, wherein the Chikungunya virus antigens are derived from one or more Chikungunya virus isolates selected from TN01610, TN015110, TN06210, TN06310, TN06410, and AP109 comprising a nucleotide sequence as provided in any one of SEQ ID NO. 1 to SEQ ID NO. 6 and SEQ ID NO. 15 to SEQ ID NO. 20.
2. The vaccine composition of claim 1, wherein the one or more Chikungunya virus isolates comprise a structural polyprotein comprising an E1 structural glycoprotein, wherein the structural polyprotein has a non-synonymous mutation K1020E corresponding to E1-K211E in the E1 structural glycoprotein, either singly or in combination with other mutations selected from A232V, D301N, K327N, G380R, K391E, V589A, P867L, G1004R, and A1035V in the structural polyprotein sequence.
3. The vaccine composition of claim 1 or claim 2, comprising one or more structural polyproteins comprising an amino acid sequence as provided in any one of SEQ ID NO. 8 to SEQ ID NO. 13.
4. The vaccine composition of claim 1, wherein the one or more Chikungunya virus antigens comprise a combination of capsid protein and structural glycoproteins of the Chikungunya virus isolates, comprising C-E3-E2-6K-E1, C-E2-E1 and E2-E1 proteins expressed as Virus Like Particles.
5. The vaccine composition of any one of claims 1 to 4, wherein the one or more Chikungunya virus antigens are recombinant polypeptides.
6. The vaccine composition of claim 5, wherein the one or more Chikungunya virus antigens were expressed in *E.coli* or *Pichia pastoris*.

7. The vaccine composition of any one of claims 1 to 6, wherein the Chikungunya virus is inactivated by any of the following methods:
  - i) Ultraviolet radiation at 254 nm for 30 min to 120 min; or
  - ii) Gamma irradiation by exposing the virus samples to a dose of 10kGy (Kilo Gray) to 25 kGy from a  $^{60}\text{Co}$  source.
8. The vaccine composition of any one of claims 1 to 7 further comprising an adjuvant selected from (a) aluminum hydroxide (b) aluminum phosphate (c) gamma inulin, (d) alammulin: a combination of aluminum hydroxide and gamma inulin (e) cholecalciferol in oil (f) an oil in water emulsion OWEM1, containing squalene, tween-80, Span-85 in 10 mM phosphate-citrate buffer, (g) oil in water emulsion OWEM2 containing squalene, tween-80, Span-85, alpha tocopherol in phosphate-citrate buffer, (h) an oil in water emulsion OWEM3 containing squalene, tween-80, Span-85, cholecalciferol in phosphate-citrate buffer.
9. The vaccine composition of any one of claims 1 to 8, wherein the Chikungunya virus antigen is at a dose ranging from 1  $\mu\text{g}$  to 100  $\mu\text{g}$  per human dose in 40 mM phosphate buffer and 150mM NaCl.
10. A combined vaccine composition comprising the vaccine composition of any one of claims 1 to 9 and inactivated Japanese Encephalitis whole virion antigen and an adjuvant selected from (a) aluminum hydroxide (b) aluminum phosphate (c) gamma inulin, (d) alammulin: a combination of aluminum hydroxide and gamma inulin) (e) cholecalciferol in oil (f) an oil in water emulsion OWEM1, containing squalene, tween-80, Span-85 in 10 mM phosphate-citrate buffer, (g) oil in water emulsion OWEM2 containing squalene, tween-80, Span-85, alpha tocopherol in phosphate-citrate buffer, (h) an oil in water emulsion OWEM3 containing squalene, tween-80, Span-85, cholecalciferol in phosphate-citrate buffer for eliciting a protective immune response against Chikungunya virus and Japanese Encephalitis virus infections in a human.

11. A method of eliciting a protective immune response in a human individual against Chikungunya virus infection comprising administering the vaccine composition of any one of claims 1 to 10 to a human.
12. Use of the vaccine composition of any one of claims 1 to 10 in the preparation of a vaccine formulation for eliciting a protective immune response in a human individual against Chikungunya virus infection.
13. The method of claim 11 or the use of claim 12, wherein the vaccine composition is administered through any of the routes selected from intramuscular, intradermal, subcutaneous, intravenous, oral or intranasal.
14. Use of one or more Chikungunya virus isolates comprising a structural polyprotein gene sequence as provided in any one of SEQ ID NO. 1 to SEQ ID NO. 6 in the preparation of an immunodiagnostic agent for detection of Chikungunya virus infection in a human.


1/2

Figure-1



2/2

Figure-2



Sequence listing-CHK-II  
SEQUENCE LISTING

<110> BHARAT BIOTECH INTERNATIONAL LIMITED

<120> Vaccine compositions for Chikungunya Virus Infection

<130> BBIL/CHK-II

<140> IN/2067/CHE/2011

<141> 2011-06-17

<160> 20

<170> PatentIn version 3.5

<210> 1

<211> 3747

<212> DNA

<213> Chikungunya virus

<400> 1

atggagttca tccaaccca aactttttac aataggaggt accagcctcg accctggact	60
ccgcgctcta ctatccaaat cattaggccc agaccgcgcc ctgagaggca agctgggcaa	120
cttgcccagc tgatctcagc agttaataaa ctgacaatgc gcgcggtacc ccaacagaag	180
ccacgcagga atcggaagaa taagaagcaa aagcaaaaac aacaggcgcc acaaaacaac	240
acaaatcaaa agaagcagcc acctaaaaag aaaccggctc aaaagaaaaa gaagccgggc	300
cgagagaga ggatgtgcat gaaaatcgaa aatgattgta ttttcgaagt caagcacgaa	360
ggtaaggtaa caggttacgc gtgcctgggtg ggggacaaaag taatgaaacc agcacacgta	420
aaggggacca tcgataacgc ggacctggcc aaactggcct ttaagcggtc atctaagtat	480
gaccttgaat gcgcgcagat acccgtgcac atgaagtccg acgcttcgaa gttcacccat	540
gagaaaccgg aggggtacta caactggcac cacggagcag tacagtactc aggaggccgg	600
ttcaccatcc ctacaggtgc tggcaaacca ggggacagcg gcagaccgat cttcgacaac	660
aagggacgcg tgggtggccat agtccttagga ggagctaata aaggagcccg tacagccctc	720
tcggtggtga cctggaataa agacattgtc actaaaatca ccccgaggg ggccgaagag	780
tggagtcttg ccatcccagt tatgtgcctg ctggcaaaca ccacgttccc ctgctcccag	840
cccccttgca cgccctgctg ctacgaaaag gaaccggagg aaaccctacg catgcttgag	900
gacaacgtca tgagacctgg gtactatcag ctgctacagg catccttaac atgttctccc	960
caccgccagc gacgcagcac caaggacaac ttcaatgtct ataaagccac aagaccatac	1020
ttagctcact gtcccgactg tggagaaggg cattcgtgcc atagtcccgt agcactagaa	1080
cgcatcagaa atgaagcgac agacgggacg ctgaaaatcc aggtctcctt gcaaatcaga	1140
ataaagacgg atgacagcca cgattggacc aagctgcgtt atatggacaa ccacatgcc	1200
gcagacgcag agagggcggg gctatttgta agaacatcag caccgtgtac gattactgga	1260



## Sequence listing-CHK-II

acaatgggac acttcatcct ggcccgatgt ccaaaagggg aaactctgac ggtgggattc	1320
actgacagta ggaagattag tcattcatgt acgcacccat ttcaccacga ccctcctgtg	1380
ataggtcggg aaaaattcca ttcccgaacc cagcacggta aagagctacc ttgcagcacg	1440
tacgtgcaga gcaccgccgc aactaccgag gagatagagg tacacatgcc cccagacacc	1500
cctgatcgca cattaatgtc acaacagtcc ggcaacgtaa agatcacagt caatggccag	1560
acggtgcggt acaagtgtaa ttgcggtggc tcaaatgaag gactaacaac tacagacaaa	1620
gtgattaata actgcaaggt tgatcaatgt catgccgcgg tcaccaatca caaaaagtgg	1680
cagtataact cccctcctgtt cccgcgtaat gctgaacttg gggaccgaaa aggaaaaatt	1740
cacatcccgt ttccgctggc aaatgcaaca tgcagggtgc ctaaagcaag gaaccccacc	1800
gtgacgtacg ggaaaaacca agtcatcatg ctactgtatc ctgaccaccc aacactcctg	1860
tcctaccgga atatgggaga agaaccaaac tatcaagaag agtgggtgat gcataagaag	1920
gaagtcgtgc taaccgtgcc gactgaaggg ctcgaggtca cgtggggcaa caacgagccg	1980
tataagtatt ggccgcagtt atctacaaac ggtacagccc atggccaccc gcatgagata	2040
attctgtatt attatgagct gtaccctact atgactgtag tagttgtgtc agtggccacg	2100
ttcatactcc tgtcgtgggt gggatatggc gcggggatgt gcatgtgtgc acgacgcaga	2160
tgcatcacac cgtatgaact gacaccagga gctaccgtcc ctttcctgct tagcctaata	2220
tgctgcatca gaacagctaa agcggccaca taccaagagg ctgcgatata cctgtggaac	2280
gagcagcaac ctttgttttg gctacaagcc cttattccgc tggcagccct gattgttcta	2340
tgcaactgtc tgagactctt accatgctgc tgtaaaacgt tggctttttt agccgtaatg	2400
agcgtcggtg cccacactgt gagcgcgtac gaacacgtaa cagtgatccc gaacacggtg	2460
ggagtaccgt ataagactct agtcaataga cctggctaca gccccatggt attggagatg	2520
gaactactgt cagtcacttt ggagccaaca ctatcgcttg attacatcac gtgcgagtac	2580
aaaaccgtca tccggtctcc gtacgtgaag tgctgcggtg cagcagagtg caaggacaaa	2640
aacctacctg actacagctg taaggctttc accggcgtct acccatttat gtggggcggc	2700
gcctactgct tctgcgacgc tgaaaacacg cagttgagcg aagcacatgt ggagaagtcc	2760
gaatcatgca aaacagaatt tgcacagca tacagggtc ataccgcatc tgcacagct	2820
aagctccgcg tcctttacca aggaaataac atcactgtaa ctgcctatgc aaacggcgac	2880
catgccgtca cagttaagga cgccaaattc attgtggggc caatgtcttc agcctggaca	2940
cctttcgaca acaaaattgt ggtgtacaaa ggtgacgtct ataacatgga ctacccgccc	3000
tttggcgag gaagaccagg acaatttggc gatatccaaa gtcgcacacc tgagagtga	3060
gacgtctatg ctaatacaca actggtactg cagagaccgg ctgcgggtac ggtacacgtg	3120
ccatactctc aggcaccatc tggctttaag tattggctaa aagaacgcgg ggcgtcactg	3180

## Sequence listing-CHK-II

cagcacacag caccatttgg ctgccaaata gcaacaaacc cggtaagagc ggtgaactgc	3240
gccgtaggga acatgcccat ctccatcgac ataccggaag cggccttcac tagggtcgtc	3300
gacgcgccct ctttaacgga catgtcgtgc gaggtaccag cctgcaccca ttcctcagac	3360
tttgggggcg tcgccattat taaatatgca gccagcaaga aaggcaagtg tgcggtgcat	3420
tcgatgacta acgccgtcac tattcgggaa gctgagatag aagtgaagg gaattctcag	3480
ctgcaaactc tttctcgcac ggccttagcc agcgcgaat tccgcgtaca agtctgttct	3540
acacaagtac actgtgcagc tgagtgccac cccccgaagg accacatagt caactacccg	3600
gcgtcacata ccaccctcgg ggtccaggac atctccgcta cggcgatgtc atgggtgcag	3660
aagatcacgg gaggtgtggg actggttgtt gctgttgccg cactgattct aatcgtggtg	3720
ctatgcgtgt cgttcagcag gcactaa	3747

<210> 2  
 <211> 3747  
 <212> DNA  
 <213> Chikungunya virus

<400> 2	
atggagtica tccaaccca aactttttac aataggaggt accagcctcg accctggact	60
ccgcgtctta ctatccaaat cattaggccc agaccgcgcc ctgagaggca agctgggcaa	120
cttgccagc tgatctcagc agttaataaa ctgacaatgc gcgcggtacc ccaacagaag	180
ccacgcagga atcggaagaa taagaagcaa aagcaaaaac aacaggcgcc acaaaacaac	240
acaaatcaaa agaagcagcc acctaaaaag aaaccggctc aaaagaaaaa gaagccgggc	300
cgagagaga ggatgtgcat gaaaatcgaa aatgattgta ttttcgaagt caagcacgaa	360
ggtaaggtaa caggttacgc gtgcctgggtg ggggacaaag taatgaaacc agcacacgta	420
aaggggacca tcgataacgc ggacctggcc aaactggcct ttaagcggtc atctaagtat	480
gaccttgaat gcgcgcagat acccgtgcac atgaagtccg acgcttcgaa gttcacccat	540
gagaaaccgg aggggtacta caactggcac cacggagcag tacagtactc aggaggccgg	600
ttcaccatcc ctacaggtgc tggcaaacca ggggacagcg gcagaccgat cttcgacaac	660
aagggacgcg tgggtggccat agtcttagga ggagctaata aaggagcccg tacagccctc	720
tcggtggtga cctggaataa aga'attgtc actaaaatca cccccgaggg ggccgaagag	780
tggagtcttg ccatcccagt tatgtgcctg ctggcaaaca ccacgttccc ctgctcccag	840
cccccttgca cgccctgctg ctacgaaaag gaaccggagg aaaccctacg catgcttgag	900
aacaacgtca tgagaccagg gtactatcag ctgctacagg catccttaac atgttctccc	960
caccgccagc gacgcagcac caaggacaac ttcaatgtct ataaagccac aagaccatac	1020
ttagctcact gtcccgaactg tggagaaggg cactcgtgcc atagtcccgt agcactagaa	1080



## Sequence listing-CHK-II

cgcatcagaa atgaagcgac agacgggacg ctgaaaatcc aggtctcctt gcaaatacga	1140
ataaagacgg atgacagcca cgattggacc aagctgcgtt atatggacaa ccacatgcca	1200
gcagacgcag agagggcggg gctatttgta agaacatcag caccgtgtac gattactgga	1260
acaatgggac acttcacccct ggcccgatgt ccaaaagggg aaactctgac ggtgggattc	1320
actgacagta ggaagattag tcattcatgt acgcacccat ttcaccacga ccctcctgtg	1380
ataggtcggg aaaaattcca ttcccgaacc cagcacggta aagagctacc ttgcagcacg	1440
tacgtgcaga gcaccgccgc aactaccgag gagatagagg tacacatgcc cccagacacc	1500
cctgatcgca cattaatgtc acaacagtcc ggcaacgtaa agatcacagt caatggccag	1560
acggtgcggt acaagtgtaa ttgcgggtggc tcaaatgaag gactaacaac tacagacaaa	1620
gtgattaata actgcaaggt tgatcaatgt catgccgcgg tcaccaatca caaaaagtgg	1680
cagtataact cccctctggt cccgcgtaat gctgaacttg gggaccgaaa aggaaaaatt	1740
cacatcccgt ttccgctggc aaatgcaaca tgcaggggtgc cttaaagcaag gaacccacc	1800
gtgacgtacg ggaaaaacca agtcacatg ctactgtatc ctgaccacc aacactcctg	1860
tcctaccgga atatgggaga agaaccaaac tatcaagaag agtgggtgat gcataagaag	1920
gaagtcgtgc taaccgtgcc gactgaaggc ctcgaggtca cgtggggcaa caacgagccg	1980
tataagtatt ggccgcagtt atctacaac ggtacagccc atggccacc gcatagagata	2040
attctgtatt attatgagct gtaccctact atgactgtag tagttgtgtc agtggccacg	2100
ttcatactcc tgtcgatggt gggatatggc gcggggatgt gcatgtgtgc acgacgcaga	2160
tgcacacac cgtatgaact gacaccagga gctaccgtcc ctttcctgct tagcctaata	2220
tgctgcatca gaacagctaa agcggccaca taccaagagg ctgcgatata cctgtggaac	2280
gagcagcaac ctttgttttg gctacaagcc cttattccgc tggcagccct gattgttcta	2340
tgcaactgtc tgagactctt accatgctgc tgtaaacgc tggctttttt agccgtaatg	2400
agcgtcgggtg cccacactgt gagcgcgtac gaacacgtaa cagtgatccc gaacacggtg	2460
ggagtaccgt ataagactct agtcaataga cctggctaca gccccatggt attggagatg	2520
gaactactgt cagtcacttt ggagccaaca ctatcgcttg attacatcac gtgcgagtac	2580
aaaaccgtca tcccgtctcc gtacgtgaag tgctgcggta cagcagagtg caaggacaaa	2640
aacctacctg actacagctg taaggctctt accggcgtct acccatttat gtggggcggc	2700
gcctactgct tctgcgacgc tgaaaacacg cagttgagcg aagcacatgt ggagaagtcc	2760
gaatcatgca aaacagaatt tgcacagca tacagggtc ataccgcac tgcacagct	2820
aagctccgcg tcctttacca aggaataac atcactgtaa ctgcctatgc aaacggcgac	2880
catgccgtca cagttaagga cgccaaattc attgtggggc caatgtcttc agcctggaca	2940

## Sequence listing-CHK-II

cctttcgaca	acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctacccgccc	3000
tttggcgcac	gaagaccagg	acaatttggc	gatatccaaa	gtcgcacacc	tgagagtga	3060
gacgtctatg	ctaatacaca	actggtactg	cagagaccgg	ctgcgggtac	ggtacacgtg	3120
ccatactctc	aggcaccatc	tggctttaag	tattggctaa	aagaacgcgg	ggcgtcactg	3180
cagcacacag	caccatttgg	ctgccaaata	gcaacaaacc	cggtaagagc	ggtgaactgc	3240
gccgtagggg	acatgcccac	ctccatcgac	ataccggaag	cggccttcac	tagggctcgtc	3300
gacgcgccct	ctttaacgga	catgtcgtgc	gaggtaccag	cctgcaccca	ttcctcagac	3360
tttgggggcy	tcgccattat	taaatacgca	gccagcaaga	aaggcaagt	tcgggtgcat	3420
tcgatgacta	acgcgcgtac	tattcgggaa	gctgagatag	aagttgaagg	gaattctcag	3480
ctgcaaactc	ctttctcgac	ggccttagcc	agcgccgaat	tccgcgtaca	agtctgttct	3540
acacaagtac	actgtgcagc	tgagtgcac	ccccgaagg	accacatagt	caactacccg	3600
gcgtcacata	ccaccctcgg	ggtccaggac	atctccgcta	cggcgatgtc	atgggtgcag	3660
aagatcacgg	gaggtgtggg	actggttgtt	gctgttgccg	cactgattct	aatcgtggtg	3720
ctatgcgtgt	cgttcagcag	gcactaa				3747

<210> 3  
 <211> 3747  
 <212> DNA  
 <213> Chikungunya virus

<400> 3	
atggagttca	tcccaacca aactttttac aataggaggt accagcctcg accctggact 60
ccgcgcctta	ctatccaaat cattaggccc agaccgcgcc ctgagaggca agctgggcaa 120
cttgcccagc	tgatctcagc agttaataaa ctgacaatgc gcgcggtacc ccaacagaag 180
ccacgcagga	atcggaagaa taagaagcaa aagcaaaaac aacaggcgcc acaaaacaac 240
acaaatcaaa	agaagcagcc acctaaaaag aaaccggctc aaaagaaaaa gaagccgggc 300
cgcagagaga	ggatgtgcat gaaaatcgaa aatgattgta ttttcgaagt caagcacgaa 360
ggtaaggtaa	caggttacgc gtgcctgggtg ggggacaaag taatgaaacc agcacacgta 420
aaggggacca	tcgataacgc ggacctggcc aaactggcct ttaagcggtc atctaagtat 480
gaccttgaat	gcgcgcagat acccgtgcac atgaagtccg acgcttcgaa gtacacccat 540
gagaaaccgg	aggggtacta caactggcac cacggagcag tacagtactc aggaggccgg 600
ttcaccatcc	ctacaggtgc tggcaaacca ggggacagcg gcagaccgat cttcgacaac 660
aagggacgcy	tgggtggccat agtcttagga ggagctaata aaggagcccg tacagccctc 720
tcggtggtga	cctggaataa agacattgtc actaaaatca ccccgagggg ggccgaagag 780
tggagtcttg	ccatcccagt tatgtgcctg ctggcaaaca ccacgttccc ctgctcccag 840



## Sequence listing-CHK-II

cccccttgca	cgccctgctg	ctacgaaaag	gaaccggagg	aaaccctacg	catgcttgag	900
gacaacgtca	tgagacctgg	gtactatcag	ctgctacagg	catccttaac	atgttctccc	960
caccgccagc	gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	1020
ttagctcact	gtcccgaactg	tggagaaggg	cactcgtgcc	atagtcccgt	agcactagaa	1080
cgcatacaga	atgaagcgac	agacgggacg	ctgaatatcc	aggtctcctt	gcaaatacga	1140
ataaagacgg	atgacagcca	cgattggacc	aagctgcggt	atatggacaa	ccacatgcca	1200
gcagacgcag	agagggcggg	gctatttgta	agaacatcag	caccgtgtac	gattactgga	1260
acaatgggac	acttcaccc	ggcccgaatg	ccaaaagggg	aaactctgac	ggtgggattc	1320
actgacagta	ggaagattag	tcattcatgt	acgcacccat	ttcaccacga	ccctcctgtg	1380
ataggtcggg	aaaaattcca	ttcccgaacc	cagcacggta	aagagctacc	ttgcagcacg	1440
tacgtgcaga	gcaccgccgc	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	1500
cctgatcgca	cattaatgtc	acaacagtcc	ggcaacgtaa	agatcacagt	caatggccag	1560
acggtgcggt	acaagtgtaa	ttgcggtggc	tcaaatgaag	gactaacaac	tacagacaaa	1620
gtgattaata	actgcaaggt	tgatcaatgt	catgccgagg	tcaccaatca	caaaaagtgg	1680
cagtataact	cccctctggt	cccgctaat	gctgaacttg	gggaccgaaa	aggaaaaatt	1740
cacatcccgt	ttccgctggc	aaatgcaaca	tgcaggggtg	ctaaagcaag	gaacccacc	1800
gtgacgtacg	ggaaaaacca	agttatcatg	ctactgtatc	ctgaccaccc	aacactcctg	1860
tcctaccgga	atatgggaga	agaaccaaac	tatcaagaag	agtgggtgat	gcataagaag	1920
gaagtctg	taaccgtgcc	gactgaaggg	ctcgaggtca	cgtggggcaa	caacgagccg	1980
tataagtatt	ggccgcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	2040
attctgtatt	attatgagct	gtaccctact	atgactgtag	tagttgtgtc	agtggccacg	2100
ttcactactc	tgtcgatgg	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	2160
tgcatacac	cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	2220
tgctgcatca	gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	2280
gagcagcaac	ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgtccta	2340
tgcaactgtc	tgagactctt	accatgctgc	tgtaaaacgt	tggctttttt	agccgtaatg	2400
agcgtcgg	cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacgg	2460
ggagtaccgt	ataagactct	agtcaataga	cctggctaca	gccccatgg	attggagatg	2520
gaactactgt	cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtac	2580
aaaaccgtca	tcccgtctcc	gtacgtgaag	tgtgcgggta	cagcagagtg	caaggacaaa	2640
aacctacctg	actacagctg	taaggtcttc	accggcgtct	acccatttat	gtggggcggc	2700
gcctactgct	tctgcgacgc	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	2760

Sequence Listing-CHK-II

gaatcatgca aaacagaatt tgcacagca tacagggtc ataccgcatc tgcacagct	2820
aagctccgcg tcctttacca aggaaataac atcactgtaa ctgcctatgc aaacggcgac	2880
catgccgtca cagttaagga cgccaaattc attgtggggc caatgtcttc agcctggaca	2940
cctttcgaca acaaaattgt ggtgtacaaa ggtgacgtct ataacatgga ctaccgccc	3000
tttggcgag gaagaccagg acaatttggc gatatccaaa gtcgcacacc tgagagtga	3060
gacgtctatg ctaatacaca actggtactg cagagaccgg ctgcgggtac ggtacacgtg	3120
ccatactctc aggcaccatc tggctttaag tattggctaa aagaacgcgg ggcgtcactg	3180
cagcacacag caccatttgg ctgccaaata gcaacaaacc cggtaaagagc ggtgaactgc	3240
gccgtaggga acatgcccat ctccatcgac ataccggaag cggccttcac tagggtcgtc	3300
gacgcgccct ctttaacgga catgtcgtgc gaggtaccag cctgcacca ttcctcagac	3360
tttggggcg tcgccattat taaatatgca gccagcaaga aaggcaagtg tgcggtgcat	3420
tcgatgacta acgccgteac tattcgggaa gctgagatag aagttgaagg gaattctcag	3480
ctgcaaactc ctttctcgac ggccttagcc agcgcgaat tccgcgtaca agtctgttct	3540
acacaagtac actgtgcagc tgagtgccac ccccggaagg accacatagt caactaccg	3600
gcgtcacata ccacccfcgg ggtccaggac atctccgcta cggcgatgtc atgggtgcag	3660
aagatcacgg gaggtgtggg actggttgtt gctgttgccg cactgattct aatcgtggtg	3720
ctatgcgtgt cgttcagcag gcactaa	3747

<210> 4  
 <211> 3747  
 <212> DNA  
 <213> Chikungunya virus

<400> 4	
atggagttca tcccaaccca aactttttac aataggaggt accagcctcg accctggact	60
ccgcgtcta ctatccaaat cattaggccc agaccgcgc ctcagaggca agctgggcaa	120
cttgcccagc tgatctcagc agttaataaa ctgacaatgc gcgcggtacc ccaacagaag	180
ccacgcagga atcgaagaa taagaagcaa aagcaaaaac aacaggcgcc acaaaacaac	240
acaaatcaaa agaagcagcc acctaaaaag aaaccggctc aaaagaaaaa gaagccgggc	300
cgcagagaga ggaatgtcat gaaaatcgaa aatgattgta ttttcgaagt caagcacgaa	360
ggtaaggtaa caggttacgc gtgcctggtg ggggacaaag taatgaaacc agcacacgta	420
aaggggacca tcgataacgc ggacctggcc aaactggcct ttaagcggtc atctaagtat	480
gaccttgaat gcgcgcagat acccgtgcac atgaagtccg acgcttcgaa gttcacccat	540
gagaaaccgg aggggtacta caactggcac cacggagcag tacagtactc aggaggccgg	600
ttcaccatcc ctacagggtgc tggcaaacca ggggacagcg gcagaccgat cttcgacaac	660



## Sequence listing-CHK-II

aagggacgcg	tgggtggccat	agtcttagga	ggagttaatg	aaggagcccg	tacagccctc	720
tcggtggtga	cctggaataa	agacattgtc	actaaaatca	cccccgaggg	ggccgaagag	780
tggagtcttg	ccatcccagt	tatgtgcctg	ctggcaaaca	ccacgttccc	ctgctcccag	840
cccccttgca	cgccctgctg	ctacgaaaag	gaaccggagg	aaaccctacg	catgcttgag	900
gacaacgtca	tgagacctgg	gtactatcag	ctgctacagg	catccttaac	atgtttctccc	960
caccgccagc	gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	1020
ttagctcact	gtcccgactg	tggagaaggg	cactcgtgcc	atagtcccg	agcactagaa	1080
cgcacagaa	atgaagcgac	agacgggacg	ctgaaaatcc	aggtctcctt	gcaaatacgga	1140
ataaagacgg	atgacagcca	cgattggacc	aagctgcgtt	atatggacaa	ccacatgcca	1200
gcagacgcag	agagggcggg	gctatttgta	agaacatcag	caccgtgtac	gattactgga	1260
acaatgggac	acttcatacct	ggcccgatgt	ccaaaagggg	aaactctgac	ggtgggattc	1320
actgacagta	ggaagattag	tcattcatgt	acgcacccat	ttcaccacga	ccctcctgtg	1380
ataggtcggg	aaaaattcca	ttcccgaccg	cagcacggta	aagagctacc	ttgcagcacg	1440
tacgtgcaga	gcaccgccgc	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	1500
cctgatcgca	cattaatgtc	acaacagtcc	ggcaacgtaa	agatcacagt	caatggccag	1560
acggtgcggt	acaagtgtaa	ttgcggtggc	tcaaataaag	gactaacaac	tacagacaaa	1620
gtgattaata	actgcaaggt	tgatcaatgt	catgccgcgg	tcaccaatca	caaaaagtgg	1680
cagtataact	cccctctggt	cccgcgtaat	gctgaacttg	gggaccgaaa	aggaaaaatt	1740
cacatcccgt	ttccgctggc	aatgcaaca	tgcaggggtg	ctaaagcaag	gaaccccacc	1800
gtgacgtacg	ggaaaaacca	agtcatacatg	ctactgtatc	ctgaccaccc	aacactcctg	1860
tcctaccgga	atatgggaga	agaaccaaac	tatcaagaag	agtgggtgat	gcataagaag	1920
gaagtcgtgc	taaccgtgcc	gactgaaggg	ctcgagggtca	cgtggggcaa	caacgagccg	1980
tataagtatt	ggccgcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	2040
attctgtatt	attatgagct	gtaccctact	atgactgtag	tagttgtgtc	agtggccacg	2100
ttcatactcc	tgtcgatggg	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	2160
tgcatacacac	cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	2220
tgctgcatca	gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	2280
gagcagcaac	ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgttcta	2340
tgcaactgtc	tgagactctt	accatgctgc	tgtaaaacgc	tggctttttt	agccgtaatg	2400
agcgtcggtg	cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacggtg	2460
ggagtaccgt	ataagactct	agtcaataga	cctggctaca	gccccatggt	attggagatg	2520

## Sequence listing-CHK-II

gaactactgt cagtcacttt ggagccaaca ctatcgcttg attacatcac gtgcgagtac	2580
aaaaccgtca tcccgtctcc gtacgtgaag tgctgcggtg cagcagagtg caaggacaaa	2640
aacctacctg actacagctg taaggtcttc accggcgctt acccatttat gtggggcggc	2700
gcctactgct tctgcgacgc tgaaaacacg cagttgagcg aagcacatgt ggagaagtcc	2760
gaatcatgca aaacagaatt tgcacagca tacagggcgc ataccgcac tgcacagct	2820
aagctccgcg tcttttacca aggaaataac atcactgtaa ctgcctatgc aaacggcgac	2880
catgccgtca cagttaagga cgccaaattc attgtggggc caatgtcttc agcctggaca	2940
cctttcgaca acaaaattgt ggtgtacaaa ggtgacgtct ataacatgga ctacccgcc	3000
tttggcgcac gaagaccagg acaatttggc gatatccaaa gtcgcacacc tgagagtga	3060
gacgtctatg ctaatacaca actggtactg cagagaccgg ctgcgggtac ggtacacgtg	3120
ccatactctc aggcaccatc tggctttaag tattggctaa aagaacgcgg ggcgtcactg	3180
cagcacacag caccatttgg ctgccaata gcaacaaacc cgtaagagc ggtgaactgc	3240
gccgtaggga acatgcccat ctccatcgac ataccggaag cggccttcac tagggtcgtc	3300
gacgcgccct ctttaacgga catgtcgtgc gaggtaccag cctgcacca ttcctcagac	3360
tttggggcg tgcattat taaatatgca gccagcaaga aaggcaagtg tgcggtgcat	3420
tcgatgacta acgccgtcac tattcgggaa gctgagatag aagttgaagg gaattctcag	3480
ctgcaaattc ctttctcgac ggccttagcc agcgccgaat tccggtaca agtctgttct	3540
acacaagtac actgtgcagc tgagtgccac cccccgaagg accacatagt caactacccg	3600
gcgtcacata ccaccctcgg ggtccaggac atctccgcta cggcgatgtc atgggtgcag	3660
aagatcacgg gaggtgtggg actggttgtt gctgttgccg cactgattct aatcgtggtg	3720
ctatgcgtgt cgttcagcag gcactaa	3747

<210> 5  
 <211> 3747  
 <212> DNA  
 <213> Chikungunya virus

<400> 5	
atggagtcca tcccaaccca aactttttac aataggaggt accagcctcg accctggact	60
ccgcgtcta ctatccaaat cattaggccc agaccgcgcc ctgagaggca agctgggcaa	120
cttgcccagc tgatctcagc agttaataaa ctgacaatgc gcgcggtacc ccaacagaag	180
ccacgcagga atcggaagaa taagaagcaa aagcaaaaac aacaggcgcc acaaaacaac	240
acaaatcaaa agaagcagcc acctaaaag aaaccggctc aaaagaaaaa gaagccgggc	300
cgcagagaga ggatgtgcat gaaaatcgaa aatgattgta ttttcgaagt caagcacgaa	360
ggtaaggtaa caggttacgc gtgcctggtg ggggacaaag taatgaaacc agcacacgta	420



## Sequence listing-CHK-II

aaggggacca	tcgataacgc	ggacctggcc	aaactggcct	ttaagcggtc	atctaagtat	480
gaccttgaat	gcgcgcagat	acccgtgcac	atgaagtccg	acgcttcgaa	gttcacccat	540
gagaaaccgg	aggggtacta	caactggcac	cacggggcag	tacagtactc	aggaggccgg	600
ttcaccatcc	ctacaggtgc	tggcaaacca	ggggacagcg	gcagaccgat	cttcgacaac	660
aaggggacgcg	tgggtggccat	agtcttagga	ggagctaattg	aaggagcccg	tacagccctc	720
tcggtggtga	cctggaataa	agacattgtc	actaaaatca	cccccgaggg	ggccgaagag	780
tggagtcttg	ccatcccagt	tatgtgcctg	ctggcaaaca	ccacgttccc	ctgtctccag	840
cccccttgca	cgccctgctg	ctacgaaaag	gaaccggagg	aaaccctacg	catgcttgag	900
gacaacgtca	tgagacctgg	gtactatcag	ctgctacagg	catccttaac	atgttctccc	960
caccgccagc	gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	1020
ttagctcact	gtcccgactg	tggagaaggg	cactcgtgcc	atagtcccgt	agcactagaa	1080
cgcatacagaa	atgaagcgac	agacgggacg	ctgaaaatcc	aggtctcctt	gcaaatacga	1140
ataaagacgg	atgacagcca	cgattggacc	gagctgcggt	atatggacaa	ccacatgcca	1200
gcagacgcag	agagggcggg	gctatttcta	agaacatcag	caccgtgtac	gattactgga	1260
acaatgggac	acttcatacct	ggcccgatgt	ccaaaagggg	aaactctgac	ggtgggattc	1320
actgacagta	ggaagattag	tcattcatgt	acgcacccat	ttcaccacga	ccctcctgtg	1380
ataggtcggg	aaaaattcca	ttcccgaccg	cagcacggta	aagagctacc	ttgcagcacg	1440
tacgtgcaga	gcaccgccgc	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	1500
cctgatcgca	cattaatgtc	acaacagtcc	ggcaacgtaa	agatcacagt	caatggccag	1560
acggtgcggt	acaagtgtaa	ttgcggtggc	tcaaatgaag	gactaacaac	tacagacaaa	1620
gtgattaata	actgcaaggt	tgatcaatgt	catgccgagg	tcaccaatca	caaaaagtgg	1680
cagtataact	cccctctggt	cccgcgtaat	gctgaacttg	gggaccgaaa	aggaaaaatt	1740
cacatcccgt	ttccgctggc	aaatgcaaca	tgcagggtgc	ctaaagcaag	gaacccacc	1800
gtgacgtacg	ggaaaaacca	agtcatactg	ctactgtatc	ctgaccaccc	aacactcctg	1860
tcctaccgga	atatgggaga	agaaccaaac	tatcaagaag	agtgggtgat	gcataagaag	1920
gaagtcgtgc	taaccgtgcc	gactgaaggg	ctcgaggtca	cgtggggcaa	caacgagccg	1980
tataagtatt	ggcggcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	2040
attctgtatt	attatgagct	gtaccctact	atgactgtag	tagttgtgtc	agtggccacg	2100
ttcatactcc	tgtcgatggt	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	2160
tgcatacacac	cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	2220
tgctgcatca	gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	2280
gagcagcaac	cittgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgttcta	2340

## Sequence listing-CHK-II

tgcaactgtc	tgagactctt	accatgctgc	tgtaaaacgc	tggctttttt	agccgtaatg	2400
agcgtcgggtg	cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacgggtg	2460
ggagtaccgt	ataagactct	agtcaataga	cctggctaca	gccccatggt	attggagatg	2520
gaactactgt	cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtac	2580
aaaaccgtca	tcccgtctcc	gtacgtgaag	tgtgctggta	cagcagagtg	caaggacaaa	2640
aacctacctg	actacagctg	taaggctctc	accggcgtct	acccatttat	gtggggcggc	2700
gcctactgct	tctgctgacg	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	2760
gaatcatgca	aaacagaatt	tgcacagca	tacagggcgc	ataccgcatc	tgcacagct	2820
aagctccgcg	tcctttacca	aggaaataac	atcactgtaa	ctgcctatgc	aaacggcgac	2880
catgccgtca	cagttaagga	cgccaaattc	attgtggggc	caatgtcttc	agcctggaca	2940
cctttcgaca	acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctaccgccc	3000
tttggcgag	gaagaccagg	acaatttggc	gatatccaaa	gtcgcacacc	tgagagtga	3060
gacgtctatg	ctaatacaca	actggtactg	cagagaccgg	ctgcgggtac	ggtacacgtg	3120
ccatactctc	aggcaccatc	tggctttaag	tattggctaa	aagaacgcgg	ggcgtcactg	3180
cagcacacag	caccatttgg	ctgccaaata	gcaacaaacc	cggtgaagagc	ggtgaactgc	3240
gccgtaggga	acatgcccat	ctccatcgac	ataccggaag	cggccttcac	tagggtcgtc	3300
gacgcgccct	ctttaacgga	catgtcgtgc	gaggtaccag	cctgcacca	ttcctcagac	3360
tttgggggag	tcgccattat	taaatatgca	gccagcaaga	aaggcaagtg	tgcggtgcat	3420
tcgatgacta	acgccgtcac	tattcgggaa	gctgagatag	aagttgaagg	gaattctcag	3480
ctgcaaattc	ctttctcgac	ggccttagcc	agcgccgaat	tccgcgtaca	agtctgttct	3540
acacaagtac	actgtgcagc	tgagtgccac	ccccgaagg	accacatagt	caactacccg	3600
gcgtcacata	ccaccctcgg	ggtccaggac	atctccgcta	cggcgatgtc	atgggtgcag	3660
aagatcacgg	gaggtgtggg	actggttgtt	gctgttgccg	cactgattct	aatcgtgggtg	3720
ctatgcgtgt	cgttcagcag	gcactaa				3747

<210> 6  
 <211> 3747  
 <212> DNA  
 <213> Chikungunya virus

<400> 6						
atggagttca	tcccaaccga	aactttttac	aataggaggt	accagcctcg	accctggact	60
ccgcgtctta	ctatccaaat	catcaggccc	agaccgcgcc	ctcagaggca	agctgggcaa	120
cttgcccagc	tgatctcagc	agttaataaa	ctgacaatgc	gcgcgggtacc	ccaacagaag	180
ccacgcagga	atcggaagaa	taagaagcaa	aagcaaaaac	aacaggcgcc	acaaaacaac	240



## Sequence listing-CHK-II

acaaatcaaa agaagcagtc acctaaaaag aaaccggctc aaaagaaaaa gaagccgggc	300
cgcagagaga ggatgtgcat gaaaatcgaa aatgattgta ttttcgaagt caagcacgaa	360
ggtaaggtaa caggttacgc gtgcctgggtg ggggacaaag taatgaaacc agcacacgta	420
aaggggacca tcgataacgc ggacctggcc aaactggcct ttaagcggtc atctaagtat	480
gaccttgaat gcgcgcagat acccgtgcac atgaagtccg acgcttcgaa gttcacccat	540
gagaaaccgg aggggtacta caactggcac cacggagcag tacaatactc aggaggccgg	600
ttcaccatcc ctacaggtgc tggcaaacca ggggacagcg gcagacctat cttcgacaac	660
aaggagcgcg tgggtggccat agtcttagga ggagctaata aaggagcccg tacagccctc	720
tcggtggtga cctggaataa agacattgtc actaaaatca ccccgagggg ggccgaagag	780
tggagtcttg ccatcccagt tatgtgcctg ttggcaaaca ccacgttccc ctgctcccag	840
cccccttgca cgccctgctg ctacgaaaag gaaccggagg aaaccctacg catgcttgag	900
gacaacgtca tgagacctgg gtactatcag ctgtacaag catccttaac atgttctccc	960
caccgccagc gacgcagcac caaggacaac ttcaatgtct ataaagccac aagaccatac	1020
ttagctcact gtcccgactg tggagaaggg cactcgtgcc atagtcccgt agcactagaa	1080
cgcatacaga atgaagcgac agacgggacg ctgaaaatcc aggtctcctt gcaaatcaga	1140
ataaagacgg atgacagcca cgattggacc aagctgcgtt atatggacaa ccacatgcca	1200
gcagacgcag agagggcggg gctatttgta agaacatcag caccgtgtac gattactgga	1260
acaatgggac acttcacctc ggcccgatgt ccaaaagggg aaactctgac ggtgggattc	1320
actgacagta ggaagattag tcattcatgt acgcacccat ttcaccacga cctcctgtg	1380
ataggtcggg aaaaattcca ttcccagccg cagcacggta aagagctacc ttgcagcacg	1440
tacgtgcaga gcaccgccc aactaccgag gagatagagg tacacatgcc cccagacacc	1500
cctgatcgca cattaatgtc acaacagtcc ggcaacgtaa agatcacagt caatggccag	1560
acggtgcggt acaagtgtaa ttgcggtggc tcaaatgaag gactaacaac tacagacaaa	1620
gtgattaata actgcaaggt tgatcaatgt catgccgcgg tcaccaatca caaaaagtgg	1680
cagtataact cccctctggt cccgcgtaat gctgaacttg gggaccgaaa aggaaaaatt	1740
cacatcccgt ttccgctggc aaatgtaaca tgcaggggtg ctaaagcaag gaaccccacc	1800
gtgacgtacg ggaaaaacca agtcatcatg ctactgtatc ctgaccaccc aacactcctg	1860
tcctaccgga atatgggaga agaaccaaac tatcaagaag agtgggtgat gcataagaag	1920
gaagtcgtgc taaccgtgcc gactgaaggg ctcgaggtca cgtggggcaa caacgagccg	1980
tataagtatt ggccgcagtt atctacaaac ggtacagccc atggccaccc gcatgagata	2040
attctgtatt attatgagct gtaccctact atgactgtag tagttgtgtc agtggccacg	2100

## Sequence listing-CHK-II

ttcatactcc	tgtcgatggt	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	2160
tgcatcacac	cgtatgaact	gacacagga	gctaccgtcc	ctttcctgct	tagcctaata	2220
tgctgcatca	gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	2280
gagcagcaac	ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgttcta	2340
tgcaactgtc	tgagactctt	accatgctgc	tgtaaacgt	tggctttttt	agccgtaatg	2400
agcgtcgggtg	cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacgggtg	2460
ggagtaccgt	ataagactct	agtcaataga	cctggctaca	gccccatggt	attggagatg	2520
gaactactgt	cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtac	2580
aaaaccgtca	tcccgctctt	gtacgtgaag	tgctgcggta	cagcagagtg	caaggacaaa	2640
aacctacctg	actacagctg	taaggctctt	accggcgtct	acccatttat	gtggggcggc	2700
gcctactgct	tctgcgacgc	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	2760
gaatcatgca	aaacagaatt	tgcatcagca	tacagggtct	ataccgcatc	tgcatcagct	2820
aagctccgcg	tcctttacca	aggaaataac	atcactgtaa	ctgcctatgc	aaacggcgac	2880
catgccgtca	cagttaagga	cgccaaattc	attgtggggc	caatgtcttc	agcctggaca	2940
cctttcgaca	acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctacccgccc	3000
tttggcgag	gaagaccagg	acaatttggc	gatatccaaa	gtcgcacacc	tgagagtga	3060
gacgtctatg	ctaatacaca	actggtactg	cagagaccgg	ctgcgggtac	ggtacacgtg	3120
ccatactctc	aggcaccatc	tggctttaag	tattggctaa	aagaacgcgg	ggcgtcactg	3180
cagcacacag	caccatttgg	ctgccaaata	gcaacaaacc	cggtaagagc	ggtgaactgc	3240
gccgtagggg	acatgcccat	ctccatcgac	ataccggaag	cggccttcac	tagggtcgtc	3300
gacgcgccct	ctttaacgga	catgtcgtgc	gaggtaccag	cctgcacca	ttcctcagac	3360
tttggggg	tcgccattat	taaatatgca	gccagcaaga	aaggcaagtg	tgcggtgcat	3420
tcgatgacta	acgcggtcac	tattcgggaa	gctgagatag	aagtgaagg	gaattctcag	3480
ctgcaaattc	ctttctcgac	ggccttagcc	agcgcggaat	tccgcgtaca	agtctgttct	3540
acacaagtac	actgtgcagc	tgagtgccac	ccccgaagg	accacatagt	caactacccg	3600
gcgtcacata	ccaccctcgg	ggtccaggac	atctccgcta	cggcgatgtc	atgggtgcag	3660
aagatcacgg	gaggtgtggg	actggttggt	gctgttgccg	cactgattct	aatcgtggtg	3720
ctatgcgtgt	cgttcagcag	gcactaa				3747

<210> 7  
 <211> 3747  
 <212> DNA  
 <213> Chikungunya virus  
 <400> 7



## Sequence listing-CHK-II

atggagttca	tcccaaccca	aactttttac	aataggaggt	accagcctcg	accctggact	60
ccgcgctcta	ctatccaaat	catcaggccc	agaccgcgcc	ctcagaggca	agctgggcaa	120
cttgcccagc	tgatctcagc	agttaataaa	ctgacaatgc	gcgcggtacc	ccaacagaag	180
ccacgcagga	atcggaagaa	taagaagcaa	aagcaaaaac	aacaggcgcc	acaaaacaac	240
acaaatcaaa	agaagcagcc	acctaataag	aaaccggctc	aaaagaaaaa	gaagccgggc	300
cgcagagaga	ggatgtgcat	gaaaatcgaa	aatgattgta	ttttcgaagt	caagcacgaa	360
ggtaaggtaa	caggttacgc	gtgcctgggtg	ggggacaaag	taatgaaacc	agcacacgta	420
aaggggacca	tcgataacgc	ggacctggcc	aaactggcct	ttaagcggtc	atctaagtat	480
gaccttgaat	gcgcgcagat	acccgtgcac	atgaagtccg	acgcttcgaa	gttcacccat	540
gagaaaccgg	aggggtacta	caactggcac	cacggagcag	tacagtactc	aggaggccgg	600
ttcaccatcc	ctacaggtgc	tggcaaacca	ggggacagcg	gcagacctat	cttcgacaac	660
aagggacgcg	tgggtggccat	agtcttagga	ggagctaata	aaggagcccc	tacagccctc	720
tcggtggtga	cctggaataa	agacattgtc	actaaaatca	cccccgaggg	ggccgaagag	780
tggagtcttg	ccatcccagt	tatgtgcctg	ttggcaaaca	ccacgttccc	ctgctcccag	840
cccccttgca	cgccttgctg	ctacgaaaag	gaaccggagg	aaaccctacg	catgcttgag	900
gacaacgtca	tgagacctgg	gtactatcag	ctgctacaag	catccttaac	atgttctccc	960
caccgccagc	gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	1020
ttagctcact	gtcccgactg	tggagaaggg	cactcgtgcc	atagtcccgt	agcactagaa	1080
cgcacagaaa	atgaagcgac	agacgggacg	ctgaaaatcc	aggtctcctt	gcaaatacga	1140
ataaagacgg	atgacagcca	cgattggacc	aagctgcgtt	atatggacaa	ccacatgcca	1200
gcagacgcag	agagggcggg	gctatttgta	agaacatcag	caccgtgtac	gattactgga	1260
acaatgggac	acttcatect	ggcccgatgt	ccaaaagggg	aaactctgac	ggtgggattc	1320
actgacagta	ggaagattag	tcactcatgt	acgcacccat	ttcaccacga	ccctcctgtg	1380
ataggtcggg	aaaaattcca	ttcccgaccg	cagcacggta	aagagctacc	ttgcagcacg	1440
tacgtgcaga	gcacccgccc	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	1500
cctgatcgca	cattaatgtc	acaacagtcc	ggcaacgtaa	agatcacagt	caatggccag	1560
acggtgcggt	acaagtgtaa	ttgcggtggc	tcaaatgaag	gactaacaac	tacagacaaa	1620
gtgattaata	actgcaaggt	tgatcaatgt	catgccgcgg	tcaccaatca	caaaaagtgg	1680
cagtataact	cccctctggt	cccgcgtaat	gctgaacttg	gggaccgaaa	aggaaaaatt	1740
cacatcccgt	ttccgctggc	aaatgtaaca	tgcagggtgc	ctaaagcaag	gaacccacc	1800
gtgacgtacg	ggaaaaacca	agtcatcatg	ctactgtatc	ctgaccaccc	aacactcctg	1860
tcctaccgga	atatgggaga	agaaccaaac	tatcaagaag	agtgggtgat	gcataagaag	1920

## Sequence listing-CHK-II

gaagtcgtgc	taaccgtgcc	gactgaaggg	ctcgaggtca	cgtggggcaa	caacgagccg	1980
tataagtatt	ggccgcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	2040
attctgtatt	attatgagct	gtacccact	atgactgtag	tagttgtgtc	agtggccacg	2100
ttcatactcc	tgtcgatggt	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	2160
tgcatcacac	cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	2220
tgctgcatca	gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	2280
gagcagcaac	ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgttcta	2340
tgcaactgtc	tgagactctt	accatgctgc	tgtaaaacgt	tggctttttt	agccgtaatg	2400
agcgtcggtg	cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacggtg	2460
ggagtaccgt	ataagactct	agtcaataga	cctggctaca	gccccatggt	attggagatg	2520
gaactactgt	cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtac	2580
aaaaccgtca	tcccgtctcc	gtacgtgaag	tgctgcggta	cagcagagtg	caaggacaaa	2640
aacctacctg	actacagctg	tagggctctt	accggcgtct	acccatttat	gtgggggtggc	2700
gcctactgct	tctgcgacgc	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	2760
gaatcatgca	aaacagaatt	tgcatcagca	tacagggctc	ataccgcata	tgcatcagct	2820
aagctccgcg	tcctttacca	aggaaataac	atcactgtaa	ctgcctatgc	aaacggcgac	2880
catgccgtca	cagttaagga	cgccaaattc	attgtggggc	caatgtcttc	agcctggaca	2940
cctttcgaca	acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctacccgccc	3000
tttggcgtag	gaagaccagg	acaatttggc	gatatccaaa	gtcgcacacc	tgagagtaaa	3060
gacgtctatg	ctaatacaca	actggtactg	cagagaccgg	ctgcgggtac	ggtacacgtg	3120
ccatactctc	aggcaccatc	tggctttaag	tattggctaa	aagaacgcgg	ggcgtcactg	3180
cagcacacag	caccatttgg	ctgccaataa	gcaacaaacc	cggtaaagagc	ggtgaactgc	3240
gccgtagggg	acatgcccat	ctccatcgac	ataccggaag	cggccttcac	tagggtcgtc	3300
gacgcgccct	ctttaacgga	catgtcgtgc	gaggtaccag	cctgcaccca	ttcctcagac	3360
tttgggggag	tggccattat	taaatatgca	gccagcaaga	aaggcaagtg	tgcggtgcat	3420
tcgatgacta	acgcccgtac	tattcgggaa	gctgagatag	aagttgaagg	gaattctcag	3480
ctgcaaatct	ctttctcgac	ggccttagcc	agcgccgaat	tccgcgtaca	agtctgttct	3540
acacaagtac	actgtgeagc	tgagtgccac	ccccgaagg	accacatagt	caactacccg	3600
gcgtcacata	ccaccctcgg	ggtccaggac	atctccgcta	cggcgatgtc	atgggtgcag	3660
aagatcacgg	gaggtgtggg	actggttgtt	gctgttgccg	cactgattct	aatcgtggtg	3720
ctatgcgtgt	cgttcagcag	gcactaa				3747

## Sequence listing-CHK-II

<210> 8  
 <211> 1248  
 <212> PRT  
 <213> Chikungunya virus

<400> 8

Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro  
 1 5 10 15  
 Arg Pro Trp Thr Pro Arg Ser Thr Ile Gln Ile Ile Arg Pro Arg Pro  
 20 25 30  
 Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val  
 35 40 45  
 Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn  
 50 55 60  
 Arg Lys Asn Lys Lys Gln Lys Gln Lys Gln Gln Ala Pro Gln Asn Asn  
 65 70 75 80  
 Thr Asn Gln Lys Lys Gln Pro Pro Lys Lys Lys Pro Ala Gln Lys Lys  
 85 90 95  
 Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp  
 100 105 110  
 Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Thr Gly Tyr Ala Cys  
 115 120 125  
 Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile  
 130 135 140  
 Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr  
 145 150 155 160  
 Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser  
 165 170 175  
 Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly  
 180 185 190  
 Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly  
 195 200 205  
 Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val  
 210 215 220



## Sequence listing-CHK-II

Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu  
 225 230 235 240  
 Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu  
 245 250 255  
 Gly Ala Glu Glu Trp Ser Leu Ala Ile Pro Val Met Cys Leu Leu Ala  
 260 265 270  
 Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr  
 275 280 285  
 Glu Lys Glu Pro Glu Glu Thr Leu Arg Met Leu Glu Asp Asn Val Met  
 290 295 300  
 Arg Pro Gly Tyr Tyr Gln Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro  
 305 310 315 320  
 His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala  
 325 330 335  
 Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser  
 340 345 350  
 Cys His Ser Pro Val Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp  
 355 360 365  
 Gly Thr Leu Lys Ile Gln Val Ser Leu Gln Ile Arg Ile Lys Thr Asp  
 370 375 380  
 Asp Ser His Asp Trp Thr Lys Leu Arg Tyr Met Asp Asn His Met Pro  
 385 390 395 400  
 Ala Asp Ala Glu Arg Ala Gly Leu Phe Val Arg Thr Ser Ala Pro Cys  
 405 410 415  
 Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys  
 420 425 430  
 Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His  
 435 440 445  
 Ser Cys Thr His Pro Phe His His Asp Pro Pro Val Ile Gly Arg Glu  
 450 455 460  
 Lys Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr  
 465 470 475 480

## Sequence listing-CHK-II

Tyr Val Gln Ser Thr Ala Ala Thr Thr Glu Glu Ile Glu Val His Met  
 485 490 495  
 Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Ser Gln Gln Ser Gly Asn  
 500 505 510  
 Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys  
 515 520 525  
 Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn  
 530 535 540  
 Cys Lys Val Asp Gln Cys His Ala Ala Val Thr Asn His Lys Lys Trp  
 545 550 555 560  
 Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg  
 565 570 575  
 Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Ala Thr Cys Arg  
 580 585 590  
 Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val  
 595 600 605  
 Ile Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn  
 610 615 620  
 Met Gly Glu Glu Pro Asn Tyr Gln Glu Glu Trp Val Met His Lys Lys  
 625 630 635 640  
 Glu Val Val Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly  
 645 650 655  
 Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr  
 660 665 670  
 Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr  
 675 680 685  
 Pro Thr Met Thr Val Val Val Val Ser Val Ala Thr Phe Ile Leu Leu  
 690 695 700  
 Ser Met Val Gly Met Ala Ala Gly Met Cys Met Cys Ala Arg Arg Arg  
 705 710 715 720  
 Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu

## Sequence listing-CHK-II

725

730

735

Leu Ser Leu Ile Cys Cys Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln  
 740 745 750  
 Glu Ala Ala Ile Tyr Leu Trp Asn Glu Gln Gln Pro Leu Phe Trp Leu  
 755 760 765  
 Gln Ala Leu Ile Pro Leu Ala Ala Leu Ile Val Leu Cys Asn Cys Leu  
 770 775 780  
 Arg Leu Leu Pro Cys Cys Cys Lys Thr Leu Ala Phe Leu Ala Val Met  
 785 790 795 800  
 Ser Val Gly Ala His Thr Val Ser Ala Tyr Glu His Val Thr Val Ile  
 805 810 815  
 Pro Asn Thr Val Gly Val Pro Tyr Lys Thr Leu Val Asn Arg Pro Gly  
 820 825 830  
 Tyr Ser Pro Met Val Leu Glu Met Glu Leu Leu Ser Val Thr Leu Glu  
 835 840 845  
 Pro Thr Leu Ser Leu Asp Tyr Ile Thr Cys Glu Tyr Lys Thr Val Ile  
 850 855 860  
 Pro Ser Pro Tyr Val Lys Cys Cys Gly Thr Ala Glu Cys Lys Asp Lys  
 865 870 875 880  
 Asn Leu Pro Asp Tyr Ser Cys Lys Val Phe Thr Gly Val Tyr Pro Phe  
 885 890 895  
 Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu  
 900 905 910  
 Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala  
 915 920 925  
 Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val  
 930 935 940  
 Leu Tyr Gln Gly Asn Asn Ile Thr Val Thr Ala Tyr Ala Asn Gly Asp  
 945 950 955 960  
 His Ala Val Thr Val Lys Asp Ala Lys Phe Ile Val Gly Pro Met Ser  
 965 970 975



## Sequence listing-CHK-II

Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp  
 980 985 990  
 Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Gly Arg Pro Gly Gln  
 995 1000 1005  
 Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Glu Asp Val Tyr  
 1010 1015 1020  
 Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Ala Gly Thr Val  
 1025 1030 1035  
 His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu  
 1040 1045 1050  
 Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys  
 1055 1060 1065  
 Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly  
 1070 1075 1080  
 Asn Met Pro Ile Ser Ile Asp Ile Pro Glu Ala Ala Phe Thr Arg  
 1085 1090 1095  
 Val Val Asp Ala Pro Ser Leu Thr Asp Met Ser Cys Glu Val Pro  
 1100 1105 1110  
 Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys  
 1115 1120 1125  
 Tyr Ala Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr  
 1130 1135 1140  
 Asn Ala Val Thr Ile Arg Glu Ala Glu Ile Glu Val Glu Gly Asn  
 1145 1150 1155  
 Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu  
 1160 1165 1170  
 Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Glu  
 1175 1180 1185  
 Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His  
 1190 1195 1200  
 Thr Thr Leu Gly Val Gln Asp Ile Ser Ala Thr Ala Met Ser Trp  
 1205 1210 1215

## Sequence listing-CHK-II

Val Gln Lys Ile Thr Gly Gly Val Gly Leu Val Val Ala Val Ala  
1220 1225 1230

Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His  
1235 1240 1245

<210> 9  
<211> 1248  
<212> PRT  
<213> Chikungunya virus

<400> 9

Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro  
1 5 10 15

Arg Pro Trp Thr Pro Arg Ser Thr Ile Gln Ile Ile Arg Pro Arg Pro  
20 25 30

Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val  
35 40 45

Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn  
50 55 60

Arg Lys Asn Lys Lys Gln Lys Gln Lys Gln Gln Ala Pro Gln Asn Asn  
65 70 75 80

Thr Asn Gln Lys Lys Gln Pro Pro Lys Lys Lys Pro Ala Gln Lys Lys  
85 90 95

Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp  
100 105 110

Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Thr Gly Tyr Ala Cys  
115 120 125

Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile  
130 135 140

Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr  
145 150 155 160

Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser  
165 170 175

Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly  
180 185 190

## Sequence listing-CHK-II

Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly  
195 200 205

Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val  
210 215 220

Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu  
225 230 235 240

Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu  
245 250 255

Gly Ala Glu Glu Trp Ser Leu Ala Ile Pro Val Met Cys Leu Leu Ala  
260 265 270

Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr  
275 280 285

Glu Lys Glu Pro Glu Glu Thr Leu Arg Met Leu Glu Asn Asn Val Met  
290 295 300

Arg Pro Gly Tyr Tyr Gln Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro  
305 310 315 320

His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala  
325 330 335

Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser  
340 345 350

Cys His Ser Pro Val Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp  
355 360 365

Gly Thr Leu Lys Ile Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp  
370 375 380

Asp Ser His Asp Trp Thr Lys Leu Arg Tyr Met Asp Asn His Met Pro  
385 390 395 400

Ala Asp Ala Glu Arg Ala Gly Leu Phe Val Arg Thr Ser Ala Pro Cys  
405 410 415

Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys  
420 425 430

Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His  
435 440 445

## Sequence listing-CHK-II

Ser Cys Thr His Pro Phe His His Asp Pro Pro Val Ile Gly Arg Glu  
 450 455 460  
 Lys Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr  
 465 470 475 480  
 Tyr Val Gln Ser Thr Ala Ala Thr Thr Glu Glu Ile Glu Val His Met  
 485 490 495  
 Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Ser Gln Gln Ser Gly Asn  
 500 505 510  
 Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys  
 515 520 525  
 Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn  
 530 535 540  
 Cys Lys Val Asp Gln Cys His Ala Ala Val Thr Asn His Lys Lys Trp  
 545 550 555 560  
 Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg  
 565 570 575  
 Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Ala Thr Cys Arg  
 580 585 590  
 Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val  
 595 600 605  
 Ile Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn  
 610 615 620  
 Met Gly Glu Glu Pro Asn Tyr Gln Glu Glu Trp Val Met His Lys Lys  
 625 630 635 640  
 Glu Val Val Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly  
 645 650 655  
 Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr  
 660 665 670  
 Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr  
 675 680 685  
 Pro Thr Met Thr Val Val Val Val Ser Val Ala Thr Phe Ile Leu Leu  
 Page 23



Sequence listing-CHK-II  
700

690

695

Ser Met Val Gly Met Ala Ala Gly Met Cys Met Cys Ala Arg Arg Arg  
 705 710 715 720  
 Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu  
 725 730 735  
 Leu Ser Leu Ile Cys Cys Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln  
 740 745 750  
 Glu Ala Ala Ile Tyr Leu Trp Asn Glu Gln Gln Pro Leu Phe Trp Leu  
 755 760 765  
 Gln Ala Leu Ile Pro Leu Ala Ala Leu Ile Val Leu Cys Asn Cys Leu  
 770 775 780  
 Arg Leu Leu Pro Cys Cys Cys Lys Thr Leu Ala Phe Leu Ala Val Met  
 785 790 795 800  
 Ser Val Gly Ala His Thr Val Ser Ala Tyr Glu His Val Thr Val Ile  
 805 810 815  
 Pro Asn Thr Val Gly Val Pro Tyr Lys Thr Leu Val Asn Arg Pro Gly  
 820 825 830  
 Tyr Ser Pro Met Val Leu Glu Met Glu Leu Leu Ser Val Thr Leu Glu  
 835 840 845  
 Pro Thr Leu Ser Leu Asp Tyr Ile Thr Cys Glu Tyr Lys Thr Val Ile  
 850 855 860  
 Pro Ser Pro Tyr Val Lys Cys Cys Gly Thr Ala Glu Cys Lys Asp Lys  
 865 870 875 880  
 Asn Leu Pro Asp Tyr Ser Cys Lys Val Phe Thr Gly Val Tyr Pro Phe  
 885 890 895  
 Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu  
 900 905 910  
 Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala  
 915 920 925  
 Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val  
 930 935 940

## Sequence listing-CHK-II

Leu Tyr Gln Gly Asn Asn Ile Thr Val Thr Ala Tyr Ala Asn Gly Asp  
 945 950 955 960  
 His Ala Val Thr Val Lys Asp Ala Lys Phe Ile Val Gly Pro Met Ser  
 965 970 975  
 Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp  
 980 985 990  
 Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Arg Arg Pro Gly Gln  
 995 1000 1005  
 Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Glu Asp Val Tyr  
 1010 1015 1020  
 Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Ala Gly Thr Val  
 1025 1030 1035  
 His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu  
 1040 1045 1050  
 Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys  
 1055 1060 1065  
 Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly  
 1070 1075 1080  
 Asn Met Pro Ile Ser Ile Asp Ile Pro Glu Ala Ala Phe Thr Arg  
 1085 1090 1095  
 Val Val Asp Ala Pro Ser Leu Thr Asp Met Ser Cys Glu Val Pro  
 1100 1105 1110  
 Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys  
 1115 1120 1125  
 Tyr Ala Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr  
 1130 1135 1140  
 Asn Ala Val Thr Ile Arg Glu Ala Glu Ile Glu Val Glu Gly Asn  
 1145 1150 1155  
 Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu  
 1160 1165 1170  
 Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Glu  
 1175 1180 1185

## Sequence listing-CHK-II

Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His  
1190 1195 1200

Thr Thr Leu Gly Val Gln Asp Ile Ser Ala Thr Ala Met Ser Trp  
1205 1210 1215

Val Gln Lys Ile Thr Gly Gly Val Gly Leu Val Val Ala Val Ala  
1220 1225 1230

Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His  
1235 1240 1245

<210> 10  
<211> 1248  
<212> PRT  
<213> Chikungunya virus

<400> 10

Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro  
1 5 10 15

Arg Pro Trp Thr Pro Arg Ser Thr Ile Gln Ile Ile Arg Pro Arg Pro  
20 25 30

Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val  
35 40 45

Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn  
50 55 60

Arg Lys Asn Lys Lys Gln Lys Gln Lys Gln Gln Ala Pro Gln Asn Asn  
65 70 75 80

Thr Asn Gln Lys Lys Gln Pro Pro Lys Lys Lys Pro Ala Gln Lys Lys  
85 90 95

Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp  
100 105 110

Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Thr Gly Tyr Ala Cys  
115 120 125

Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile  
130 135 140

Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr  
145 150 155 160

## Sequence listing-CHK-II

Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser  
 165 170 175  
 Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly  
 180 185 190  
 Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly  
 195 200 205  
 Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val  
 210 215 220  
 Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu  
 225 230 235 240  
 Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu  
 245 250 255  
 Gly Ala Glu Glu Trp Ser Leu Ala Ile Pro Val Met Cys Leu Leu Ala  
 260 265 270  
 Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr  
 275 280 285  
 Glu Lys Glu Pro Glu Glu Thr Leu Arg Met Leu Glu Asp Asn Val Met  
 290 295 300  
 Arg Pro Gly Tyr Tyr Gln Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro  
 305 310 315 320  
 His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala  
 325 330 335  
 Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser  
 340 345 350  
 Cys His Ser Pro Val Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp  
 355 360 365  
 Gly Thr Leu Asn Ile Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp  
 370 375 380  
 Asp Ser His Asp Trp Thr Lys Leu Arg Tyr Met Asp Asn His Met Pro  
 385 390 395 400  
 Ala Asp Ala Glu Arg Ala Gly Leu Phe Val Arg Thr Ser Ala Pro Cys  
 405 410 415



## Sequence listing-CHK-II

Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys  
 420 425 430  
 Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His  
 435 440 445  
 Ser Cys Thr His Pro Phe His His Asp Pro Pro Val Ile Gly Arg Glu  
 450 455 460  
 Lys Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr  
 465 470 475 480  
 Tyr Val Gln Ser Thr Ala Ala Thr Thr Glu Glu Ile Glu Val His Met  
 485 490 495  
 Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Ser Gln Gln Ser Gly Asn  
 500 505 510  
 Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys  
 515 520 525  
 Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn  
 530 535 540  
 Cys Lys Val Asp Gln Cys His Ala Ala Val Thr Asn His Lys Lys Trp  
 545 550 555 560  
 Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg  
 565 570 575  
 Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Ala Thr Cys Arg  
 580 585 590  
 Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val  
 595 600 605  
 Ile Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn  
 610 615 620  
 Met Gly Glu Glu Pro Asn Tyr Gln Glu Glu Trp Val Met His Lys Lys  
 625 630 635 640  
 Glu Val Val Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly  
 645 650 655  
 Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr  
 Page 28

## Sequence listing-CHK-II

660

665

670

Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr  
 675 680 685  
 Pro Thr Met Thr Val Val Val Val Ser Val Ala Thr Phe Ile Leu Leu  
 690 695 700  
 Ser Met Val Gly Met Ala Ala Gly Met Cys Met Cys Ala Arg Arg Arg  
 705 710 715 720  
 Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu  
 725 730 735  
 Leu Ser Leu Ile Cys Cys Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln  
 740 745 750  
 Glu Ala Ala Ile Tyr Leu Trp Asn Glu Gln Gln Pro Leu Phe Trp Leu  
 755 760 765  
 Gln Ala Leu Ile Pro Leu Ala Ala Leu Ile Val Leu Cys Asn Cys Leu  
 770 775 780  
 Arg Leu Leu Pro Cys Cys Cys Lys Thr Leu Ala Phe Leu Ala Val Met  
 785 790 795 800  
 Ser Val Gly Ala His Thr Val Ser Ala Tyr Glu His Val Thr Val Ile  
 805 810 815  
 Pro Asn Thr Val Gly Val Pro Tyr Lys Thr Leu Val Asn Arg Pro Gly  
 820 825 830  
 Tyr Ser Pro Met Val Leu Glu Met Glu Leu Leu Ser Val Thr Leu Glu  
 835 840 845  
 Pro Thr Leu Ser Leu Asp Tyr Ile Thr Cys Glu Tyr Lys Thr Val Ile  
 850 855 860  
 Pro Ser Pro Tyr Val Lys Cys Cys Gly Thr Ala Glu Cys Lys Asp Lys  
 865 870 875 880  
 Asn Leu Pro Asp Tyr Ser Cys Lys Val Phe Thr Gly Val Tyr Pro Phe  
 885 890 895  
 Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu  
 900 905 910

## Sequence Listing-CHK-II

Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala  
 915 920 925  
 Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val  
 930 935 940  
 Leu Tyr Gln Gly Asn Asn Ile Thr Val Thr Ala Tyr Ala Asn Gly Asp  
 945 950 955 960  
 His Ala Val Thr Val Lys Asp Ala Lys Phe Ile Val Gly Pro Met Ser  
 965 970 975  
 Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp  
 980 985 990  
 Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Gly Arg Pro Gly Gln  
 995 1000 1005  
 Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Glu Asp Val Tyr  
 1010 1015 1020  
 Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Ala Gly Thr Val  
 1025 1030 1035  
 His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu  
 1040 1045 1050  
 Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys  
 1055 1060 1065  
 Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly  
 1070 1075 1080  
 Asn Met Pro Ile Ser Ile Asp Ile Pro Glu Ala Ala Phe Thr Arg  
 1085 1090 1095  
 Val Val Asp Ala Pro Ser Leu Thr Asp Met Ser Cys Glu Val Pro  
 1100 1105 1110  
 Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys  
 1115 1120 1125  
 Tyr Ala Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr  
 1130 1135 1140  
 Asn Ala Val Thr Ile Arg Glu Ala Glu Ile Glu Val Glu Gly Asn  
 1145 1150 1155

## Sequence listing-CHK-II

Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu  
1160 1165 1170

Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Glu  
1175 1180 1185

Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His  
1190 1195 1200

Thr Thr Leu Gly Val Gln Asp Ile Ser Ala Thr Ala Met Ser Trp  
1205 1210 1215

Val Gln Lys Ile Thr Gly Gly Val Gly Leu Val Val Ala Val Ala  
1220 1225 1230

Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His  
1235 1240 1245

<210> 11  
<211> 1248  
<212> PRT  
<213> Chikungunya virus

<400> 11

Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro  
1 5 10 15

Arg Pro Trp Thr Pro Arg Ser Thr Ile Gln Ile Ile Arg Pro Arg Pro  
20 25 30

Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val  
35 40 45

Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn  
50 55 60

Arg Lys Asn Lys Lys Gln Lys Gln Lys Gln Ala Pro Gln Asn Asn  
65 70 75 80

Thr Asn Gln Lys Lys Gln Pro Pro Lys Lys Lys Pro Ala Gln Lys Lys  
85 90 95

Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp  
100 105 110

Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Thr Gly Tyr Ala Cys  
115 120 125

## Sequence listing-CHK-II

Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile  
 130 135 140  
 Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr  
 145 150 155 160  
 Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser  
 165 170 175  
 Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly  
 180 185 190  
 Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly  
 195 200 205  
 Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val  
 210 215 220  
 Val Ala Ile Val Leu Gly Gly Val Asn Glu Gly Ala Arg Thr Ala Leu  
 225 230 235 240  
 Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu  
 245 250 255  
 Gly Ala Glu Glu Trp Ser Leu Ala Ile Pro Val Met Cys Leu Leu Ala  
 260 265 270  
 Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr  
 275 280 285  
 Glu Lys Glu Pro Glu Glu Thr Leu Arg Met Leu Glu Asp Asn Val Met  
 290 295 300  
 Arg Pro Gly Tyr Tyr Gln Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro  
 305 310 315 320  
 His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala  
 325 330 335  
 Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser  
 340 345 350  
 Cys His Ser Pro Val Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp  
 355 360 365  
 Gly Thr Leu Lys Ile Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp  
 370 375 380



## Sequence listing-CHK-II

Asp Ser His Asp Trp Thr Lys Leu Arg Tyr Met Asp Asn His Met Pro  
 385 390 395 400  
 Ala Asp Ala Glu Arg Ala Gly Leu Phe Val Arg Thr Ser Ala Pro Cys  
 405 410 415  
 Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys  
 420 425 430  
 Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His  
 435 440 445  
 Ser Cys Thr His Pro Phe His His Asp Pro Pro Val Ile Gly Arg Glu  
 450 455 460  
 Lys Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr  
 465 470 475 480  
 Tyr Val Gln Ser Thr Ala Ala Thr Thr Glu Glu Ile Glu Val His Met  
 485 490 495  
 Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Ser Gln Gln Ser Gly Asn  
 500 505 510  
 Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys  
 515 520 525  
 Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn  
 530 535 540  
 Cys Lys Val Asp Gln Cys His Ala Ala Val Thr Asn His Lys Lys Trp  
 545 550 555 560  
 Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg  
 565 570 575  
 Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Ala Thr Cys Arg  
 580 585 590  
 Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val  
 595 600 605  
 Ile Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn  
 610 615 620  
 Met Gly Glu Glu Pro Asn Tyr Gln Glu Glu Trp Val Met His Lys Lys

## Sequence listing-CHK-II

Sequence Alignment																
Protein: 1000																
Residue Number																
625	Glu	Val	Val	Leu	Thr	Val	Pro	Thr	Glu	Gly	Leu	Glu	Val	Thr	Trp	Gly
				645						650					655	
Asn	Asn	Glu	Pro	Tyr	Lys	Tyr	Trp	Pro	Gln	Leu	Ser	Thr	Asn	Gly	Thr	
			660					665					670			
Ala	His	Gly	His	Pro	His	Glu	Ile	Ile	Leu	Tyr	Tyr	Tyr	Glu	Leu	Tyr	
		675					680					685				
Pro	Thr	Met	Thr	Val	Val	Val	Val	Ser	Val	Ala	Thr	Phe	Ile	Leu	Leu	
	690					695					700					
Ser	Met	Val	Gly	Met	Ala	Ala	Gly	Met	Cys	Met	Cys	Ala	Arg	Arg	Arg	
705					710				715						720	
Cys	Ile	Thr	Pro	Tyr	Glu	Leu	Thr	Pro	Gly	Ala	Thr	Val	Pro	Phe	Leu	
				725					730					735		
Leu	Ser	Leu	Ile	Cys	Cys	Ile	Arg	Thr	Ala	Lys	Ala	Ala	Thr	Tyr	Gln	
			740					745					750			
Glu	Ala	Ala	Ile	Tyr	Leu	Trp	Asn	Glu	Gln	Gln	Pro	Leu	Phe	Trp	Leu	
		755					760					765				
Gln	Ala	Leu	Ile	Pro	Leu	Ala	Ala	Leu	Ile	Val	Leu	Cys	Asn	Cys	Leu	
	770					775					780					
Arg	Leu	Leu	Pro	Cys	Cys	Cys	Lys	Thr	Leu	Ala	Phe	Leu	Ala	Val	Met	
785					790					795					800	
Ser	Val	Gly	Ala	His	Thr	Val	Ser	Ala	Tyr	Glu	His	Val	Thr	Val	Ile	
				805					810					815		
Pro	Asn	Thr	Val	Gly	Val	Pro	Tyr	Lys	Thr	Leu	Val	Asn	Arg	Pro	Gly	
			820					825					830			
Tyr	Ser	Pro	Met	Val	Leu	Glu	Met	Glu	Leu	Leu	Ser	Val	Thr	Leu	Glu	
		835					840					845				
Pro	Thr	Leu	Ser	Leu	Asp	Tyr	Ile	Thr	Cys	Glu	Tyr	Lys	Thr	Val	Ile	
	850					855					860					
Pro	Ser	Pro	Tyr	Val	Lys	Cys	Cys	Gly	Thr	Ala	Glu	Cys	Lys	Asp	Lys	
865					870					875					880	

## Sequence listing-CHK-II

Asn Leu Pro Asp Tyr Ser Cys Lys Val Phe Thr Gly Val Tyr Pro Phe  
885 890 895

Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu  
900 905 910

Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala  
915 920 925

Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val  
930 935 940

Leu Tyr Gln Gly Asn Asn Ile Thr Val Thr Ala Tyr Ala Asn Gly Asp  
945 950 955 960

His Ala Val Thr Val Lys Asp Ala Lys Phe Ile Val Gly Pro Met Ser  
965 970 975

Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp  
980 985 990

Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Arg Arg Pro Gly Gln  
995 1000 1005

Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Glu Asp Val Tyr  
1010 1015 1020

Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Ala Gly Thr Val  
1025 1030 1035

His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu  
1040 1045 1050

Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys  
1055 1060 1065

Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly  
1070 1075 1080

Asn Met Pro Ile Ser Ile Asp Ile Pro Glu Ala Ala Phe Thr Arg  
1085 1090 1095

Val Val Asp Ala Pro Ser Leu Thr Asp Met Ser Cys Glu Val Pro  
1100 1105 1110

Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys  
1115 1120 1125



## Sequence listing-CHK-II

Tyr Ala Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr  
1130 1135 1140

Asn Ala Val Thr Ile Arg Glu Ala Glu Ile Glu Val Glu Gly Asn  
1145 1150 1155

Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu  
1160 1165 1170

Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Glu  
1175 1180 1185

Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His  
1190 1195 1200

Thr Thr Leu Gly Val Gln Asp Ile Ser Ala Thr Ala Met Ser Trp  
1205 1210 1215

Val Gln Lys Ile Thr Gly Gly Val Gly Leu Val Val Ala Val Ala  
1220 1225 1230

Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His  
1235 1240 1245

<210> 12  
<211> 1248  
<212> PRT  
<213> Chikungunya virus

<400> 12

Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro  
1 5 10 15

Arg Pro Trp Thr Pro Arg Ser Thr Ile Gln Ile Ile Arg Pro Arg Pro  
20 25 30

Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val  
35 40 45

Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn  
50 55 60

Arg Lys Asn Lys Lys Gln Lys Gln Lys Gln Gln Ala Pro Gln Asn Asn  
65 70 75 80

Thr Asn Gln Lys Lys Gln Pro Pro Lys Lys Lys Pro Ala Gln Lys Lys  
85 90 95

## Sequence listing-CHK-II

Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp  
 100 105 110  
 Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Thr Gly Tyr Ala Cys  
 115 120 125  
 Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile  
 130 135 140  
 Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr  
 145 150 155 160  
 Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser  
 165 170 175  
 Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly  
 180 185 190  
 Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly  
 195 200 205  
 Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val  
 210 215 220  
 Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu  
 225 230 235 240  
 Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu  
 245 250 255  
 Gly Ala Glu Glu Trp Ser Leu Ala Ile Pro Val Met Cys Leu Leu Ala  
 260 265 270  
 Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr  
 275 280 285  
 Glu Lys Glu Pro Glu Glu Thr Leu Arg Met Leu Glu Asp Asn Val Met  
 290 295 300  
 Arg Pro Gly Tyr Tyr Gln Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro  
 305 310 315 320  
 His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala  
 325 330 335  
 Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser  
 340 345 350

## Sequence listing-CHK-II

Cys His Ser Pro Val Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp  
 355 360 365  
 Gly Thr Leu Lys Ile Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp  
 370 375 380  
 Asp Ser His Asp Trp Thr Glu Leu Arg Tyr Met Asp Asn His Met Pro  
 385 390 395 400  
 Ala Asp Ala Glu Arg Ala Gly Leu Phe Val Arg Thr Ser Ala Pro Cys  
 405 410 415  
 Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys  
 420 425 430  
 Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His  
 435 440 445  
 Ser Cys Thr His Pro Phe His His Asp Pro Pro Val Ile Gly Arg Glu  
 450 455 460  
 Lys Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr  
 465 470 475 480  
 Tyr Val Gln Ser Thr Ala Ala Thr Thr Glu Glu Ile Glu Val His Met  
 485 490 495  
 Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Ser Gln Gln Ser Gly Asn  
 500 505 510  
 Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys  
 515 520 525  
 Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn  
 530 535 540  
 Cys Lys Val Asp Gln Cys His Ala Ala Val Thr Asn His Lys Lys Trp  
 545 550 555 560  
 Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg  
 565 570 575  
 Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Ala Thr Cys Arg  
 580 585 590  
 Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val  
 Page 38

## Sequence listing-CHK-II

595

600

605

Ile Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn  
610 615 620

Met Gly Glu Glu Pro Asn Tyr Gln Glu Glu Trp Val Met His Lys Lys  
625 630 635 640

Glu Val Val Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly  
645 650 655

Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr  
660 665 670

Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr  
675 680 685

Pro Thr Met Thr Val Val Val Val Ser Val Ala Thr Phe Ile Leu Leu  
690 695 700

Ser Met Val Gly Met Ala Ala Gly Met Cys Met Cys Ala Arg Arg Arg  
705 710 715 720

Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu  
725 730 735

Leu Ser Leu Ile Cys Cys Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln  
740 745 750

Glu Ala Ala Ile Tyr Leu Trp Asn Glu Gln Gln Pro Leu Phe Trp Leu  
755 760 765

Gln Ala Leu Ile Pro Leu Ala Ala Leu Ile Val Leu Cys Asn Cys Leu  
770 775 780

Arg Leu Leu Pro Cys Cys Cys Lys Thr Leu Ala Phe Leu Ala Val Met  
785 790 795 800

Ser Val Gly Ala His Thr Val Ser Ala Tyr Glu His Val Thr Val Ile  
805 810 815

Pro Asn Thr Val Gly Val Pro Tyr Lys Thr Leu Val Asn Arg Pro Gly  
820 825 830

Tyr Ser Pro Met Val Leu Glu Met Glu Leu Leu Ser Val Thr Leu Glu  
835 840 845

## Sequence listing-CHK-II

Pro Thr Leu Ser Leu Asp Tyr Ile Thr Cys Glu Tyr Lys Thr Val Ile  
 850 855 860

Pro Ser Pro Tyr Val Lys Cys Cys Gly Thr Ala Glu Cys Lys Asp Lys  
 865 870 875 880

Asn Leu Pro Asp Tyr Ser Cys Lys Val Phe Thr Gly Val Tyr Pro Phe  
 885 890 895

Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu  
 900 905 910

Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala  
 915 920 925

Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val  
 930 935 940

Leu Tyr Gln Gly Asn Asn Ile Thr Val Thr Ala Tyr Ala Asn Gly Asp  
 945 950 955 960

His Ala Val Thr Val Lys Asp Ala Lys Phe Ile Val Gly Pro Met Ser  
 965 970 975

Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp  
 980 985 990

Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Gly Arg Pro Gly Gln  
 995 1000 1005

Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Glu Asp Val Tyr  
 1010 1015 1020

Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Ala Gly Thr Val  
 1025 1030 1035

His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu  
 1040 1045 1050

Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys  
 1055 1060 1065

Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly  
 1070 1075 1080

Asn Met Pro Ile Ser Ile Asp Ile Pro Glu Ala Ala Phe Thr Arg  
 1085 1090 1095



## Sequence listing-CHK-II

Val Val Asp Ala Pro Ser Leu Thr Asp Met Ser Cys Glu Val Pro  
1100 1105 1110

Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys  
1115 1120 1125

Tyr Ala Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr  
1130 1135 1140

Asn Ala Val Thr Ile Arg Glu Ala Glu Ile Glu Val Glu Gly Asn  
1145 1150 1155

Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu  
1160 1165 1170

Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Glu  
1175 1180 1185

Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His  
1190 1195 1200

Thr Thr Leu Gly Val Gln Asp Ile Ser Ala Thr Ala Met Ser Trp  
1205 1210 1215

Val Gln Lys Ile Thr Gly Gly Val Gly Leu Val Val Ala Val Ala  
1220 1225 1230

Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His  
1235 1240 1245

<210> 13  
<211> 1248  
<212> PRT  
<213> Chikungunya virus

<400> 13

Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro  
1 5 10 15

Arg Pro Trp Thr Pro Arg Ser Thr Ile Gln Ile Ile Arg Pro Arg Pro  
20 25 30

Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val  
35 40 45

Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn  
50 55 60

## Sequence listing-CHK-II

Arg Lys Asn Lys Lys Gln Lys Gln Lys Gln Gln Ala Pro Gln Asn Asn  
 65 70 75 80  
 Thr Asn Gln Lys Lys Gln Pro Pro Lys Lys Lys Pro Ala Gln Lys Lys  
 85 90 95  
 Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp  
 100 105 110  
 Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Thr Gly Tyr Ala Cys  
 115 120 125  
 Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile  
 130 135 140  
 Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr  
 145 150 155 160  
 Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser  
 165 170 175  
 Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly  
 180 185 190  
 Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly  
 195 200 205  
 Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val  
 210 215 220  
 Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu  
 225 230 235 240  
 Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu  
 245 250 255  
 Gly Ala Glu Glu Trp Ser Leu Ala Ile Pro Val Met Cys Leu Leu Ala  
 260 265 270  
 Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr  
 275 280 285  
 Glu Lys Glu Pro Glu Glu Thr Leu Arg Met Leu Glu Asp Asn Val Met  
 290 295 300  
 Arg Pro Gly Tyr Tyr Gln Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro  
 305 310 315 320

## Sequence listing-CHK-II

His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala  
 325 330 335  
 Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser  
 340 345 350  
 Cys His Ser Pro Val Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp  
 355 360 365  
 Gly Thr Leu Lys Ile Gln Val Ser Leu Gln Ile Arg Ile Lys Thr Asp  
 370 375 380  
 Asp Ser His Asp Trp Thr Lys Leu Arg Tyr Met Asp Asn His Met Pro  
 385 390 395 400  
 Ala Asp Ala Glu Arg Ala Gly Leu Phe Val Arg Thr Ser Ala Pro Cys  
 405 410 415  
 Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys  
 420 425 430  
 Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His  
 435 440 445  
 Ser Cys Thr His Pro Phe His His Asp Pro Pro Val Ile Gly Arg Glu  
 450 455 460  
 Lys Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr  
 465 470 475 480  
 Tyr Val Gln Ser Thr Ala Ala Thr Thr Glu Glu Ile Glu Val His Met  
 485 490 495  
 Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Ser Gln Gln Ser Gly Asn  
 500 505 510  
 Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys  
 515 520 525  
 Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn  
 530 535 540  
 Cys Lys Val Asp Gln Cys His Ala Ala Val Thr Asn His Lys Lys Trp  
 545 550 555 560  
 Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg  
 Page 43

## Sequence listing-CHK-II

565

570

575

Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Val Thr Cys Arg  
 580 585 590  
 Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val  
 595 600 605  
 Ile Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn  
 610 615 620  
 Met Gly Glu Glu Pro Asn Tyr Gln Glu Glu Trp Val Met His Lys Lys  
 625 630 635 640  
 Glu Val Val Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly  
 645 650 655  
 Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr  
 660 665 670  
 Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr  
 675 680 685  
 Pro Thr Met Thr Val Val Val Val Ser Val Ala Thr Phe Ile Leu Leu  
 690 695 700  
 Ser Met Val Gly Met Ala Ala Gly Met Cys Met Cys Ala Arg Arg Arg  
 705 710 715 720  
 Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu  
 725 730 735  
 Leu Ser Leu Ile Cys Cys Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln  
 740 745 750  
 Glu Ala Ala Ile Tyr Leu Trp Asn Glu Gln Gln Pro Leu Phe Trp Leu  
 755 760 765  
 Gln Ala Leu Ile Pro Leu Ala Ala Leu Ile Val Leu Cys Asn Cys Leu  
 770 775 780  
 Arg Leu Leu Pro Cys Cys Cys Lys Thr Leu Ala Phe Leu Ala Val Met  
 785 790 795 800  
 Ser Val Gly Ala His Thr Val Ser Ala Tyr Glu His Val Thr Val Ile  
 805 810 815

## Sequence listing-CHK-II

Pro Asn Thr Val Gly Val Pro Tyr Lys Thr Leu Val Asn Arg Pro Gly  
820 825 830

Tyr Ser Pro Met Val Leu Glu Met Glu Leu Leu Ser Val Thr Leu Glu  
835 840 845

Pro Thr Leu Ser Leu Asp Tyr Ile Thr Cys Glu Tyr Lys Thr Val Ile  
850 855 860

Pro Ser Leu Tyr Val Lys Cys Cys Gly Thr Ala Glu Cys Lys Asp Lys  
865 870 875 880

Asn Leu Pro Asp Tyr Ser Cys Lys Val Phe Thr Gly Val Tyr Pro Phe  
885 890 895

Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu  
900 905 910

Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala  
915 920 925

Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val  
930 935 940

Leu Tyr Gln Gly Asn Asn Ile Thr Val Thr Ala Tyr Ala Asn Gly Asp  
945 950 955 960

His Ala Val Thr Val Lys Asp Ala Lys Phe Ile Val Gly Pro Met Ser  
965 970 975

Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp  
980 985 990

Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Gly Arg Pro Gly Gln  
995 1000 1005

Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Glu Asp Val Tyr  
1010 1015 1020

Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Ala Gly Thr Val  
1025 1030 1035

His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu  
1040 1045 1050

Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys  
1055 1060 1065



## Sequence listing-CHK-II

Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly  
 1070 1075 1080

Asn Met Pro Ile Ser Ile Asp Ile Pro Glu Ala Ala Phe Thr Arg  
 1085 1090 1095

Val Val Asp Ala Pro Ser Leu Thr Asp Met Ser Cys Glu Val Pro  
 1100 1105 1110

Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys  
 1115 1120 1125

Tyr Ala Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr  
 1130 1135 1140

Asn Ala Val Thr Ile Arg Glu Ala Glu Ile Glu Val Glu Gly Asn  
 1145 1150 1155

Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu  
 1160 1165 1170

Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Glu  
 1175 1180 1185

Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His  
 1190 1195 1200

Thr Thr Leu Gly Val Gln Asp Ile Ser Ala Thr Ala Met Ser Trp  
 1205 1210 1215

Val Gln Lys Ile Thr Gly Gly Val Gly Leu Val Val Ala Val Ala  
 1220 1225 1230

Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His  
 1235 1240 1245

<210> 14  
 <211> 1248  
 <212> PRT  
 <213> Chikungunya virus

<400> 14

Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro  
 1 5 10 15

Arg Pro Trp Thr Pro Arg Ser Thr Ile Gln Ile Ile Arg Pro Arg Pro  
 20 25 30

## Sequence listing-CHK-II

Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val  
 35 40 45  
 Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn  
 50 55 60  
 Arg Lys Asn Lys Lys Gln Lys Gln Lys Gln Gln Ala Pro Gln Asn Asn  
 65 70 75 80  
 Thr Asn Gln Lys Lys Gln Pro Pro Lys Lys Lys Pro Ala Gln Lys Lys  
 85 90 95  
 Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp  
 100 105 110  
 Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Thr Gly Tyr Ala Cys  
 115 120 125  
 Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile  
 130 135 140  
 Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr  
 145 150 155 160  
 Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser  
 165 170 175  
 Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly  
 180 185 190  
 Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly  
 195 200 205  
 Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val  
 210 215 220  
 Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu  
 225 230 235 240  
 Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu  
 245 250 255  
 Gly Ala Glu Glu Trp Ser Leu Ala Ile Pro Val Met Cys Leu Leu Ala  
 260 265 270  
 Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr  
 275 280 285

## Sequence listing-CHK-II

Glu Lys Glu Pro Glu Glu Thr Leu Arg Met Leu Glu Asp Asn Val Met  
 290 295 300  
 Arg Pro Gly Tyr Tyr Gln Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro  
 305 310 315 320  
 His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala  
 325 330 335  
 Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser  
 340 345 350  
 Cys His Ser Pro Val Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp  
 355 360 365  
 Gly Thr Leu Lys Ile Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp  
 370 375 380  
 Asp Ser His Asp Trp Thr Lys Leu Arg Tyr Met Asp Asn His Met Pro  
 385 390 395 400  
 Ala Asp Ala Glu Arg Ala Gly Leu Phe Val Arg Thr Ser Ala Pro Cys  
 405 410 415  
 Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys  
 420 425 430  
 Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His  
 435 440 445  
 Ser Cys Thr His Pro Phe His His Asp Pro Pro Val Ile Gly Arg Glu  
 450 455 460  
 Lys Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr  
 465 470 475 480  
 Tyr Val Gln Ser Thr Ala Ala Thr Thr Glu Glu Ile Glu Val His Met  
 485 490 495  
 Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Ser Gln Gln Ser Gly Asn  
 500 505 510  
 Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys  
 515 520 525  
 Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn  
 Page 48

Sequence listing-CHK-II  
540

530

535

Cys Lys Val Asp Gln Cys His Ala Ala Val Thr Asn His Lys Lys Trp  
 545 550 555 560  
 Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg  
 565 570 575  
 Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Val Thr Cys Arg  
 580 585 590  
 Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val  
 595 600 605  
 Ile Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn  
 610 615 620  
 Met Gly Glu Glu Pro Asn Tyr Gln Glu Glu Trp Val Met His Lys Lys  
 625 630 635 640  
 Glu Val Val Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly  
 645 650 655  
 Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr  
 660 665 670  
 Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr  
 675 680 685  
 Pro Thr Met Thr Val Val Val Val Ser Val Ala Thr Phe Ile Leu Leu  
 690 695 700  
 Ser Met Val Gly Met Ala Ala Gly Met Cys Met Cys Ala Arg Arg Arg  
 705 710 715 720  
 Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu  
 725 730 735  
 Leu Ser Leu Ile Cys Cys Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln  
 740 745 750  
 Glu Ala Ala Ile Tyr Leu Trp Asn Glu Gln Gln Pro Leu Phe Trp Leu  
 755 760 765  
 Gln Ala Leu Ile Pro Leu Ala Ala Leu Ile Val Leu Cys Asn Cys Leu  
 770 775 780

## Sequence listing-CHK-II

Arg Leu Leu Pro Cys Cys Cys Lys Thr Leu Ala Phe Leu Ala Val Met  
 785 790 800  
 Ser Val Gly Ala His Thr Val Ser Ala Tyr Glu His Val Thr Val Ile  
 805 810 815  
 Pro Asn Thr Val Gly Val Pro Tyr Lys Thr Leu Val Asn Arg Pro Gly  
 820 825 830  
 Tyr Ser Pro Met Val Leu Glu Met Glu Leu Leu Ser Val Thr Leu Glu  
 835 840 845  
 Pro Thr Leu Ser Leu Asp Tyr Ile Thr Cys Glu Tyr Lys Thr Val Ile  
 850 855 860  
 Pro Ser Pro Tyr Val Lys Cys Cys Gly Thr Ala Glu Cys Lys Asp Lys  
 865 870 875 880  
 Asn Leu Pro Asp Tyr Ser Cys Arg Val Phe Thr Gly Val Tyr Pro Phe  
 885 890 895  
 Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu  
 900 905 910  
 Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala  
 915 920 925  
 Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val  
 930 935 940  
 Leu Tyr Gln Gly Asn Asn Ile Thr Val Thr Ala Tyr Ala Asn Gly Asp  
 945 950 955 960  
 His Ala Val Thr Val Lys Asp Ala Lys Phe Ile Val Gly Pro Met Ser  
 965 970 975  
 Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp  
 980 985 990  
 Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Gly Arg Pro Gly Gln  
 995 1000 1005  
 Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Lys Asp Val Tyr  
 1010 1015 1020  
 Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Ala Gly Thr Val  
 1025 1030 1035



## Sequence listing-CHK-II

His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu  
 1040 1045 1050  
 Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys  
 1055 1060 1065  
 Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly  
 1070 1075 1080  
 Asn Met Pro Ile Ser Ile Asp Ile Pro Glu Ala Ala Phe Thr Arg  
 1085 1090 1095  
 Val Val Asp Ala Pro Ser Leu Thr Asp Met Ser Cys Glu Val Pro  
 1100 1105 1110  
 Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys  
 1115 1120 1125  
 Tyr Ala Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr  
 1130 1135 1140  
 Asn Ala Val Thr Ile Arg Glu Ala Glu Ile Glu Val Glu Gly Asn  
 1145 1150 1155  
 Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu  
 1160 1165 1170  
 Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Glu  
 1175 1180 1185  
 Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His  
 1190 1195 1200  
 Thr Thr Leu Gly Val Gln Asp Ile Ser Ala Thr Ala Met Ser Trp  
 1205 1210 1215  
 Val Gln Lys Ile Thr Gly Gly Val Gly Leu Val Val Ala Val Ala  
 1220 1225 1230  
 Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His  
 1235 1240 1245

<210> 15  
 <211> 11234  
 <212> DNA  
 <213> Chikungunya virus  
 <400> 15

## Sequence listing-CHK-II

atggatcctg	tgtacgtgga	catagacgct	gacagcgctt	ttttgaaggc	cctgcaacgt	60
gcgtacccca	tgtttgaggt	ggaaccaagg	caggtcacac	cgaatgacca	tgctaattgct	120
agagcgttct	cgcattctagc	tataaaacta	atagagcagg	aaattgaccc	cgactcaacc	180
atcctggata	tcggcagtgc	gccagcaagg	aggatgatgt	cggacaggaa	gtaccactgc	240
gtctgcccga	tgcgacgtgc	ggaagatccc	gagagactcg	ctaattatgc	gagaaaagcta	300
gcatctgccc	caggaaaagt	cctggacaga	aacatctctg	gaaagatcgg	ggacttacaa	360
gcagtaattg	ccgtgccaga	caaggagacg	ccaacattct	gcttacacac	agacgtctca	420
tgtagacaga	gagcagacgt	cgctatatac	caagacgtct	atgctgtaca	cgacccacg	480
tcgctatacc	accaggcgat	taaaggggtc	cgagtggcgt	actgggttgg	gttcgacaca	540
accccgttca	tgtacaatgc	catggcgggt	gcctaccctt	catactcgac	aaactgggca	600
gatgagcagg	tactgaaggc	taagaacata	ggattatgtt	caacagacct	gacggaaggt	660
agacgaggca	agttgtctat	tatgagaggg	aaaaagctaa	aaccgtgcga	ccgtgtgctg	720
ttctcagtag	ggtcaacgct	ttacccggaa	agccgcaagc	tacttaagag	ctggcacctg	780
ccatcgggtg	tccattttaa	gggcaaactc	agcttcacat	gccgctgtga	tacagtgggt	840
tcgtgtgagg	gctacgtcgt	taagagaata	acgatgagcc	caggccttta	tggaaaaacc	900
acagggatat	cggtaaccca	ccacgcagac	ggattcctga	tgtgcaagac	taccgacacg	960
gttgacggcg	aaagagtgtc	attctcgggt	tgcacatacg	tgccggcgac	catttgtgat	1020
caaatgaccg	gcatccttgc	tacagaagtc	acgccggagg	atgcacagaa	gctgttggtg	1080
gggctgaacc	agagaatagt	ggttaacggc	agaacgcaac	ggaatatgaa	caccatgaaa	1140
aattatctgc	ttcccgtggt	cgcccaagcc	ttcagtaagt	gggcaaagga	gtgccggaaa	1200
gacatggaag	atgaaaaact	cctgggggtc	agagaaagaa	cactgacctg	ctgctgtcta	1260
tgggcattca	agaagcagaa	aacacacacg	gtctacaaga	ggcctgatac	ccagtcaatt	1320
cagaagggtc	aggccgagtt	tgacagcttt	gtggtaccga	gtctgtggtc	gtccgggttg	1380
tcaatccctt	tgaggactag	aatcaaatgg	ttgttaagca	aggtgccaaa	aaccgacctg	1440
atcccataca	gcggagacgc	ccgagaagcc	cgggacgcag	aaaaagaagc	agaggaagaa	1500
cgagaagcag	aactgactcg	cgaagcccta	ccacctctac	aggcagcaca	ggaagatgtt	1560
caggtcgaag	tcgacgtgga	acagcttgag	gacagagcgg	gcgcaggaat	aatagagact	1620
ccgagaggag	ctatcaaagt	tactgcccga	ccaacagacc	acgtcgtggg	agagtacctg	1680
gtactctccc	cgcagaccgt	actacgtagc	cagaagctca	gtctgattca	cgctttggcg	1740
gagcaagtga	agacgtgcac	gcacaacgga	cgagcaggga	ggtatgcggg	cgaagcgtac	1800
gacggccgag	tcctagtgcc	ctcaggctat	gcaatctcgc	ctgaagactt	ccagagtcta	1860
agcgaaagcg	caacgatggg	gtataacgaa	agagagttcg	taaacagaaa	gctacaccat	1920

## Sequence listing-CHK-II

attgcatg	acggaccagc	cctgaacacc	gacgaagagt	cgatgagct	ggtgagggca	1980
gagaggacag	aacacgagta	cgtctacgac	gtggatcaga	gaagatgctg	taagaaggaa	2040
gaagccgag	gactgggtact	ggtgggcgac	ttgactaatc	cgccctacca	cgaattcgca	2100
tatgaagggc	taaaaatccg	ccctgcctgc	ccatacaaaa	ttgcagtcac	aggagtcttc	2160
ggagtaccgg	gatctggcaa	gtcagctatt	atcaagaacc	tagttaccag	gcaggacctg	2220
gtgactagt	gaaagaaaga	aaactgcca	gaaatcacca	ccgacgtgat	gagacagaga	2280
ggtctagaga	tatctgcacg	tacggttgac	tcgctgctct	tgaatggatg	caacagacca	2340
gtcgacgtgt	tgtacgtaga	cgaggcggtt	gcgtgccact	ctggaacgct	acttgctttg	2400
atcgcttgg	tgagaccaag	gcagaaagt	gtactttgtg	gtgacccgaa	gcagtgcggc	2460
ttcttcaata	tgatgcagat	gaaagtcaac	tacaatcaca	acatctgcac	ccaagtgtac	2520
cacaaaagta	tctccaggcg	gtgtacactg	cctgtgaccg	ccattgtgtc	atcgttgcac	2580
tacgaaggca	aaatgcgcac	tacgaatgag	tacaacaagc	cgattgtagt	ggacactaca	2640
ggctcaacaa	aacctgacct	tggagacctc	gtgttaacgt	gcttcagagg	gtgggttaaa	2700
caactgcaaa	ttgactatcg	tggatacgag	gtcatgacag	cagccgcac	ccaaggggta	2760
accagaaaag	gagtttacgc	agttagacaa	aaagttaatg	aaaacccgct	ctatgcatca	2820
acgtcagagc	acgtcaacgt	actcctaacg	cgtacggaag	gtaaactggg	atggaagaca	2880
ctttccggcg	acctgtggat	aaagacgctg	cagaaccac	cgaaaggaaa	cttcaaagca	2940
actattaagg	agtgggaggt	ggagcatgca	tcaataatgg	cgggcatctg	cagtcaccaa	3000
atgaccttcg	atacattcca	aaataaagcc	aacgtttgtt	gggctaagag	cttggtccct	3060
atcctcga	agcggggat	aaaactaaat	gataggcagt	ggtctcagat	aattcaagcc	3120
ttcaaagaag	acaagcata	ctcacctgaa	gtagccctga	atgaaatatg	tacgcgcatg	3180
tatggggtgg	atctagacag	cgggctat	ttctaaaccgt	tggtgtctgt	gtattacgcg	3240
gataaccact	gggataatag	gcctggagg	aaaatgttcg	gatttaaccc	cgaggcagca	3300
tccattctag	aaagaaagta	tccattcaca	aaagggaggt	ggaacatcaa	caagcagatc	3360
tgctgacta	ccaggaggat	agaagacttt	aaccctacca	ccaacatcat	accggccaac	3420
aggagactac	cacactcatt	agtggccgaa	caccgcccag	taaaagggga	aagaatggaa	3480
tggtgtggt	acaagataaa	cggccaccac	gtgctcctgg	tcagtggcta	taaccttgca	3540
ctgcctacta	agagagtcac	ttgggtagcg	ccgttaggtg	tccgcggagc	ggactacaca	3600
tacaacctag	agttgggtct	gccagcaacg	cttggtaggt	atgaccttgt	ggtcataaac	3660
atccacacac	cttttcgcac	acaccattac	caacagtgcg	tcgaccacgc	aatgaaactg	3720
caaatgctcg	ggggtgactc	attgagactg	ctcaaaccgg	gcggctctct	attgatcaga	3780



## Sequence listing-CHK-II

gcatatggtt	acgcagatag	aaccagtga	cgagtcatt	gcgtattggg	acgcaagttt	3840
agatcgtcta	gagcgttgaa	accaccatgt	gtcaccagca	acactgagat	gtttttccta	3900
ttcagcaact	ttgacaatgg	cagaaggaat	ttcacaactc	atgtcatgaa	caatcaactg	3960
aatgcagcct	tcgtaggaca	ggtcacccga	gcaggatgtg	caccgtcgtg	ccgggtaaaa	4020
cgcatggaca	tcgcgaagaa	cgatgaagag	tgcgtagtca	acgccgctaa	ccctcgcggg	4080
ttaccgggtg	acggtgtttg	caaggcagta	tacaaaaaat	ggccggagtc	ctttaagaac	4140
agtgcacac	cagtgggaac	cgcaaaaaca	gttatgtgcg	gtacgtatcc	agtaatccac	4200
gctgttgga	caaacttctc	taattattcg	gagtcgtgaag	gggaccggga	attggcagct	4260
gcctatcgag	aagtcgaaa	ggaagtaact	aggctgggag	taaatagtgt	agctatacct	4320
ctcctctcca	caggtgtata	ctcaggaggg	aaagacaggc	tgaccagtc	actgaaccac	4380
ctctttacag	ccatggactc	gacggatgca	gacgtggtca	tctactgccg	cgacaaagaa	4440
tgggagaaga	aaatatctga	ggccatacag	atgcggaccc	aagtagagct	gctggatgag	4500
cacatctcca	tagactgcga	tattgttcgc	gtgcaccctg	acagcagctt	ggcaggcaga	4560
aaaggataca	gcaccacgga	aggcgcactg	tactcatatc	tagaaggga	ccgttttcat	4620
cagacggctg	tggatatggc	ggagatacat	actatgtggc	caaagcaaac	agaggccaat	4680
gagcaagtct	gcctatatgc	cctgggggaa	agtattgaat	cgatcaggca	gaaatgcccg	4740
gtggatgatg	cagacgcatt	atctccccc	aaaactgtcc	cgtgcctttg	ccgttacgct	4800
atgactccag	aacgcgtcac	ccggcttcgc	atgaaccacg	tcacaagcat	aattgtgtgt	4860
tcttcgtttc	ccctcccaa	gtacaaaata	gaaggagtgc	aaaaagtcaa	atgctctaag	4920
gtaatgctat	ttgaccacaa	cgtgccatcg	cgcgtaagtc	caagggaata	tagatcttcc	4980
caggagtctg	cacaggaggc	gagtacaatc	acgtcactga	cgcatagtca	attcgaccta	5040
agcgttgatg	gcgagatact	gcccgtccc	tcagacctgg	atgctgacgc	cccagcccta	5100
gaaccagcac	tagacgacgg	ggcgacacac	acgtgccat	ccacaaccgg	aaaccttgcg	5160
gccgtgtctg	actgggtaat	gagcaccgta	cctgtcgcgc	cgcccagaag	aaggcgaggg	5220
agaaacctga	ctgtgacatg	tgacgagaga	gaagggaata	taacacccat	ggctagcgtc	5280
cgattcttta	gggagagct	gtgtccggtc	gtacaagaaa	cagcggagac	gcgtgacaca	5340
gcaatgtctc	ttcaggcacc	accgaatacc	gccacggaac	cgaatcatcc	gccgatctcc	5400
ttcggagcat	caagcgagac	gttccccatt	acatttgggg	acttcaacga	aggagaaatc	5460
gaaagcttgt	cttctgagct	actaactttc	ggagacttct	taccaggaga	agtggatgac	5520
ttgacagaca	gcgactggtc	cacgtgctca	gacacggacg	acgagttatg	actagacagg	5580
gcagggtggg	atatattctc	gtcggacacc	ggtccaggtc	atttacaaca	gaagtcagta	5640
cgccagtcag	tgctgccggt	gaacaccctg	gaggaagtcc	acgaggagaa	gtgttaccca	5700

## Sequence listing-CHK-II

cctaagctgg atgaagcaaa ggagcaacta ttacttaaga aactccagga gagtgcattcc	5760
atggccaaca gaagcaggta tcagtcgcgc aaagtagaaa atatgaaagc agcaatcatc	5820
cagagactaa agagaggctg tagactatac ttaatgtcag agaccccaaa agtccttact	5880
taccggacta catatccggc gcctgtgtac tcgcctccga tcaacgtccg attgtccaat	5940
cccaggtccg cagtggcagc atgcaatgag ttcttagcta gaaactatcc aactgtctca	6000
tcataccaaa ttaccgacga gtatgatgca tatctagaca tgggtggacgg gtcggagagt	6060
tgcttgacc gagcgacatt caatccgtca aaactcagga gctaccgaa acagcacgct	6120
taccacgcgc cctccatcag aagcgtgtga ccgtcccat tccagaacac actacagaat	6180
gtactggcag cagccacgaa aagaaactgc aacgtcacac agatgaggga attaccact	6240
ttggactccg cagtattcaa cgtggagtgt ttcaaaaaat tcgcatgcaa ccaagaatac	6300
tggaagaat ttgctgccag ccctattagg ataacaactg agaatttagc aacctatgtt	6360
actaaactaa aagggccaaa agcagcagcg ctattcgcaa aaaccataa tctactgcca	6420
ctacaggaag taccaatgga taggttcaca gtagatatga aaaggacgt gaaggtgact	6480
cctggtacaa agcatacaga ggaaagacct aaggtgcagg ttatacaggc ggctgaacct	6540
ttggcgacag catacctatg tgggattcac agagagctgg ttaggaggct gaacgccgtc	6600
ctcctacca atgtacatac actatttgac atgtctgccg aggatttcga tgccatcata	6660
gccgcacact ttaagccagg agacactgtt ttggaaacgg acatagcctc ctttgataag	6720
agccaagatg attcacttgc gcttactgct ttgatgctgt tagaggattt aggggtggat	6780
cactccctgc tggacttgat agaggctgct ttcggagaga tttccagctg tcacctaccg	6840
acaggtacgc gcttcaagtt cggcgccatg atgaaatcag gtatgttcct aactctgttc	6900
gtcaacacat tgttaaakat caccatcgcc agccgagtgc tgggaagatc tctgacaaaa	6960
tccgcgtgcg cggccttcat cggcgacgac aacataatac atggagtcgt ctccgatgaa	7020
ttgatggcag ccagatgtgc cacttggtatg aacatggaag tgaagatcat agatgcagtt	7080
gtatccttga aagccccta cttttgtgga gggttttatac tgcacgatac tgtgacagga	7140
acagcttgca gagtggcaga cccgctaaaa aggcttttta aactgggcaa accgctagcg	7200
gcaggtgacg aacaagatga agatagaaga cgagcgtggt ctgacgaagt gatcagatgg	7260
caacgaacag ggctaattga tgagctggag aaagcggat actctaggta cgaagtgcag	7320
ggtatatcag ttgtggtaat gtccatggcc acctttgcaa gctccagatc caacttcgag	7380
aagctcagag gaccggtcat aactttgtac ggcggctcta aataggatg cactacagct	7440
acctattttg cagaagccga cagcaagtat ctaaacacta atcagctaca atggagttca	7500
tccaaccaca aactttttac aataggaggt accagcctcg accctggact ccgcgctcta	7560



## Sequence listing-CHK-II

ctatccaaat cattagggccc agaccgcgcc ctcagaggca agctgggcaa cttgcccagc	7620
tgatctcagc agttaataaa ctgacaatgc gcgcggtacc ccaacagaag ccacgcagga	7680
atcggaagaa taagaagcaa aagcaaaaac aacaggcgcc acaaaacaac acaaatacaa	7740
agaagcagcc acctaaaaag aaaccggctc aaaagaaaaa gaagccgggc cgagagaga	7800
ggatgtgcat gaaaatcgaa aatgattgta ttttcgaagt caagcacgaa ggtaaggtaa	7860
caggttacgc gtgcctgggtg ggggacaaag taatgaaacc agcacacgta aaggggacca	7920
tcgataacgc ggacctggcc aaactggcct ttaagcggtc atctaagtat gaccttgaat	7980
gcgcgcagat acccgtgcac atgaagtccg acgcttcgaa gttcacccat gagaaaccgg	8040
aggggtacta caactggcac cacggagcag tacagtactc agggaggccg ttcaccatcc	8100
ctacaggtgc tggcaaacca ggggacagcg gcagaccgat cttcgacaac aagggacgcg	8160
tggtggccat agtcttagga ggagctaata aaggagcccc tacagccctc tcggtggtga	8220
cctggaataa agacattgtc actaaaatca ccccgagggg ggccgaagag tggagtcttg	8280
ccatcccagt tatgtgcctg ctggcaaaca ccacgttccc ctgctcccag ccccttgca	8340
cgccctgctg ctacgaaaag gaaccggagg aaaccctacg catgcttgag gacaacgtca	8400
tgagacctgg gtactatcag ctgctacagg catccttaac atgttctccc caccgccagc	8460
gacgcagcac caaggacaac ttcaatgtct ataaagccac aagaccatac ttagctcact	8520
gtcccgactg tggagaaggg cattcgtgcc atagtcccgt agcactagaa cgcacagaa	8580
atgaagcgac agacgggacg ctgaaaatcc aggtctcctt gcaaatacaga ataaagacgg	8640
atgacagcca cgattggacc aagctgcgtt atatggacaa ccacatgcca gcagacgcag	8700
agagggcggg gctatttga agaacatcag caccgtgtac gattactgga acaatgggac	8760
acttcatacct ggcccgatgt ccaaaagggg aaactctgac ggtgggattc actgacagta	8820
ggaagattag tcattcatgt acgcacccat ttcaccacga ccctcctgtg ataggtcggg	8880
aaaaattcca ttcccagccg cagcacggta aagagctacc ttgcagcacg tacgtgcaga	8940
gcaccgccgc aactaccgag gagatagagg tacacatgcc cccagacacc cctgatcgca	9000
cattaatgtc acaacagtcc ggcaacgtaa agatcacagt caatggccag acggtgcggt	9060
acaagtgtaa ttgcggtggc tcaaatgaag gactaacaac tacagacaaa gtgattaata	9120
actgcaaggt tgatcaatgt catgccgcgg tcaccaatca caaaaagtgg cagtataact	9180
cccctctggt cccgcgtaat gctgaacttg gggaccgaaa aggaaaaatt cacatcccgt	9240
ttccgctggc aaatgcaaca tgcaggggtgc ctaaagcaag gaacccacc gtgacgtacg	9300
ggaaaaacca agtcataatg ctactgtatc ctgaccaccc aacactcctg tcctaccgga	9360
atatgggaga agaaccaaac tatcaagaag agtgggtgat gcataagaag gaagtcgtgc	9420
taaccgtgcc gactgaaggg ctcgaggtca cgtggggcaa caacgagccg tataagtatt	9480

## Sequence listing-CHK-II

ggccgcagtt atctacaaac ggtacagccc atggccaccc gcatgagata attctgtatt	9540
attatgagct gtaccctact atgactgtag tagttgtgtc agtggccacg ttcatactcc	9600
tgatgatggt gggatatggca gcggggatgt gcatgtgtgc acgacgcaga tgcatacacac	9660
cgtatgaact gacaccagga gctaccgtcc ctttcctgct tagcctaata tgctgcatca	9720
gaacagctaa agcggccaca taccaagagg ctgcgatata cctgtggaac gagcagcaac	9780
ctttgttttg gctacaagcc cttattccgc tggcagccct gattgttcta tgcaactgtc	9840
tgagactctt accatgctgc tgtaaaacgt tggctttttt agccgtaatg agcgtcggtg	9900
cccacactgt gagcgcgtac gaacacgtaa cagtgatccc gaacacgggtg ggagtaccgt	9960
ataagactct agtcaataga cctggctaca gccccatggt attggagatg gaactactgt	10020
cagtcacttt ggagccaaca ctatcgcttg attacatcac gtgcgagtac aaaaccgtca	10080
tcccgtctcc gtacgtgaag tgctgcggta cagcagagtg caaggacaaa aacctacctg	10140
actacagctg taaggctctc accggcgtct acccatttat gtggggcggc gcctactgct	10200
tctgcgacgc tgaaaacacg cagttgagcg aagcacatgt ggagaagtcc gaatcatgca	10260
aaacagaatt tgcatacaga tacagggctc ataccgcac tgcatacagct aagctccgcg	10320
tcctttacca aggaaataac atcactgtaa ctgcctatgc aaacggcgac catgccgtca	10380
cagttaagga cgccaaattc attgtggggc caatgtcttc agcctggaca cttttcgaca	10440
acaaaattgt ggtgtacaaa ggtgacgtct ataacatgga ctaccgcgcc tttggcgag	10500
gaagaccagg acaatttggc gatatccaaa gtcgcacacc tgagagtga gacgtctatg	10560
ctaatacaca actggtagct cagagaccgg ctgcgggtac ggtacacgtg ccatactctc	10620
aggcaccatc tggctttaag tattggctaa aagaacgcgg ggcgtcactg cagcacacag	10680
caccatttgg ctgccaata gcaacaaacc cggtgaagagc ggtgaactgc gccgtaggga	10740
acatgcccat ctccatcgac ataccggaag cggccttcac tagggtcgtc gacgcgccct	10800
ctttaacgga catgtcgtgc gaggtaccag cctgcaccca ttcctcagac tttggggcg	10860
tcgccattat taaatatgca gccagcaaga aaggcaagtg tgcgggtgcat tcgatgacta	10920
acgccgtcac tattcgggaa gctgagatag aagttgaagg gaattctcag ctgcaaattc	10980
ctttctcgac ggcttagcc agcgccgaat tccgcgtaca agtctgttct acacaagtac	11040
actgtgcagc tgagtgcac ccccggaagg accacatagt caactaccg gcgtcacata	11100
ccaccctcgg ggtccaggac atctccgcta cggcgatgtc atgggtgcag aagatcacgg	11160
gaggtgtggg actgggtgtt gctgttgccg cactgattct aatcgtggtg ctatgcgtgt	11220
cgttcagcag gcac	11234

## Sequence listing-CHK-II

&lt;211&gt; 11234

&lt;212&gt; DNA

&lt;213&gt; Chikungunya virus

&lt;400&gt; 16

atggatcctg tgtacgtgga catagacgct gacagcgcct ttttgaaggc cctgcaacgt	60
gcgtacccca tgtttgaggt ggaaccaagg caggtcacac cgaatgacca tgctaattgct	120
agagcggttct cgcattctagc tataaaacta atagagcagg aaattgaccc cgactcaacc	180
atcctggata tcggcagtgcc gccagcaagg aggatgatgt cggacaggaa gtaccactgc	240
gtctgcccga tgcgcagtgcc ggaagatccc gagagactcg ctaattatgc gagaaagcta	300
gcatctgccg caggaaaagt cctggacaga aacatctctg gaaagatcgg ggacttacia	360
gcagtaatgg ccgtgccaga caaggagacg ccaacattct gcttacacac agacgtctca	420
tgtagacaga gagcagacgt cgctatatac caagacgtct atgctgtaca cgcaccacg	480
tcgctatacc accaggcgat taaaggggtc cgagtggcgt actgggttggt gttcgacaca	540
accccgttca tgtacaatgc catggcgggt gcctaccctt catactcgac aaactgggca	600
gatgagcagg tactgaaggc taagaacata ggattatggt caacagacct gacggaaggt	660
agacgaggca agttgtctat tatgagaggg aaaaagctaa aaccgtgcga ccgtgtgctg	720
ttctcagtag ggtcaacgct ttaccgggaa agccgcaagc tacttaagag ctggcacctg	780
ccatcgggtg tccatttaaa gggcaaactc agcttcacat gccgctgtga tacagtgggt	840
tcgtgtgagg gctacgtcgt taagagaata acgatgagcc caggccttta tggaaaaacc	900
acaggggatg cggtaaccca ccacgcagac ggattcctga tgtgcaagac tactgacacg	960
gttgacggcg aaagagtgtc attctcgggt tgcacatacg tgccggcgac catttgtgat	1020
caaatgaccg gcatccttgc tacagaagtt acgccggagg atgcacagaa gctgttggtg	1080
gggctgaacc agagaatagt ggttaacggc agaacgcaac ggaatatgaa caccatgaaa	1140
aattatctgc ttcccgtggt cgcccaagcc ttcagtaagt gggcaaagga gtgccggaaa	1200
gacatggaag atgaaaaact cctgggggtc agagaaagaa cactgacctg ctgctgtcta	1260
tgggcattca agaagcagaa aacacacacg gtctacaaga ggcctgatac ccagtcaatt	1320
cagaaggttc aggccgagtt tgacagcttt gtggtaccga gtctgtgggt gtccgggttg	1380
tcaatccctt tgaggactag aatcaaattg ttgttaagca aggtgccaaa aaccgacctg	1440
atcccataca gcggagacgc ccgagaagcc cgggacgcag aaaaagaagc agaggaagaa	1500
cgagaagcag aactgactcg cgaagcccta ccacctctac aggcagcaca ggaagatggt	1560
caggtcgaaa tcgacgtgga acagcttgag gacagagcgg gcgcaggaat aatagagact	1620
ccgagaggag ctatcaaagt tactgcccaa ccaacagacc acgtcgtggg agagtacctg	1680
gtactctccc cgcagaccgt actacgtagc cagaagctca gtctgattca cgctttggcg	1740



## Sequence listing-CHK-II

gagcaagtga agacgtgcac gcacaacgga cgagcagggga ggtatgctgt cgaagcgtac	1800
gacggccgag tcttagtgcc ctcaggctat gcaatctcgc ctgaagactt ccagagtcta	1860
agcgaaagcg caacgatggg gtataacgaa agagagttcg taaacagaaa gctacaccat	1920
attgcatgac acggaccagc cctgaacacc gacgaagagt cgtatgagct ggtgagggca	1980
gagaggacag aacacgagta cgtctacgac gtggatcaga gaagatgctg taagaaggaa	2040
gaagccgag gactgggtact ggtgggcgac ttgactaatc cgccctacca cgaattcgca	2100
tatgaagggc taaaaatccg ccctgcctgc ccatacaaaa ttgcagtcac aggagtcttc	2160
ggagtaccgg gatctggcaa gtcagctatt atcaagaacc tagttaccag gcaggacctg	2220
gtgactagt gaaagaaaga aaactgccaa gaaatcacca ccgacgtgat gagacagaga	2280
ggtctagaga tatctgcacg tacggttgac tcgctgctct tgaatggatg caacagacca	2340
gtcgacgtgt tgtacgtaga cgaggcgttt gcgtgccact ctggaacgct acttgctttg	2400
atcgcttg gtagaccaag gcagaaagt gtactttgtg gtgaccgaa gcagtgcggc	2460
ttcttcaata tgatgcagat gaaagtcaac tacaatcaca acatctgcac ccaagtgtac	2520
cacaaaagta tctccaggcg gtgtacactg cctgtgaccg ccattgtgtc atcgttgcat	2580
tacgaaggca aaatgcgcac tacgaatgag tacaacaagc cgattgtagt ggacactaca	2640
ggctcaacaa aacctgacct tggagacctc gtgttaacgt gcttcagagg gtgggttaaa	2700
caactgcaaa ttgactatcg tggatacgag gtcattgacag cagccgcac ccaagggtta	2760
accagaaaag gagtttacgc agttagacaa aaagttaatg aaaacccgct ctatgcatca	2820
acgtcagagc acgtcaacgt actcctaacg cgtacggaag gtaaactggg atggaagaca	2880
ctttccggcg acccgtggat aaagacgctg cagaaccac cgaaaggaaa cttcaaagca	2940
actattaagg agtgggaggt ggagcatgca tcaataatgg cgggcatctg cagtcaccaa	3000
atgaccttcg atacattcca aaataaagcc aacgtttgtt gggctaagag cttggtccct	3060
atcctcgaaa cagcggggat aaaactaaat gataggcagt ggtctcagat aattcaagcc	3120
ttcaaagaag acaaagcata ctacactgaa gtagccctga atgaaatatg tacgcgcatg	3180
tatgggggtg atctagacag cgggctatct tctaaaccgt tgggtgtctgt gtattacgcg	3240
gataaccact gggataatag gcctggaggg aaaatgttcg gatttaacct cgaggcagca	3300
tccattctag aaagaaaagta tccattcaca aaagggaagt ggaacatcaa caagcagatc	3360
tgctgacta ccaggaggat agaagacttt aaccctacca ccaacatcat accggccaac	3420
aggagactac cacactcatt agtggccgaa caccgccag taaaagggga aagaatggaa	3480
tggctgggtt acaagataaa cggccaacac gtgctcctgg tcagtggcta taaccttgca	3540
ctgcctacta agagagtcac ttgggtagcg ccgttaggtg tccgcggagc ggactacaca	3600
tacaacctag agttgggtct gccagcaacg cttggtaggt atgaccttgt ggtcataaac	3660

## Sequence listing-CHK-II

atccacacac	cttttcgcat	acaccattac	caacagtgcg	tcgaccacgc	aatgaaactg	3720
caaatgctcg	ggggtgactc	attgagactg	ctcaaaccgg	gcggtctctt	attgatcaga	3780
gcatatgggt	acgcagatag	aaccagtgaa	cgagtcatct	gcgtattggg	acgcaagttt	3840
agatcgtcta	gagcgttgaa	accaccatgt	gtcaccagca	acactgagat	gtttttccta	3900
ttcagcaact	ttgacaatgg	cagaaggaat	ttcacaactc	atgtcatgaa	caatcaactg	3960
aatgcagcct	tcgtaggaca	ggtcacccga	gcaggatgtg	caccgtcgtg	ccgggtaaaa	4020
cgatggaca	tcgcgaagaa	cgatgaagag	tgcgtagtca	acgccgctaa	ccctcgcggg	4080
ttaccgggtg	acgggtgttg	caaggcagta	tacaaaaaat	ggccggagtc	ctttaagaac	4140
agtgaacac	cagtgggaac	cgaaaaaca	gttatgtgcg	gtacgtatcc	agtaatccac	4200
gctgttgac	caaacttctc	taattattcg	gagtctgaag	gggaccggga	attggcagct	4260
gcctatcgag	aagtcgcaaa	ggaagtaacc	aggctgggag	taaatagtgt	agctatacct	4320
ctcctctcca	caggtgtata	ctcaggaggg	aaagacaggc	tgaccacagtc	actgaaccac	4380
ctctttacag	ccatggactc	gacggatgca	gacgtggtca	tctactgccg	cgacaaagaa	4440
tgggagaaga	aaatatctga	ggccatacag	atgcggaccc	aagtagagct	gctggatgag	4500
cacatctcca	tagactgcga	tattgttcgc	gtgcaccctg	acagcagctt	ggcaggcaga	4560
aaaggataca	gcaccacgga	aggcgcactg	tactcatatc	tagaagggaac	ccgttttcat	4620
cagacggctg	tggatatggc	ggagatacat	actatgtggc	caaagcaaac	agaggccaat	4680
gagcaagcct	gcctatatgc	cctgggggaa	agtattgaat	cgatcaggca	gaaatgcccg	4740
gtggatgatg	cagacgcac	atctcccccc	aaaactgtcc	cgtgcctttg	ccgttacgct	4800
atgactccag	aacgcgtcac	ccggcttcgc	atgaaccacg	tcacaagcat	aattgtgtgt	4860
tcttcgtttc	ccctcccaaa	gtacaaaata	gaaggagtgc	aaaaagtcaa	atgctctaag	4920
gtaatgctat	ttgaccacaa	cgtgccatcg	cgcgtaagtc	caagggaata	tagatcttcc	4980
caggagtctg	cacaggaggc	gagtacaatc	acgtcactga	cgcatagtca	attcgaccta	5040
agcgttgatg	gcgagatact	gcccgtcccg	tcagacctgg	atgctgacgc	cccagcccta	5100
gaaccagcac	tagacgacgg	ggcgacacac	acgtgccat	ccacaaccgg	aaaccttgcg	5160
gccgtgtctg	actgggtaat	gagcaccgta	cctgtcgcgc	cgcccagaag	aaggcgaggg	5220
agaaacctga	ctgtgacatg	tgacgagaga	gaagggaata	taacacccat	ggctagcgtc	5280
cgattcttta	gggtagagct	gtgtccggtc	gtacaagaaa	cagcggagac	gcgtgacaca	5340
gcaatgtctc	ttcaggcacc	accgagtacc	gccacggaac	cgaatcatcc	gccgatctcc	5400
ttcggagcat	caagcgagac	gttccccatt	acatttgggg	acttcaacga	aggagaaatc	5460
gaaagcttgt	cttctgagct	actaactttc	ggagacttct	taccaggaga	agtggatgac	5520



## Sequence listing-CHK-II

ttgacagaca	gcgactgggtc	cacgtgctca	gacacggacg	acgagttatg	actagacagg	5580
gcaggtgggt	atatattctc	gtcggacacc	ggtccagggtc	atttacaaca	gaagtcagta	5640
cgccagtcag	tgctgccggt	gaacaccctg	gaggaagtcc	acgaggagaa	gtgttaccca	5700
cctaagctgg	atgaagcaaa	ggagcaacta	ttacttaaga	aactccagga	gagtgcattc	5760
atggccaaca	gaagcaggta	tcagtcgcgc	aaagtagaaa	acatgaaagc	agcaatcatc	5820
cagagactaa	agagaggctg	tagactatac	ttaatgtcag	agaccccaaa	agtccttact	5880
taccggacta	tatatccggc	gcctgtgtac	tcgcctccga	tcaacgtccg	attgtccaat	5940
cccagatccg	cagtggcagc	atgcaatgag	ttcttagcta	gaaactatcc	aactgtctca	6000
tcatacaaaa	ttaccgacga	gtatgatgca	tatctagaca	tggtggacgg	gtcggagagt	6060
tgcttgacc	gagcgacatt	caatccgtca	aaactcagga	gctaccgaa	acagcacgct	6120
taccacgcgc	cctccatcag	aagcgtgta	ccgtcccat	tccagaacac	actacagaat	6180
gtactggcag	cagccacgaa	aagaaactgc	aacgtcacac	agatgaggga	attaccact	6240
ttggactccg	cagtattcaa	cgtggagtgt	ttcaaaaaat	tcgcatgcaa	ccaagaatac	6300
tggaagaat	ttgctgccag	ccctattagg	ataacaactg	agaatttagc	aacttatggt	6360
actaaactaa	aagggccaaa	agcagcagcg	ctattcgcaa	aaaccataa	tctactgcca	6420
ctacaggaag	taccaatgga	taggttcaca	gtagatatga	aaagggacgt	gaaggtgact	6480
cctggtacaa	agcatacaga	ggaaagacct	aaggtgcagg	ttatacaggc	ggctgaaccc	6540
ttggcgacag	catacctatg	tgggattcac	agagagctgg	ttaggaggct	gaacgctgtc	6600
ctcctacca	atgtacatac	actatttgac	atgtctgccg	aggatttcga	tgccatcata	6660
gccgcacact	ttaagccagg	agacactgtt	ttggaaacgg	acatagcctc	ctttgataag	6720
agccaagatg	attcacttgc	gcttactgct	ttgatgctgt	tagaggattt	aggggtggat	6780
cactccctgc	tggacttgat	agaggctgct	ttcgagaga	tttccagctg	tcacctaccg	6840
acaggtacgc	gcttcaagtt	cggcgccatg	atgaaatcag	gtatgttcct	aactctgttc	6900
gtcaacacat	tgtaaacaat	caccatcgcc	agccgagtgc	tggaagatcg	tctgacaaaa	6960
tccgcgtgcg	cggccttcct	cggcgacgat	aacataatac	atggagtcgt	ctccgatgaa	7020
ttgatggcag	ccagatgtgc	cacttggtatg	aacatggaag	tgaagatcat	agatgcagtt	7080
gtatctttga	aagcccctta	cttttggtga	gggtttatac	tgacagatac	tgtgacagga	7140
acagcttgca	gagtggcaga	cccgtctaaa	aggcttttta	aactgggcaa	accgctagcg	7200
gcaggtgacg	aacaagatga	agatagaaga	cgagcgctgg	ctgacgaagt	gatcagatgg	7260
caacgaacag	ggctaattga	tgagctggag	aaagcggtat	actctaggtg	cgaagtgcag	7320
ggtatatcag	ttgtggtaat	gtccatggcc	acctttgcaa	gctccagatc	caacttcgag	7380
aagctcagag	gacccgtcat	aactttgtac	ggcggctcta	aataggtacg	cactacagct	7440

## Sequence listing-CHK-II

acctattttg	cagaagccga	cagcaagtat	ctaaacacta	atcagctaca	atggagttca	7500
tcccaaccca	aactttttac	aataggaggt	accagcctcg	accctggact	ccgcgctcta	7560
ctatccaaat	cattaggccc	agaccgcgcc	ctcagaggca	agctgggcaa	cttgcccagc	7620
tgatctcagc	agttaataaa	ctgacaatgc	gcgcggtacc	ccaacagaag	ccacgcagga	7680
atcggaagaa	taagaagcaa	aagcaaaaac	aacaggcgcc	acaaaacaac	acaaatcaaa	7740
agaagcagcc	acctaanaag	aaaccggctc	aaaagaaaaa	gaagccgggc	cgagagaga	7800
ggatgtgcat	gaaaatcgaa	aatgattgta	ttttcgaagt	caagcacgaa	ggtaaggtaa	7860
caggttacgc	gtgcctgggtg	ggggacaaaag	taatgaaacc	agcacacgta	aaggggacca	7920
tcgataacgc	ggacctggcc	aaactggcct	ttaagcggtc	atctaagtat	gaccttgaat	7980
gcgcgcagat	acccgtgcac	atgaagtccg	acgcttcgaa	gttcacccat	gagaaaaccg	8040
aggggtacta	caactggcac	cacggagcag	tacagtactc	aggaggccgg	ttcaccatcc	8100
ctacaggtgc	tggcaaacca	ggggacagcg	gcagaccgat	cttcgacaac	aagggacgcg	8160
tggtggccat	agtcttagga	ggagctaata	aaggagcccc	tacagccctc	tcggtggtga	8220
cctggaataa	agacattgtc	actaaaatca	ccccgaggg	ggccgaagag	tggagtcttg	8280
ccatcccagt	tatgtgcctg	ctggcaaaaca	ccacgttccc	ctgctcccag	cccccttgca	8340
cgccctgctg	ctacgaaaag	gaaccggagg	aaacctacg	catgcttgag	aacaacgtca	8400
tgagaccagg	gtactatcag	ctgctaagag	catccttaac	atgttctccc	caccgccagc	8460
gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	ttagctcact	8520
gtcccgaactg	tggagaaggg	cactcgtgcc	atagtcccgt	agcactagaa	cgcatcagaa	8580
atgaagcgac	agacgggacg	ctgaaaatcc	aggtctcctt	gcaaatacga	ataaagacgg	8640
atgacagcca	cgattggacc	aagctgcgtt	atatggacaa	ccacatgcc	gcagacgcag	8700
agagggcggg	gctatttgta	agaacatcag	caccgtgtac	gattactgga	acaatgggac	8760
acttcacctt	ggcccgatgt	ccaaaagggg	aaactctgac	ggtgggattc	actgacagta	8820
ggaagattag	tcattcatgt	acgcacccat	ttcaccacga	ccctcctgtg	ataggtcggg	8880
aaaaattcca	ttcccagacc	cagcacggta	aagagctacc	ttgcagcacg	tacgtgcaga	8940
gcaccgccgc	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	cctgatcgca	9000
cattaatgtc	acaacagtc	ggcaacgtaa	agatcacagt	caatggccag	acggtgcggt	9060
acaagtgtaa	ttgcggtggc	tcaaatgaag	gactaacaac	tacagacaaa	gtgattaata	9120
actgcaaggt	tgatcaatgt	catgccgcgg	tcaccaatca	caaaaagtgg	cagtataact	9180
cccctctggt	cccgcgtaat	gctgaacttg	gggaccgaaa	aggaaaaatt	cacatcccgt	9240
ttccgctggt	aaatgcaaca	tgaggggtgc	ctaaagcaag	gaaccccacc	gtgacgtacg	9300



## Sequence listing-CHK-II

ggaaaaacca	agtcacatg	ctactgtatc	ctgaccaccc	aacactcctg	tcctaccgga	9360
atatgggaga	agaaccaaac	tatcaagaag	agtgggtgat	gcataagaag	gaagtcgtgc	9420
taaccgtgcc	gactgaaggg	ctcgagggtca	cgtggggcaa	caacgagccg	tataagtatt	9480
ggccgcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	attctgtatt	9540
attatgagct	gtaccctact	atgactgtag	tagttgtgtc	agtggccacg	ttcatactcc	9600
tgtcgatggt	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	tgcatacacac	9660
cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	tgctgcatca	9720
gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	gagcagcaac	9780
ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgttcta	tgcaactgtc	9840
tgagactctt	accatgctgc	tgtaaaacgc	tggctttttt	agccgtaatg	agcgtcgggtg	9900
cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacggtg	ggagtaccgt	9960
ataagactct	agtcaataga	cctggctaca	gccccatggt	attggagatg	gaactactgt	10020
cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtac	aaaaccgtca	10080
tcccgtctcc	gtacgtgaag	tgctgcggta	cagcagagtg	caaggacaaa	aacctacctg	10140
actacagctg	taaggctctc	accggcgtct	accattttat	gtggggcggc	gcctactgct	10200
tctgcgacgc	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	gaatcatgca	10260
aaacagaatt	tgcatacagca	tacagggctc	ataccgcatac	tgcatacagct	aagctccgcg	10320
tcctttacca	aggaaataac	atcactgtaa	ctgcctatgc	aaacggcgac	catgccgtca	10380
cagttaagga	cgccaaattc	attgtggggc	caatgtcttc	agcctggaca	cctttcgaca	10440
acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctacccgccc	tttggcgcac	10500
gaagaccagg	acaatttggc	gatatccaaa	gtcgacacacc	tgagagtga	gacgtctatg	10560
ctaatacaca	actggtactg	cagagaccgg	ctgcgggtac	ggtacacgtg	ccatactctc	10620
aggcaccatc	tggttttaag	tattggctaa	aagaacgcgg	ggcgtcactg	cagcacacag	10680
caccatttgg	ctgccaata	gcaacaaacc	cggtaagagc	ggtgaactgc	gccgtagggg	10740
acatgcccac	ctccatcgac	ataccggaag	cggccttcac	tagggtcgtc	gacgcgccct	10800
ctttaacgga	catgtcgtgc	gaggtaccag	cctgcacca	ttcctcagac	tttgggggcg	10860
tcgccattat	taaatatgca	gccagcaaga	aaggcaagtg	tgcggtgcat	tcgatgacta	10920
acgccgtcac	tattcgggaa	gctgagatag	aagttgaagg	gaattctcag	ctgcaaatct	10980
ctttctcgac	ggccttagcc	agcgcgaat	tccgcgtaca	agtctgttct	acacaagtac	11040
actgtgcagc	tgagtgccac	ccccgaagg	accacatagt	caactacccg	gcgtcacata	11100
ccaccctcgg	ggtccaggac	atctccgcta	cggcgatgtc	atgggtgcag	aagatcacgg	11160
gagggtg999	actggtt999	gctgttgccg	cactgattct	aatcgtggtg	ctatgcgtgt	11220

## Sequence listing-CHK-II

cgttcagcag gcac

11234

&lt;210&gt; 17

&lt;211&gt; 11234

&lt;212&gt; DNA

&lt;213&gt; Chikungunya virus

&lt;400&gt; 17

atggatcctg	tgtacgtgga	catagacgct	gacagcgctt	ttttgaaggc	cctgcaacgt	60
gcgtacccca	tggttgaggt	ggaaccaagg	caggtcacac	cgaatgacca	tgctaattgct	120
agagcgttct	cgcattctagc	tataaaacta	atagagcagg	aaattgaccc	cgactcaacc	180
atcctggata	tcggcagtg	gccagcaagg	aggatgatgt	cggacaggaa	gtaccactgc	240
gtctgcccga	tgcgagtg	ggaagatccc	gagagactcg	ctaattatgc	gagaaagcta	300
gcatctgccg	caggaaaagt	cctggacaga	aacatctctg	gaaagatcgg	ggacttacia	360
gcagtaatgg	ccgtgccaga	caaggagacg	ccaacattct	gcttacacac	agacgtctca	420
tgtagacaga	gagcagacgt	cgctatatac	caagacgtct	atgctgtaca	cgacccacg	480
tcgctatacc	accaggcgat	taaaggggtc	cgagtggcgt	actgggttgg	gttcgacaca	540
accccggttc	tgtacaatgc	catggcgggt	gcctaccctt	catactcgac	aaactgggca	600
gatgagcagg	tactgaaggc	taagaacata	ggattatggt	caacagacct	gacggaaggt	660
agacgaggca	agttgtctat	tatgagaggg	aaaaagctaa	aaccgtgcga	ccgtgtgctg	720
ttctcagtag	ggtcaacgct	ttacccggaa	agccgcaagc	tacttaagag	ctggcacctg	780
ccatcggtgt	tccatttaaa	gggcaaaact	agcttcacat	gccgctgtga	tacagtgggt	840
tcgtgtgagg	gctacgtcgt	taagagaata	acgatgagcc	caggccttta	tggaaaaacc	900
acagggtag	cggtaaccca	ccacgcagac	ggattcctga	tgtgcaagac	taccgacacg	960
gttgacggcg	aaagagtgtc	attctcgggt	tgcacatacg	tgccggcgac	catttgtgat	1020
caaatgaccg	gcatccttgc	tacagaagtc	acgccggagg	atgcacagaa	gctgttggtg	1080
gggtgaacc	agagaatagt	ggttaacggc	agaacgcaac	ggaatacgaa	caccatgaaa	1140
aattatctgc	ttcccgtggt	cgcccaagcc	ttcagtaagt	gggcaaagga	gtgccggaaa	1200
gacatggaag	atgaaaaact	cctgggggtc	agagaaagaa	cactgacctg	ctgctgtcta	1260
tgggcattca	agaagcagaa	aacacacacg	gtctacaaga	ggcctgatac	ccagtcaatt	1320
cagaagggtc	aggccgagtt	tgacagcttt	gtggtaccga	gtctgtgggt	gtccgggttg	1380
tcaatccctt	tgaggactag	aatcaaatgg	ttgttaagca	aggtgccaaa	aaccgacctg	1440
atccataca	gcggagacgc	ccgagaagcc	cgggacgcag	aaaaagaagc	agaggaagaa	1500
cgagaagcag	aactgactcg	cgaagcccta	ccacctctac	aggcagcaca	ggaagatggt	1560
caggtcgaaa	tcgacgtgga	acagcttgag	gacagagcgg	gcgcaggaat	aatagagact	1620



## Sequence listing-CHK-II

ccgagaggag	ctatcaaagt	tactgccc	ccaacagacc	acgtcgtggg	agagtacctg	1680
gtactctccc	cgcagaccgt	actacgtagc	cagaagctca	gtctgattca	cgctttggcg	1740
gagcaagtga	agacgtgcac	gcacaacgga	cgagcaggga	ggatatgcgt	cgaagcgtac	1800
gacggccgag	tcctagtggc	ctcaggctat	gcaatctcgc	ctgaagactt	ccagagtcta	1860
agcgaaagcg	caacgatggg	gtataacgaa	agagagttcg	taaacagaaa	gtacacccat	1920
attgcgatgc	acggaccagc	cctgaacacc	gacgaagagt	cgtatgagct	ggtgagggca	1980
gagaggacag	aacacgagta	cgtctacgac	gtggatcaga	gaagatgctg	taagaaggaa	2040
gaagccgcag	gactggta	ggtgggagac	ttgactaatc	cgcctacca	cgaattcgca	2100
tatgaagggc	taaaaatccg	ccctgcctgc	ccatacaaaa	ttgcagtcac	aggagtcttc	2160
ggagtaccgg	gatctggcaa	gtcagctatt	atcaagaacc	tagttaccag	gcaggacctg	2220
gtgactagt	gaaagaaaga	aaactgccaa	gaaatcacca	ccgacgtgat	gagacaaaga	2280
ggtctagaga	tatctgcacg	tacggttgac	tcgctgctct	tgaatggatg	caacagacca	2340
gtcgacgtgt	tgtacgtaga	cgaggcggtt	gcgtgccact	ctggaacgct	acttgctttg	2400
atcgctttgg	tgagaccaag	gcagaaaagt	gtactttgtg	gtgacccgaa	gcagtgcggc	2460
ttcttcaata	tgatgcagat	gaaagtcaac	tacaatcaca	acatctgcac	ccaagtgtac	2520
cacaaaagta	tctccaggcg	gtgtacactg	cctgtgaccg	ccattgtgtc	atcgttgcat	2580
tacgaaggca	aaatgcgcac	tacgaatgag	tacaacaagc	cgattgtagt	ggacactaca	2640
ggctcaacaa	aacctgaccc	tggagacctc	gtgttaacgt	gcttcagagg	gtgggttaaa	2700
caactgcaaa	ttgactatcg	tggatacgag	gtcatgacag	cagccgcac	ccaaggggta	2760
accagaaaag	gagtttacgc	agttagacaa	aaagttaatg	aaaaccgcgt	ctatgcatca	2820
acgtcagagc	acgtcaacgt	actcctaacg	cgtacgggaag	gtaaactggt	atggaagaca	2880
ctttccggcg	acccgtggat	aaagacgctg	cagaaccac	cgaaggaaa	cttcaaagca	2940
actattaagg	agtgggaggt	ggagcatgca	tcaataatgg	cgggcatctg	cagtcaccaa	3000
atgaccttcg	atacattcca	aaataaagcc	aacgtttggt	gggctaagag	cttggtcctt	3060
atcctcgaaa	cagcggggat	aaaactaaat	gataggcagt	ggtctcagat	aattcaagcc	3120
ttcaaagaag	acaaaacata	ctcacctgaa	gtagccctga	atgaaatatg	tacgcgcatg	3180
tatgggggtg	atctagacag	cgggctat	tctaaaccgt	tgggtgtctg	gtattacg	3240
gataaccact	gggataatag	gcctggaggg	aaaatgttcg	gatttaacc	cgaggcagca	3300
tccattctag	aaagaaagta	tccattcaca	aaaggaag	ggaacatcaa	caagcagatc	3360
tgctgacta	ccaggaggat	agaagacttt	aaccctacca	ccaacatcat	accggccaac	3420
aggagactac	cacactcatt	agtggccgaa	caccgcccag	taaaagggga	aagaatggaa	3480



## Sequence listing-CHK-II

tggctggtta	acaagataaa	cgccaccac	gtgctcctgg	tcagtggcta	taaccttgca	3540
ctgcctacta	agagagtcac	ttgggtagcg	ccgttaggtg	tccgcggagc	ggactacaca	3600
tacaacctag	agttgggtct	gccagcaacg	cttggtaggt	atgaccttgt	ggtcataaac	3660
atccacacac	cttttcgcat	acaccattac	caacagtgcg	tcgaccacgc	aatgaaactg	3720
caaatgctcg	ggggtgactc	attgagactg	ctcaaaccgg	gcggctctct	attgatcaga	3780
gcatatggtt	acgcagatag	aaccagtga	cgagtcattct	gcgtattggg	acgcaagttt	3840
agatcgctta	gagcgttgaa	accaccatgt	gtcaccagca	acactgagat	gtttttccta	3900
ttcagcaact	ttgacaatgg	cagaaggaat	ttcacaactc	atgtcatgaa	caatcaactg	3960
aatgcagcct	tcgtaggaca	ggtcacccga	gcaggatgtg	caccgtcgta	ccgggtaaaa	4020
cgcatggaca	tcgcgaagaa	cgatgaagag	tgcgtagtta	acgccgctaa	ccctcgcggg	4080
ttaccgggtg	acggtgtttg	caaggcagta	tacaaaaaat	ggccggagtc	ctttaagaac	4140
agtgaacac	cagtgggaac	cgcaaaaaca	gttatgtgcy	gtacgtatcc	agtaatccac	4200
gctgttgga	caaacttctc	taattattcg	gagcctgaag	gggaccggga	attggcagct	4260
gcctatcgag	aagtcgcaaa	ggaagtaact	aggctgggag	taaatagtgt	agctatacct	4320
ctcctctcca	caggtgtata	ctcaggaggg	aaagacaggc	tgaccagtc	actgaaccac	4380
ctctttacag	ccatggactc	gacggatgca	gacgtggtca	tctactgccg	cgacaaagaa	4440
tgggagaaga	aaatatctga	ggccatacag	atgcggaccc	aagtagagct	gctggatgag	4500
cacatctcca	tagactgcga	tattgttcgc	gtgcaccctg	acagcagctt	ggcaggcaga	4560
aaaggataca	gcaccacgga	aggcgcactg	tactcatatc	tagaaggga	ccgttttcat	4620
cagacggctg	tggatatggc	ggagatacat	actatgtggc	caaagcaaac	agaggccaat	4680
gagcaagtct	gcctatatgc	cctgggggaa	agtattgaat	cgatcaggca	gaaatgcccg	4740
gtggatgatg	cagacgcac	atctcccccc	aaaactgtcc	cgtgcctttg	ccgttacgct	4800
atgactccag	aacgcgtcac	ccggcttcgc	atgaaccacg	tcacaagcat	aattgtgtgt	4860
tcttcgtttc	ccctcccaaa	gtacaaaata	gaaggagtgc	aaaaagtcaa	atgctctaag	4920
gtaatgctat	ttgaccacaa	cgtgccatcg	cgcgtaagtc	caagggaata	tagatcttcc	4980
caggagtctg	cacaggaggc	gagtacaatc	acgtcactga	cgcatagtca	attcgacct	5040
agcgttgatg	gcgagatact	gcccgctccg	tcagacctgg	atgctgacgc	cccagcccta	5100
gaaccagcac	tagacgacgg	ggcgacacac	acgtgcccat	ccacaaccgg	aaaccttgcy	5160
gccgtgtctg	actgggtaat	gagcaccgta	cctgtcgcgc	cgcccagaag	aaggcgaggg	5220
agaaacctga	ctgtgacatg	tgacgagaga	gaagggaata	taacacccat	ggctagcgtc	5280
cgattcttta	gggcagagct	gtgtccggtc	gtacaagaaa	cagcgagagc	gcgtgacaca	5340
gcaatgtctc	ttcaggcacc	accgagtacc	gccacggaac	cgaatcatcc	gccgatctcc	5400

## Sequence listing-CHK-II

ttcggagcat	caagcgagac	gttccccatt	acatttgggg	acttcaacga	aggagaaatc	5460
gaaagcttgt	cttctgagct	actaactttc	ggagacttct	taccaggaga	agtggatgac	5520
ttgacagaca	gcgactggtc	cacgtgctca	gacacggacg	acgagttatg	actagacagg	5580
gcaggtgggt	atatattctc	gtcggacacc	ggtccaggtc	atttacaaca	gaagtcagta	5640
cgccagtcag	tgctgccggt	gaacaccctg	gaggaagtcc	acgaggagaa	gtgttaccca	5700
cctaagctgg	atgaagcaaa	ggagcaacta	ttacttaaga	aactccagga	gagtgcattc	5760
atggccaaca	gaagcaggta	tcagtcgcgc	aaagtagaaa	acatgaaagc	agcaatcatc	5820
cagagactaa	agagaggctg	tagactatac	ttaatgtcag	agaccccaaa	agtccctact	5880
taccggacta	catatccggc	gcctgtgtac	tcgcctccga	tcaacgtccg	attgtccaat	5940
cccaggtccg	cagtggcagc	atgcaatgag	ttcttagcta	gaaactatcc	aactgtctca	6000
tcatacaaaa	ttaccgacga	gtatgatgca	tatctagaca	tggtggacgg	gtcggagagt	6060
tgcttgacc	gagcgacatt	caatccgtca	aaactcagga	gctacccgaa	acagcacgct	6120
taccacgcgc	cctccatcag	aagcgctgta	ccgtcccat	tccagaacac	actacagaat	6180
gtactggcag	cagccacgaa	aagaaactgc	aacgtcacac	agatgaggga	attacccact	6240
ttggactccg	cagtattcaa	cgtggagtgt	ttcaaaaaat	tcgcatgcaa	ccaagaatac	6300
tggaagaagt	ttgctgccag	ccctattagg	ataacaactg	agaatttagc	aacctatgtt	6360
actaaactaa	aagggccaaa	agcagcagcg	ctattcgcaa	aaaccataa	tctactgcca	6420
ctacaggaag	taccaatgga	taggttcaca	gtagatatga	aaaggacgt	gaaggtgact	6480
cctggtacaa	agcatacaga	ggaaagacct	aagggtcagg	ttatacaggc	ggctgaaccc	6540
ttggcgacag	catacctatg	tgggattcac	agagagctgg	ttaggaggct	gaacgccgtc	6600
ctcctaccca	atgtacatac	actatttgac	atgtctgccg	aggatttcga	tgccatcata	6660
gccgcacact	ttaagccagg	agacactgtt	ttggaacgg	acatagcctc	ctttgataag	6720
agccaagatg	attcacttgc	gcttactgct	ttgatgctgt	tagaggattt	aggggtggat	6780
cactccctgc	tggacttgat	agaggctgct	ttcggagaga	tttccagctg	tcacctaccg	6840
acaggtacgc	gcttcaagt	cggcgccatg	atgaaatcag	gtatgttcct	aactctgttc	6900
gtcaacacat	tgtaaacat	caccatcgcc	agccgagtgc	tggaagatcg	tctgacaaaa	6960
tccgcgtgcg	cggccttcac	cggcgacgac	aacataatac	atggagtcgt	ctccgatgaa	7020
ttgatggcag	ccagatgtgc	cacttggatg	aacatggaag	tgaagatcat	agatgcagtt	7080
gtatccttga	aagcccttta	cttttgtgga	gggtttatac	tgacacgatac	tgtgacagga	7140
acagcttgca	gagtggcaga	cccgcataaa	aggcttttta	aactgggcaa	accgctagcg	7200
gcaggtgacg	aacaagatga	agatagaaga	cgagcgctgg	ctgacgaagt	gatcagatgg	7260



## Sequence listing-CHK-II

caacgaacag	ggctaattga	tgagctggag	aaagcggat	actctaggta	cgaagtgcag	7320
ggtatatcag	ttgtggtaat	gtccatggcc	acctttgcaa	gctccagatc	caacttcgag	7380
aagctcagag	gacccgtcat	aactttgtac	ggcggctcta	aataggtacg	cactacagct	7440
acctattttg	cagaagccga	cagcaagtat	ctaaacacta	atcagctaca	atggagttca	7500
tcccaaccca	aactttttac	aataggaggt	accagcctcg	accctggact	ccgcgctcta	7560
ctatccaaat	cattaggccc	agaccgcgcc	ctcagaggca	agctgggcaa	cttgcccagc	7620
tgatctcagc	agttaataaa	ctgacaatgc	gcgcgggtacc	ccaacagaag	ccacgcagga	7680
atcggagaa	taagaagcaa	aagcaaaaac	aacaggcgcc	acaaaacaac	acaaatcaaa	7740
agaagcagcc	acctaataaag	aaaccggctc	aaaagaaaaa	gaagccgggc	cgagagaga	7800
ggatgtgcat	gaaaatcgaa	aatgattgta	ttttcgaagt	caagcacgaa	ggtaaggtaa	7860
caggttacgc	gtgcctggtg	ggggacaaag	taatgaaacc	agcacacgta	aaggggacca	7920
tcgataacgc	ggacctggcc	aaactggcct	ttaagcggtc	atctaagtat	gaccttgaat	7980
gcgcgcagat	acccgtgcac	atgaagtccg	acgcttcgaa	gttcacccat	gagaaaccgg	8040
aggggtacta	caactggcac	cacggagcag	tacagtactc	aggaggccgg	ttcaccatcc	8100
ctacaggtgc	tggcaaacca	ggggacagcg	gcagaccgat	cttcgacaac	aagggacgcg	8160
tggtggccat	agtcttagga	ggagctaattg	aaggagcccg	tacagccctc	tcggtggtga	8220
cctggaataa	agacattgtc	actaaaatca	ccccgaggg	ggccgaagag	tggagtcttg	8280
ccatcccagt	tatgtgcctg	ctggcaaaca	ccacgttccc	ctgctcccag	cccccttgca	8340
cgccctgctg	ctacgaaaag	gaaccggagg	aaacctacg	catgcttgag	gacaacgtca	8400
tgagacctgg	gtactatcag	ctgctacagg	catccttaac	atgttctccc	caccgccagc	8460
gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	ttagctcact	8520
gtcccgactg	tggagaaggg	cactcgtgcc	atagtcccgt	agcactagaa	cgcatcagaa	8580
atgaagcgac	agacgggacg	ctgaatatcc	aggtctcctt	gcaaatacga	ataaagacgg	8640
atgacagcca	cgattggacc	aagctgcgtt	atatggacaa	ccacatgcca	gcagacgcag	8700
agagggcggg	gctatttgta	agaacatcag	caccgtgtac	gattactgga	acaatgggac	8760
acttcacctt	ggcccgatgt	ccaaaagggg	aaactctgac	ggtgggattc	actgacagta	8820
ggaagattag	tcattcatgt	acgcacccat	ttcaccacga	ccctcctgtg	ataggtcggg	8880
aaaaattcca	ttcccgaccg	cagcacggta	aagagctacc	ttgcagcacg	tacgtgcaga	8940
gcaccgcgcg	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	cctgatcgca	9000
cattaatgtc	acaacagtcc	ggcaacgtaa	agatcacagt	caatggccag	acggtgcggt	9060
acaagtgtaa	ttgcggtggc	tcaaatgaag	gactaacaac	tacagacaaa	gtgattaata	9120
actgcaaggt	tgatcaatgt	catgccgcgg	tcaccaatca	caaaaagtgg	cagtataact	9180

## Sequence listing-CHK-II

cccctctggt	cccgcgtaat	gctgaacttg	gggaccgaaa	aggaaaaatt	cacatcccgt	9240
ttccgctggc	aaatgcaaca	tgcagggtgc	ctaaagcaag	gaaccccacc	gtgacgtacg	9300
ggaaaaacca	agttatcatg	ctactgtatc	ctgaccaccc	aacactcctg	tcctaccgga	9360
atatgggaga	agaaccaaac	tatcaagaag	agtgggtgat	gcataagaag	gaagtcgtgc	9420
taaccgtgcc	gactgaagg	ctcgagggtca	cgtggggcaa	caacgagccg	tataagtatt	9480
ggccgcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	attctgtatt	9540
attatgagct	gtaccctact	atgactgtag	tagttgtgtc	agtggccacg	ttcatactcc	9600
tgtcgatggt	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	tgcatacac	9660
cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	tgctgcatca	9720
gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	gagcagcaac	9780
ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgtccta	tgcaactgtc	9840
tgagactcct	accatgctgc	tgtaaaacgt	tggctttttt	agccgtaatg	agcgtcgggtg	9900
cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacgggtg	ggagtaccgt	9960
ataagactct	agtcaataga	cctggctaca	gccccatggt	attggagatg	gaactactgt	10020
cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtag	aaaaccgtca	10080
tcccgctctc	gtacgtgaag	tgctgcggta	cagcagagtg	caaggacaaa	aacctacctg	10140
actacagctg	taaggctctc	accggcgtct	acccatttat	gtggggcggc	gcctactgct	10200
tctgcgacgc	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	gaatcatgca	10260
aaacagaatt	tgcatacagca	tacagggtct	ataccgcata	tgcatacagct	aagctccgcg	10320
tcctttacca	aggaaataac	atcactgtaa	ctgcctatgc	aaacggcgac	catgccgtca	10380
cagttaagga	cgccaaattc	attgtggggc	caatgtcttc	agcctggaca	cctttcgaca	10440
acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctacccgcc	tttggcgcag	10500
gaagaccagg	acaatttggc	gatatccaaa	gtcgacaccc	tgagagtga	gacgtctatg	10560
ctaatacaca	actggtaactg	cagagaccgg	ctgcgggtac	ggtacacgtg	ccatactctc	10620
aggcaccatc	tggctttaag	tattggctaa	aagaacgcgg	ggcgtcactg	cagcacacag	10680
caccatttgg	ctgccaaata	gcaacaaacc	cggtaagagc	ggtgaactgc	gccgtagggg	10740
acatgcccat	ctccatcgac	ataccggaag	cggccttcac	tagggtcgtc	gacgcgccct	10800
ctttaacgga	catgtcgtgc	gaggtaecag	cctgcaccca	ttcctcagac	tttggggg	10860
tcgccattat	taaatatgca	gccagcaaga	aaggcaagtg	tcgggtgcat	tcgatgacta	10920
acgccgtcac	tattcgggaa	gctgagatag	aagttgaagg	gaattctcag	ctgcaaattc	10980
ctttctcgac	ggccttagcc	agcgcggaat	tccgcgtaca	agtctgttct	acacaagtac	11040

## Sequence listing-CHK-II

actgtgcagc tgagtgccac ccccgaagg accacatagt caactacccg gcgtcacata 11100  
 ccaccctcgg ggtccaggac atctccgcta cggcgatgtc atgggtgcag aagatcacgg 11160  
 gaggtgtggg actggttgtt gctgttgccg cactgattct aatcgtggtg ctatgcgtgt 11220  
 cgttcagcag gcac 11234

<210> 18  
 <211> 11234  
 <212> DNA  
 <213> Chikungunya virus

<400> 18  
 atggatcctg tgtacgtgga catagacgct gacagcgcct ttttgaaggc cctgcaacgt 60  
 gcgtacccca tgtttgaggt ggaaccaagg caggtcacac cgaatgacca tgctaattgct 120  
 agagcgttct cgcatctagc tataaaacta atagagcagg aaattgaccc cgactcaacc 180  
 atcctggata tcggcagtgcc gccagcaagg aggatgatgt cggacaggaa gtaccactgc 240  
 gtctgcccga tgcgcagtgcc ggaagatccc gagagactcg ctaattatgc gagaaagcta 300  
 gcatctgccg caggaaaagt cctggacaga aacatctctg gaaagatcgg ggacttacia 360  
 gcagtaaatg cctgtgccga caaggagacg ccaacattct gcttacacac agacgtctca 420  
 thtagacaga gagcagacgt cgctatatac caagacgtct atgctgtaca cgcaccacg 480  
 tcgctatacc accaggcgat taaaggggtc caagtggcgt actgggttgg gttcgacaca 540  
 acccgttca tgtacaatgc catggcgggt gcctaccctt catactcgac aaactgggca 600  
 gatgagcagg tactgaaggc taagaacata ggattatggt caacagacct gacggaagggt 660  
 agacgaggca agttgtctat tatgagaggg aaaaagctaa aaccgtgcga ccgtgtgctg 720  
 ttctcagtag ggtcaacgct ttaccgggaa agccgcaagc tacttaagag ctggcacctg 780  
 ccacggtgt tccatttaaa gggcaaactc agcttcacat gccgctgtga tacagtgggt 840  
 tcgtgtgagg gctacgtcgt taagagaata acgatgagcc caggccttta tggaaaaacc 900  
 acagggtatg cggtaaccac ccacgcagac ggattcctga tgtgcaagac taccgacacg 960  
 gttgacggcg aaagagtgtc attctcgtg tgcacatacg tgccggcgac catttgtgat 1020  
 caaatgaccg gcatccttgc tacagaagtc acgccggagg atgcacagaa gctgttggtg 1080  
 gggctgaacc agagaatagt ggtaaacggc agaacgcaac ggaatacgaa caccatgaaa 1140  
 aattatctgc ttcccgtggt cgccaagcc tttagtaagt gggcaaagga gtgccggaaa 1200  
 gacatggaag atgaaaaact cctgggggtc agagaaagaa cactgacctg ctgctgtcta 1260  
 tgggcattca agaagcagaa aacacacacg gtctacaaga ggcctgatac ccagtcaatt 1320  
 cagaaggttc aggccgagtt tgacagcttt gtggtaccga gtctgtgggt gtccgggttg 1380  
 tcaatccctt tgaggactag aatcaaattg ttgttaagca aggtgccaaa aaccgacctg 1440



## Sequence listing-CHK-II

atcccataca	gcgagagcgc	ccgagaagcc	cgggacgcag	aaaaagaagc	agaggaagaa	1500
cgagaagcag	aactgactcg	cgaagcccta	ctacctctac	aggcagcaca	ggaagatggt	1560
caggtcgaaa	tcgacgtgga	acagcttgag	gacagagcgg	gcgaggaat	aatagagact	1620
ccgagaggag	ctatcaaagt	tactgcccaa	ccaacagacc	acgtcgtggg	agagtacctg	1680
gtactctccc	cgagaccgt	actacgtagc	cagaagctca	gtctgattca	cgctttggcg	1740
gagcaagtga	agacgtgcac	gcacaacgga	cgagcaggga	ggtatgcggt	cgaagcgtac	1800
gacggccgag	tcctagtgcc	ctcaggctat	gcaatctcgc	ctgaagactt	ccagagtcta	1860
agcgaaagcg	caacgatggg	gtataacgaa	agagagttcg	taaacagaaa	gctacaccat	1920
attgcgatgc	acggaccagc	cctgaacacc	gacgaagagt	cgatgagct	ggtgagggca	1980
gagaggacag	aacacgagta	cgcttacgac	gtggatcaga	gaagatgctg	taagaaggaa	2040
gaagccgag	gactggtact	ggtgggcgac	ttgactaatc	cgccctacca	cgaattcgca	2100
tatgaagggc	taaaaatccg	ccctgcctgc	ccatacaaaa	ttgcagtcac	aggagtcttc	2160
ggagtaccgg	gatctggcaa	gtcagctatt	atcaagaacc	tagttaccag	gcaggacctg	2220
gtgactagt	gaaagaaaga	aaactgccaa	gaaatcacca	ccgacgtgat	gagacagaga	2280
ggtctagaga	tatctgcacg	tacggttgac	tcgctgctct	tgaatggatg	caacagacca	2340
gtcgacgtgt	tgtacgtaga	cgaggcggtt	gcgtgccact	ctggaacgct	acttgctttg	2400
atcgcttg	tgagaccaag	gcagaaagtt	gtactttgtg	gtgaccgaa	gcagtgcggc	2460
ttcttcaata	tgatgcagat	gaaagtcaac	tacaatcaca	acatctgcac	ccaagtgtac	2520
cacaaaagta	tctccaggcg	gtgtacactg	cctgtgaccg	ccattgtgtc	atcgttgcat	2580
tacgaaggca	aaatgcgcac	tacgaatgag	tacaacaagc	cgattgtagt	ggacactaca	2640
ggctcaacaa	aacctgacct	tggagacctc	gtgttaacgt	gcttcagagg	gtgggttaaa	2700
caactgcaaa	ttgactatcg	tggatacgag	gtcatgacag	cagccgcac	ccaagggtta	2760
accagaaaag	gagtttacgc	agttagacaa	aaagttaatg	aaaacccgct	ctatgcatca	2820
acgtcagagc	acgtcaacgt	actcctaacg	cgtacggaag	gtaaactggg	atggaagaca	2880
ctttccggcg	acctgtggat	aaagacgctg	cagaaccac	cgaaaggaaa	cttcaaagca	2940
actattaagg	agtgggaggt	ggagcatgca	tcaataatgg	cgggcatctg	cagtcaccaa	3000
atgaccttcg	atacattcca	aaataaagcc	aacgtttgtt	gggctaagag	cttggtcctt	3060
atcctcgaaa	cagcggggat	aaaactaaat	gataggcagt	ggtctcagat	aattcaagcc	3120
ttcaaagaag	acaaagcata	ctcacctgaa	gtagccctga	atgaaatatg	tacgcgcatg	3180
tatggggtg	atctagacag	cgggctat	tctaaaccgt	tgggtgtctg	gtattacg	3240
gataaccact	gggataatag	gcctggagg	aaaatgttcg	gatttaacct	cgaggcagca	3300
tccattctag	aaagaaagta	tccattcaca	aaagggaagt	ggaacatcaa	caagcagatc	3360

## Sequence Listing-CHK-II

tgctgacta	ccaggaggat	agaagacttt	aaccctacca	ccaacatcat	accggccaac	3420
aggagactac	cacactcatt	agtggccgaa	caccgcccag	taaaagggga	aagaatggaa	3480
tggctggtta	acaagataaa	cggccaccac	gtgctcctgg	tcagtggcta	taaccttgca	3540
ctgcctacta	agagagtcac	ttgggtagcg	ccgttaggtg	tccgcggagc	ggactacaca	3600
tacaacctag	agttgggtct	gccagcaacg	cttggtaggt	atgaccttgt	ggtcataaac	3660
atccacacac	cttttcgcac	acaccattac	caacagtgcg	tcgaccacgc	aatgaaactg	3720
caaagtctcg	gggggtgactc	attgagactg	ctcaaacggg	gcggtctctt	attgatcaga	3780
gcatatggtt	acgcagatag	aaccagtga	cgagtcattc	gcgtattggg	acgcaagttt	3840
agatcgtcta	gagcgttgaa	accaccatgt	gtcaccagca	acactgagat	gtttttccta	3900
ttcagcaact	ttgacaatgg	cagaaggaat	ttcacaactc	atgtcatgaa	caatcaactg	3960
aatgcagcct	tcgtaggaca	ggtcacccga	gcaggatgtg	caccgtcgtc	ccgggtaaaa	4020
cgcatggaca	tcgcgaagaa	cgatgaagag	tgctgagtca	acgccgctaa	ccctcgcggg	4080
ttaccgggtg	acggtgtttg	caaggcagta	tacaaaaaat	ggccggagtc	ctttaagaac	4140
agtgaacac	cagtgggaac	cgcaaaaaca	gttatgtgcg	gtacgtatcc	agtaatccac	4200
gctgttgac	caaacttctc	taattattcg	gagtctgaag	gggaccggga	attggcagct	4260
gcctatcgag	aagtcgaaa	ggaagtaact	aggctgggag	taaatagtgt	agctatacct	4320
ctcctctcca	caggtgtata	ctcaggaggg	aaagacaggc	tgaccagtc	actgaaccac	4380
ctctttacag	ccatggactc	gacggatgca	gacgtgggtc	tctactgccg	cgacaaagaa	4440
tgggagaaga	aaatatctga	ggccatacag	atgcggaccc	aagtagagct	gctggatgag	4500
cacatctcca	tagactgcga	tattgttcgc	gtgcaccctg	acagcagctt	ggcaggcaga	4560
aaaggataca	gcaccacgga	aggcgcactg	tactcatatc	tagaaggggc	ccgttttcat	4620
cagacggctg	tggatatggc	ggagatacat	actatgtggc	caaagcaaac	agaggccaat	4680
gagcaagtct	gcctatatgc	cctgggggaa	agtattgaat	cgatcaggca	gaaatgcccg	4740
gtggatgatg	cagacgcac	atctccccc	aaaactgtcc	cgtgcctttg	ccgttacgct	4800
atgactccag	aacgcgtcac	ccggcttcgc	atgaatcacg	tcacaagcat	aattgtgtgt	4860
tcttcgtttc	ccttcccaa	gtacaaaata	gaaggagtgc	aaaaagtcaa	atgctctaag	4920
gtaatgctat	ttgaccacaa	cgtgccatcg	cgcgtaagtc	caagggaata	tagatcttcc	4980
caggagtctg	cacaggaggc	gagtacaatc	acgtcactga	cgcatagtca	attcgacctc	5040
agcgttgatg	gcgagatact	gccegtcccg	tcagacctgg	atgctgacgc	cccagcccta	5100
gaaccagcac	tagacgacgg	ggcgacacac	acgtgcccat	ccacaaccgg	aaaccttgcg	5160
gccgtgtctg	actgggtaat	gagcaccgta	cctgtcgcgc	cgcccagaag	aaggcgaggg	5220



## Sequence listing-CHK-II

agaaacctga	ctgtgacatg	tgacgagaga	gaagggaata	taacacccat	ggctagcgtc	5280
cgattcttta	gggcagagct	gtgtccggtc	gtacaagaaa	cagcggagac	gcgtgacaca	5340
gcaatgtctc	ttcaggcacc	accgagtacc	gccacggaac	cgaatcatcc	gccgatctcc	5400
ttcggagcat	caagcgagac	gttccccatt	acatttgggg	acttcaacga	aggagaaatc	5460
gaaagcttgt	cttctgagct	actaactttc	ggagacttct	taccaggaga	agtggatgac	5520
ttgacagaca	gcgactgggtc	cacgtgctca	gacacggacg	acgagttatg	actagacagg	5580
gcagggtgggt	atatattctc	gtcggacacc	ggtccagggtc	atttacaaca	gaagtcagta	5640
cgccagtcag	tgctgccggt	gaacaccctg	gaggaagtcc	acgaggagaa	gtgttaccca	5700
cctaagctgg	atgaagcaaa	ggagcaacta	ttacttaaga	aactccagga	gagtgcattc	5760
atggccaaca	gaagcaggta	tcagtcgcgc	aaagtagaaa	acatgaaagc	agcaatcatc	5820
cagagactaa	agagaggctg	tagactatac	ttaatgtcag	agaccccaaa	agtcctact	5880
taccggacta	catatccggc	gcctgtgtac	tcgcctccga	tcaacgtccg	attgtccaat	5940
cccgagtccg	cagtggcagc	atgcaatgag	ttcttagcta	gaaactatcc	aactgtctca	6000
tcatacaaaa	ttaccgacga	gtatgatgca	tatctagaca	tggtggacgg	gtcggagagt	6060
tgcttgacc	gagcgacatt	caatccgtca	aaactcagga	gctacccgaa	acagcacgct	6120
taccacgcgc	cctccatcag	aagcgtgta	ccgtcccat	tccagaacac	actacagaat	6180
gtactggcag	cagccacgaa	aagaaactgc	aacgtcacac	agatgaggga	attacccact	6240
ttggactccg	cagtattcaa	cgtggagtgt	ttcaaaaaat	tcgcatgcaa	ccaagaatac	6300
tggaagaat	ttgtgcccag	ccctattagg	ataacaactg	agaatttagc	aacttatgtt	6360
actaaactaa	aagggccaaa	agcagcagcg	ctattcgcaa	aaaccataa	tctactgcca	6420
ctacaggaag	taccaatgga	taggttcaca	gtagatatga	aaagggacgt	gaaggtgact	6480
cctggtacaa	agcatacaga	ggaaagacct	aaggtgcagg	ttatacaggc	ggctgaaccc	6540
ttggcgacag	catacctatg	tgggattcac	agagagctgg	ttaggaggct	gaacgccgtc	6600
ctcctaccca	atgtacatac	actatttgac	atgtctgccg	aggatttcga	tgccatcata	6660
gccgcacact	ttaagccagg	agacactggt	ttggaaacgg	acatagcctc	ctttgataag	6720
agccaagatg	attcacttgc	gcttactgct	ttgatgctgt	tagaggattt	aggggtggat	6780
cactccctgc	tggacttgat	agaggctgct	ttcggagaga	ttccagctg	tcacctaccg	6840
acaggtagcg	gcttcaagtt	cggcgccatg	atgaaatcag	gtatgttcct	aactctgttc	6900
gtcaacacat	tgttaaacad	caccatcgcc	agccgagtgc	tggaagatcg	tctgacaaaa	6960
tccgcgtgcg	cggccttcac	cggcgacgac	aacataatac	atggagtcgt	ctccgatgaa	7020
ttgatggcag	ccagatgtgc	caottggatg	aacatggaag	tgaagatcat	agatgcagtt	7080
gtatccttga	aagcccttta	cttttgtgga	gggtttatatac	tgcacgatac	tgtgacagga	7140

## Sequence listing-CHK-II

acagcttgca	gagtggcaga	cccgcataaaa	aggcttttta	aactgggcaa	accgctagcg	7200
gcaggtgacg	aacaagatga	agatagaaga	cgagcgctgg	ctgacgaagt	gatcagatgg	7260
caacgaacag	ggctaattga	tgagctggag	aaagcggat	actctaggta	cgaagtgcag	7320
ggtatatcag	ttgtggtaat	gtccatggcc	acctttgcaa	gctccagatc	caacttcgag	7380
aagctcagag	gacccgtcat	aactttgtac	ggcggtccta	aataggtagc	cactacagct	7440
acctattttg	cagaagccga	cagcaagtat	ctaaacacta	atcagctaca	atggagttca	7500
tcccaaccga	aactttttac	aataggaggt	accagcctcg	accctggact	ccgcgctcta	7560
ctatccaaat	cattaggccc	agaccgcgcc	ctcagaggca	agctgggcaa	cttgcccagc	7620
tgatctcagc	agttaataaa	ctgacaatgc	gcgcgggtacc	ccaacagaag	ccacgcagga	7680
atcggaagaa	taagaagcaa	aagcaaaaac	aacaggcgcc	acaaaacaac	acaaatcaaa	7740
agaagcagcc	acctaaaaag	aaaccggctc	aaaagaaaaa	gaagccgggc	cgagagaga	7800
ggatgtgcat	gaaaatcgaa	aatgattgta	ttttcgaagt	caagcacgaa	ggtaaggtaa	7860
caggttacgc	gtgcctggtg	ggggacaaag	taatgaaacc	agcacacgta	aaggggacca	7920
tcgataacgc	ggacctggcc	aaactggcct	ttaagcggtc	atctaagtat	gaccttgaat	7980
gcgcgcagat	acccgtgcac	atgaagtccg	acgcttcgaa	gttcacccat	gagaaaccgg	8040
aggggtacta	caactggcac	cacggagcag	tacagtactc	aggaggccgg	ttcaccatcc	8100
ctacaggtgc	tggcaaacca	ggggacagcg	gcagaccgat	cttcgacaac	aaggggacgcg	8160
tggtggccat	agtcttagga	ggagttaatg	aaggagcccc	tacagccctc	tcggtggtga	8220
cctggaataa	agacattgtc	actaaaatca	cccccgaggg	ggccgaagag	tggagtcttg	8280
ccatcccagt	tatgtgcctg	ctggcaaaca	ccacgttccc	ctgctcccag	cccccttgca	8340
cgccctgctg	ctacgaaaag	gaaccggagg	aaaccctacg	catgcttgag	gacaacgtca	8400
tgagacctgg	gtactatcag	ctgctacagg	catccttaac	atgttctccc	caccgccagc	8460
gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	ttagctcact	8520
gtcccgaactg	tggagaaggg	cactcgtgcc	atagtcccg	agcactagaa	cgcatcagaa	8580
atgaagcgac	agacgggacg	ctgaaaatcc	aggctctcct	gcaaatcgga	ataaagacgg	8640
atgacagcca	cgattggacc	aagctgcgtt	atatggacaa	ccacatgcca	gcagacgcag	8700
agagggcggg	gctattttgta	agaacatcag	caccgtgtac	gattactgga	acaatgggac	8760
acttcatcct	ggcccgatgt	ccaaaagggg	aaactctgac	ggtgggattc	actgacagta	8820
ggaagattag	tcattcatgt	acgcacccat	ttcaccacga	ccctcctgtg	ataggtcggg	8880
aaaaattcca	ttcccagaccg	cagcacggta	aagagctacc	ttgcagcacg	tacgtgcaga	8940
gcaccgcggc	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	cctgatcgca	9000



## Sequence listing-CHK-II

cattaatgtc	acaacagtcc	ggcaacgtaa	agatcacagt	caatggccag	acggtgcggt	9060
acaagtgtaa	ttgcggtggc	tcaaatgaag	gactaacaac	tacagacaaa	gtgattaata	9120
actgcaaggt	tgatcaatgt	catgccgcgg	tcaccaatca	caaaaagtgg	cagtataact	9180
cccctctggt	cccgcgtaat	gctgaacttg	gggaccgaaa	aggaaaaatt	cacatcccgt	9240
ttccgctggc	aaatgcaaca	tgcaggggtgc	ctaaagcaag	gaaccccacc	gtgacgtacg	9300
ggaaaaacca	agtcacatg	ctactgtatc	ctgaccaccc	aacactcctg	tcctaccgga	9360
atatgggaga	agaaccaaac	tatcaagaag	agtgggtgat	gcataagaag	gaagtcgtgc	9420
taaccgtgcc	gactgaaggg	ctcgaggtca	cgtggggcaa	caacgagccg	tataagtatt	9480
ggccgcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	attctgtatt	9540
attatgagct	gtacccctact	atgactgtag	tagttgtgtc	agtggccacg	ttcatactcc	9600
tgtcgatggt	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	tgcatacacac	9660
cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	tgctgcatca	9720
gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	gagcagcaac	9780
ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgttcta	tgcaactgtc	9840
tgagactctt	accatgctgc	tgtaaaacgc	tggctttttt	agccgtaatg	agcgtcgggtg	9900
cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacggtg	ggagtaccgt	9960
ataagactct	agtcaataga	cctggctaca	gccccatggt	attggagatg	gaactactgt	10020
cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtac	aaaaccgtca	10080
tcccgtctcc	gtacgtgaag	tgctgcggta	cagcagagtg	caaggacaaa	aacctacctg	10140
actacagctg	taaggctctc	accggcgtct	acccatttat	gtggggcggc	gcctactgct	10200
tctgcgacgc	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	gaatcatgca	10260
aaacagaatt	tgcatacagca	tacagggcgc	ataccgcatac	tgcatacagct	aagctccgcg	10320
tcctttacca	aggaaataaac	atcactgtaa	ctgcctatgc	aaacggcgac	catgccgtca	10380
cagttaagga	cgccaaatcc	attgtggggc	caatgtcttc	agcctggaca	cctttcgaca	10440
acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctaccgccc	tttggcgcac	10500
gaagaccagg	acaatttggtc	gatatccaaa	gtcgcacacc	tgagagtga	gacgtctatg	10560
ctaatacaca	actggtactg	cagagaccgg	ctgcgggtac	ggtacacgtg	ccatactctc	10620
aggcaccatc	tggctttaag	tattggctaa	aagaacgcgg	ggcgctactg	cagcacacag	10680
caccatttgg	ctgccaaata	gcaacaaacc	cggtgaagagc	ggtgaactgc	gccgtaggga	10740
acatgcccat	ctccatcgac	ataccggaag	cggccttcac	tagggctcgtc	gacgcgccct	10800
ctttaacgga	catgtcgtgc	gaggtaccag	cctgcaccca	ttcctcagac	tttgggggcg	10860
tcgccattat	taaatatgca	gccagcaaga	aaggcaagtg	tgcggtgcat	tcgatgacta	10920

## Sequence Listing-CHK-II

acgccgtcac	tattcgggaa	gctgagatag	aagttgaagg	gaattctcag	ctgcaaattct	10980
ctttctcgac	ggccttagcc	agcgccgaat	tccgcgtaca	agtctgttct	acacaagtac	11040
actgtgcagc	tgagtgccac	cccccggaagg	accacatagt	caactacccg	gcgtcacata	11100
ccaccctcgg	ggtcaggac	atctccgcta	cggcgatgtc	atgggtgcag	aagatcacgg	11160
gaggtgtggg	actggttgtt	gctgttgccg	caactgattct	aatcgtggtg	ctatgcgtgt	11220
cgttcagcag	gcac					11234

<210> 19  
 <211> 11234  
 <212> DNA  
 <213> Chikungunya virus

<400> 19						
atggatcctg	tgtacgtgga	catagacgct	gacagcgctt	ttttgaaggc	cctgcaacgt	60
gcgtacccca	tgtttgaggt	ggaaccaagg	caggtcacac	cgaatgacca	tgctaattgct	120
agagcgttct	cgcattctagc	tataaaacta	atagagcagg	aaattgacct	cgactcaacc	180
atcctggata	tcggcagtg	gccagcaagg	aggatgatgt	cggacaggaa	gtaccactgc	240
gtctgcccga	tgccagtg	ggaagatccc	gagagactcg	ctaattatgc	gagaaagcta	300
gcatctgccg	caggaaaagt	cctggacaga	aacatctctg	gaaagatcgg	ggacttacia	360
gcagtaattg	ccgtgccaga	caaggagacg	ccaacattct	gcttacacac	agacgtctca	420
tgtagacaga	gagcagacgt	cgctatatac	caagacgtct	atgctgtaca	cgacccacg	480
tcgtataacc	accaggcgat	taaaggggtc	cgagtggcgt	actgggttgg	gttcgacaca	540
accccgttca	tgtacaatgc	catggcgggt	gcctaccctt	catactcgac	aaactgggca	600
gatgagcagg	tactgaaggc	taagaacata	ggattatggt	caacagacct	gacggaaggt	660
agacgaggca	agttgtctat	tatgagaggg	aaaaagctaa	aaccgtgcga	cagtgtgctg	720
ttctcagtag	ggtcaacgct	ttaccgggaa	agccgcaagc	tacttaagag	ctggcacctg	780
ccatcggtgt	tccattttaa	gggcaaactc	agcttcacat	gccgctgtga	tacagtgggt	840
tcgtgtgagg	gctacgtcgt	taagagaata	acgatgagcc	caggccttta	tgaaaaaacc	900
acaggggtatg	cggtaaccac	ccacgcagac	ggattcctga	tgtgcaagac	taccgacacg	960
gttgacggcg	aaagagtgtc	attctcgggt	tgacatacag	tgccggcgac	catttgtgat	1020
caaatgaccg	gcattccttg	tacagaagtc	acgccggagg	atgcacagaa	gctgttggtg	1080
gggctgaacc	agagaatagt	ggttaacggc	agaacgcaac	ggaatacgaa	caccatgaaa	1140
aattatctgc	ttcccggtgt	cgcccaagcc	ttcagtaagt	gggcaaagga	gtgccggaaa	1200
gacatggaag	atgaaaaact	cctgggggtc	agagaaagaa	caactgacctg	ctgctgtcta	1260
tgggcattca	agaagcagaa	aacacacacg	gtctacaaga	ggcctgatac	ccagtcaatt	1320



## Sequence listing-CHK-II

cagaaggttc	aggccgagtt	tgacagcttt	gtggtaccga	gtctgtggtc	gtccgggttg	1380
tcaatccctt	tgaggactag	aatcaaattg	ttgttaagca	aggtgccaaa	aaccgacctg	1440
atcccataca	gaggagacgc	ccgagaagcc	cgggacgcag	aaaaagaagc	agaggaagaa	1500
cgagaagcag	aactgactcg	cgaagcccta	ctacctctac	aggcagcaca	ggaagatgtt	1560
caggtcgaaa	tgcagctgga	acagcttgag	gacagagcgg	gcgcaggaat	aatagagact	1620
ccgagaggag	ctatcaaagt	tactgcccaa	ccaacagacc	acgtcgtggg	agagtacctg	1680
gtactctccc	cgcagaccgt	actacgtagc	cagaagctca	gtctgattca	cgctttggcg	1740
gagcaagtga	agacgtgcac	gcacaacgga	cgagcaggga	ggtatgcggt	cgaagcgta	1800
gacggccgag	tectagtgcc	ctcaggctat	gcaatctcgc	ctgaagactt	ccagagtcta	1860
agcgaaagcg	caacgatggt	gtataacgaa	agagagttcg	taaacagaaa	gctacaccat	1920
attgcatgac	acggaccagc	cctgaacacc	gacgaagagt	cgtatgagct	ggtgagggca	1980
gagaggacag	aacacgagta	cgtctacgac	gtggatcaga	gaagatgctg	taagaaggaa	2040
gaagccgcag	gactggtact	ggtgggcgac	ttgactaatc	cggcctacca	cgaattcgca	2100
tatgaagggc	taaaaatccg	ccctgcctgc	ccatacaaaa	ttgcagtcac	aggagtcttc	2160
ggagtaccgg	gatctggcaa	gtcagctatt	atcaagaacc	tagttaccag	gcaggacctg	2220
gtgactagt	gaaagaaaga	aaactgccaa	gaaatcacca	ccgacgtgat	gagacagaga	2280
ggtctagaga	tatctgcacg	tacggttgac	tcgctgctct	tgaatggatg	caacagacca	2340
gtcgacgtgt	tgtacgtaga	cgaggcggtt	gcgtgccact	ctggaacgct	acttgctttg	2400
atcgcccttg	tgagaccaag	gcagaaagtt	gtactttgtg	gtgacccgaa	gcagtgcggc	2460
ttcttcaata	tgatgcagat	gaaagtcaac	tacaatcaca	acatctgcac	ccaagtgtac	2520
cacaaaagta	tctccaggcg	gtgtacactg	cctgtgaccg	ccattgtgtc	atcgttgcat	2580
tacgaaggca	aatgctgcac	tacgaatgag	tacaacaagc	cgattgtagt	ggacactaca	2640
ggctcaacaa	aacctgacc	tggagacctc	gtgttaacgt	gcttcagagg	gtgggttaaa	2700
caactgcaaa	ttgactatcg	tggatacgag	gtcatgacag	cagccgcac	ccaagggtta	2760
accagaaaag	gagtttacgc	agttagacaa	aaagttaatg	aaaacccgct	ctatgcatca	2820
acgtcagagc	acgttaacgt	actcctaacg	cgtacggaag	gtaaactggt	atggaagaca	2880
ctttccggcg	acctgtggat	aaagacgctg	cagaaccac	cgaaggaaa	cttcaaagca	2940
actattaagg	agtgggaggt	ggagcatgca	tcaataatgg	cgggcatctg	cagtcaccaa	3000
atgaccttcg	atacatcca	aaataaagcc	aacgtttgtt	gggctaagag	cttggtccct	3060
atcctcgaaa	cagcggggat	aaaactaaat	gataggcagt	ggtctcagat	aattcaagcc	3120
ttcaaagaag	acaaagcata	ctcacctgaa	gtagccctga	atgaaatatg	tacgcgcatg	3180

## Sequence listing-CHK-II

tatggggtg	atctagacag	cggtctat	tctaaaccgt	tggtgtctgt	gtattacg	3240
gataaccact	gggataatag	gcctggaggg	aaaatgttcg	gatttaaccc	cgaggcagca	3300
tccattctag	aaagaaagta	tccattcaca	aaaggaagt	ggaacatcaa	caagcagatc	3360
tgctgacta	ccaggaggat	agaagacttt	aaccctacca	ccaacatcat	accggccaac	3420
aggagactac	cacactcatt	agtggccgaa	caccgccag	taaaagggga	aagaatggaa	3480
tggttggtta	acaagataaa	cgccaccac	gtgctcctgg	tcagtggcta	taaccttgca	3540
ctgcctacta	agagagtcac	ttgggtagcg	ccgttaggtg	tccgcggagc	ggactacaca	3600
tacaacctag	agttgggtct	gccagcaacg	cttggtaggt	atgaccttgt	ggtcataaac	3660
atccacacac	cttttcgcat	acaccattac	caacagtgcg	tcgaccacgc	aatgaaactg	3720
caaatgtctg	gggtgactc	attgagactg	ctcaaaccgg	gcggtctctt	attgatcaga	3780
gcatatggtt	acgcagatag	aaccagtga	cgagtcatt	gcgtattggg	acgcaagttt	3840
agatcgtcta	gagcgttgaa	accaccatgt	gtcaccagca	acactgagat	gtttttccta	3900
ttcagcaact	ttgacaatgg	cagaaggaat	ttcacaactc	atgtcatgaa	caatcaactg	3960
aatgcagcct	tcgtaggaca	ggtcaccga	gcaggatgtg	caccgtcgta	ccgggtaaaa	4020
cgcatggaca	tcgcgaagaa	cgatgaagag	tgctagtca	acgccgctaa	ccctcgcg	4080
ttaccgggtg	acggtgtttg	caaggcagta	tacaaaaaat	ggccggagtc	ctttaagaac	4140
agtgaacac	cagtgggaac	cgcaaaaaca	gttatgtgcg	gtacgtatcc	agtaatccac	4200
gctgttgac	caaacttctc	taattattcg	gagtctgaag	gggaccggga	attggcagct	4260
gcctatcgag	aagtcgaaa	ggaagtaact	aggctgggag	taaatagtgt	agctatacct	4320
ctcctctcca	caggtgtata	ctcaggaggg	aaagacaggc	tgaccagtc	actgaaccac	4380
ctctttacag	ccatggactc	gacggatgca	gacgtggtca	tctactgccg	cgacaaagaa	4440
tgggagaaga	aaatatctga	ggccatacag	atgcggaccc	aagtagagct	gctggatgag	4500
cacatctcca	tagactgcga	tattgttcgc	gtgcaccctg	acagcagctt	ggcaggcaga	4560
aaaggataca	gcaccacgga	aggcgactg	tactcatatc	tagaaggga	ccgttttcat	4620
cagacggctg	tggatatggc	ggagatacat	actatgtggc	caaagcaa	agaggccaat	4680
gagcaagtct	gcctatatgc	cctgggggaa	agtattgaat	cgatcaggca	gaaatgccc	4740
gtggatgatg	cagacgcac	atctcccccc	aaaactgtcc	cgtgcctttg	ccgttacgct	4800
atgactccag	aacgcgtcac	ccggcttcgc	atgaatcacg	tcacaagcat	aattgtgtgt	4860
tcttcgtttc	ccctccaaa	gtacaaaata	gaaggagtgc	aaaaagtcaa	atgctctaag	4920
gtaatgctat	ttgaccacaa	cgtgccatcg	cgcgtaagtc	caagggaata	tagatcttcc	4980
caggagtctg	cacaggaggc	gagtacaatc	acgtcactga	cgcatagtca	attcgacct	5040
agcgttgatg	gcgagatact	gcccgctccg	tcagacctgg	atgctgacgc	cccagcccta	5100



## Sequence listing-CHK-II

gaaccagcac	tagacgacgg	ggcgacacac	acgctgccat	ccacaaccgg	aaaccttgcg	5160
gccgtgtctg	actgggtaat	gagcaccgta	cctgtcgcgc	cgcccagaag	aaggcgaggg	5220
agaaacctga	ctgtgacatg	tgacgagaga	gaagggaata	taacacccat	ggctagcgtc	5280
cgattcttta	gggcagagct	gtgtccggtc	gtacaagaaa	cagcggagac	gcgtgacaca	5340
gcaatgtctc	ttcaggcacc	accgagtacc	gccacggaac	cgaatcatcc	gccgatctcc	5400
ttcggagcat	caagcgagac	gttccccatt	acatttgggg	acttcaacga	aggagaaatc	5460
gaaagcttgt	cttctgagct	actaactttc	ggagacttct	taccaggaga	agtggatgac	5520
ttgacagaca	gcgactggtc	cacgtgctca	gacacggacg	acgagttatg	actagacagg	5580
gcaggtgggt	atatattctc	gtcggacacc	gggccaggtc	atttacaaca	gaagtcagta	5640
cgccagtcag	tgctgccggt	gaacaccctg	gaggaagtcc	acgaggagaa	gtgttaccca	5700
cctaagctgg	atgaagcaaa	ggagcaacta	ttacttaaga	aactccagga	gagtgcattc	5760
atggccaaca	gaagcaggta	tcagtcgcgc	aaagtagaaa	acatgaaagc	agcaatcatc	5820
cagagactaa	agagaggctg	tagactatac	ttaatgtcag	agaccccaaa	agtccttact	5880
taccggacta	catatccggc	gcctgtgtac	tcgcctccga	tcaacgtccg	attgtccaat	5940
cccaggtccg	cagtggcagc	atgcaatgag	ttcttagcta	gaaactatcc	aactgtctca	6000
tcataccaaa	ttaccgacga	gtatgatgca	tatctagaca	tggtggacgg	gtcggagagt	6060
tgcttgacc	gagcgacatt	caatccgtca	aaactcagga	gctacccgaa	acagcacgct	6120
taccacgcgc	cctccatcag	aagcgctgta	ccgtcccat	tccagaacac	actacagaat	6180
gtactggcag	cagccacgaa	aagaaactgc	aacgtcacac	agatgaggga	attacccact	6240
ttggactccg	cagtattcaa	cgtggagtgt	ttcaaaaaat	tcgcatgcaa	ccaagaatac	6300
tggaagaat	ttgctgccag	ccctattagg	ataacaactg	agaatttagc	aacttatgtt	6360
actaaactaa	aagggccaaa	agcagcagcg	ctattcgcaa	aaaccataa	tctactgcca	6420
ctacaggaag	taccaatgga	taggttcaca	gtagatatga	aaaggacgt	gaaggtgact	6480
cctggtacaa	agcatacaga	ggaaagacct	aaggtgcagg	ttatacaggc	ggctgaaccc	6540
ttggcgacag	catacctatg	tgggattcac	agagagctgg	ttaggaggct	gaacgccgtc	6600
ctcctacce	atgtacatac	actatttgac	atgtctgccg	aggatttcga	tgccatcata	6660
gccgcacact	ttaagccagg	agacactggt	ttggaaacgg	acatagcctc	ctttgataag	6720
agccaagatg	attcacttgc	gcttactgct	ttgatgctgt	tagaggattt	aggggtggat	6780
cactccctgc	tggacttgat	agaggctgct	ttcggagaga	tttcagctg	tcacctaccg	6840
acaggtacgc	gcttcaagtt	cgggcccag	atgaaatcag	gtatgttcct	aactctgttc	6900
gtcaacacat	tggttaacat	caccatcgcc	agccgagtgc	tggaagatcg	tctgacaaaa	6960



## Sequence listing-CHK-II

tccgcgtgcg	cggccttcac	cggcgacgac	aacataatac	atggagtcgt	ctccgatgaa	7020
ttgatggcag	ccagatgtgc	cacttggatg	aacatggaag	tgaagatcat	agatgcagtt	7080
gtatccttga	aagcccccta	cttttgtgga	gggtttatac	tgcacgatac	tgtgacagga	7140
acagcttgca	gagtggcaga	cccgtaaaa	aggcttttta	aactgggcaa	accgctagcg	7200
gcaggtgacg	aacaagatga	agatagaaga	cgagcgctgg	ctgacgaagt	gatcagatgg	7260
caacgaacag	ggctaattga	tgagctggag	aaagcggat	actctaggta	cgaagtgcag	7320
ggatatcag	ttgtggtaat	gtccatggcc	acctttgcaa	gctccagatc	caacttcgag	7380
aagctcagag	gacccgtcat	aactttgtac	ggcggtccta	aataggtacg	cactacagct	7440
acctattttg	cagaagccga	cagcaagtat	ctaaacacta	atcagctaca	atggagttca	7500
tcccaacca	aactttttac	aataggaggt	accagcctcg	accctggact	ccgcgctcta	7560
ctatccaaat	cattaggccc	agaccgcgcc	ctcagaggca	agctgggcaa	cttgcccagc	7620
tgatctcagc	agttaataaa	ctgacaatgc	gcgcggtacc	ccaacagaag	ccacgcagga	7680
atcggaagaa	taagaagcaa	aagcaaaaac	aacaggcgcc	acaaaacaac	acaaatcaaa	7740
agaagcagcc	acataaaaag	aaaacggctc	aaaagaaaaa	gaagccgggc	cgcagagaga	7800
ggatgtgcat	gaaaatcgaa	aatgattgta	ttttcgaagt	caagcacgaa	ggtaaggtaa	7860
caggttacgc	gtgcctggtg	ggggacaaag	taatgaaacc	agcacacgta	aaggggacca	7920
tcgataacgc	ggacctggcc	aaactggcct	ttaagcggtc	atctaagtat	gaccttgaat	7980
gcgcgcagat	accctgtcac	atgaagtccg	acgcttcgaa	gttcacccat	gagaaaccgg	8040
aggggtacta	caactggcac	cacggggcag	tacagtactc	aggaggccgg	ttcaccatcc	8100
ctacaggtgc	tggcaaacca	ggggacagcg	gcagaccgat	cttcgacaac	aagggacgcg	8160
tgggtggccat	agtcttagga	ggagctaata	aaggagcccc	tacagccctc	tcggtggtga	8220
cctggaataa	agacattgtc	actaaaatca	cccccgaggg	ggccgaagag	tggagtcttg	8280
ccatcccagt	tatgtgcctg	ctggcaaaaca	ccacgttccc	ctgctcccag	cccccttgca	8340
cgccctgctg	ctacgaaaag	gaaccggagg	aaaccctacg	catgcttgag	gacaacgtca	8400
tgagacctgg	gtactatcag	ctgctacagg	catccttaac	atgttctccc	caccgccagc	8460
gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	ttagctcact	8520
gtcccgactg	tggagaaggg	cactcgtgcc	atagtcccgt	agcactagaa	cgcatcagaa	8580
atgaagcgac	agacgggacg	ctgaaaatcc	aggctctcct	gcaaatacga	ataaagacgg	8640
atgacagcca	cgattggacc	gagctgcggt	atatggacaa	ccacatgcca	gcagacgcag	8700
agagggcggg	gctatttgta	agaacatcag	caccgtgtac	gattactgga	acaatgggac	8760
acttcatect	ggcccgatgt	ccaaaagggg	aaactctgac	ggtgggattc	actgacagta	8820
ggaagattag	tcattcatgt	acgcacccat	ttcaccacga	ccctcctgtg	ataggtcggg	8880



## Sequence listing-CHK-II

aaaaattcca	ttcccgaccg	cagcacggta	aagagctacc	ttgcagcacg	tacgtgcaga	8940
gcaccgccgc	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	cctgatcgca	9000
cattaatgtc	acaacagtcc	ggcaacgtaa	agatcacagt	caatggccag	acggtgcggt	9060
acaagtgtaa	ttgcggtggc	tcaaataaag	gactaacaac	tacagacaaa	gtgattaata	9120
actgcaagg	tgatcaatgt	catgccgcgg	tcaccaatca	caaaaagtgg	cagtataact	9180
ccccctctgg	cccgcgtaat	gctgaacttg	gggaccgaaa	aggaaaaatt	cacatcccgt	9240
ttccgctggc	aaatgcaaca	tgcagggtgc	ctaaagcaag	gaacccacc	gtgacgtacg	9300
ggaaaaacca	agtcacatgc	ctactgtatc	ctgaccaccc	aacactcctg	tcctaccgga	9360
atatgggaga	agaaccaaac	tateaagaag	agtgggtgat	gcataagaag	gaagtcgtgc	9420
taaccgtgcc	gactgaaggg	ctcgaggtca	cgtggggcaa	caacgagccg	tataagtatt	9480
ggccgcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	attctgtatt	9540
attatgagct	gtaccctact	atgactgtag	tagttgtgtc	agtggccacg	ttcatactcc	9600
tgatgatgg	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	tgatcacac	9660
cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	tgctgcatca	9720
gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	gagcagcaac	9780
ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgttcta	tgcaactgtc	9840
tgagactctt	accatgctgc	tgtaaaacgc	tggctttttt	agccgtaatg	agcgtcgggtg	9900
cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacgggtg	ggagtaccgt	9960
ataagactct	agtcaataga	cctggctaca	gccccatgg	attggagatg	gaactactgt	10020
cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtac	aaaaccgtca	10080
tcccgtctcc	gtacgtgaag	tgctgcggta	cagcagagtg	caaggacaaa	aacctacctg	10140
actacagctg	taaggtcttc	accggcgtct	acccatttat	gtggggcggc	gcctactgct	10200
tctgcgacgc	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	gaatcatgca	10260
aaacagaatt	tgatcagca	tacagggcgc	ataccgcac	tgatcagct	aagctccgcg	10320
tcctttacca	aggaaataac	atcactgtaa	ctgcctatgc	aaacggcgac	catgccgtca	10380
cagttaagga	cgccaaattc	attgtggggc	caatgtcttc	agcctggaca	cctttcgaca	10440
acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctacccgccc	tttggcgag	10500
gaagaccagg	acaatttggc	gatatccaaa	gtcgcacacc	tgagagtga	gacgtctatg	10560
ctaatacaca	actggtactg	cagagaccgg	ctgcgggtac	ggtacacgtg	ccatactctc	10620
aggcaccatc	tggctttaag	tattggctaa	aagaacgcgg	ggcgctactg	cagcacacag	10680
caccatttgg	ctgccaata	gcaacaaacc	cgtaagagc	ggtgaactgc	gccgtaggga	10740

## Sequence listing-CHK-II

acatgccc	at	ctccatcgac	ataccggaag	cggccttcac	tagggtcg	gacgcgcct	10800
ctttaacgga	catgtcgtgc	gaggtaccag	cctgcaccca	ttcctcagac	tttggggg	cg	10860
tcgccattat	taaatatgca	gccagcaaga	aaggcaagtg	tgcggtgcat	tcgatgacta		10920
acgccgtcac	tattcgggaa	gctgagatag	aagttgaagg	gaattctcag	ctgcaaatct		10980
ctttctcgac	ggccttagcc	agcgccgaat	tccgcgtaca	agtctgttct	acacaagtac		11040
actgtgcagc	tgagtgccac	cccccgagg	accacatagt	caactacccg	gcgtcacata		11100
ccaccctcgg	ggtccaggac	atctccgcta	cggcgatg	atgggtgcag	aagatcacgg		11160
gaggtgtggg	actggttg	gctgttgccg	cactgattct	aatcggtg	ctatgcgtgt		11220
cgttcagcag	gcac						11234

<210> 20  
 <211> 11234  
 <212> DNA  
 <213> Chikungunya virus

<400> 20							
atggatcctg	tgtacgtgga	catagacgct	gacagcgct	tttgaaggc	cctgcaacgt		60
gcgtacccca	tgtttgaggt	ggaaccaagg	caggtcacac	cgaatgacca	tgctaattgt		120
agagcgttct	cgcatctagc	tataaaacta	atagagcagg	aaattgacc	cgactcaacc		180
atcctggata	tcggcagtg	gccagcaagg	aggatgatgt	cggacaggaa	gtaccactgc		240
gtctgcccga	tgcgagtg	ggaagatccc	gagagactcg	ctaattatgc	gagaaaagcta		300
gcatctgccg	caggaaaagt	cctggacaga	aacatctctg	gaaagatcgg	ggacttacaa		360
gcagtaattg	ccgtgccaga	caaggagacg	ccaacattct	gcttacacac	agacgtctca		420
tgtagacaga	gagcagacgt	cgctatatac	caagacgtct	atgctgtaca	cgacccacg		480
tcgctatacc	accaggcgat	taaaggggtc	cgagtggcgt	actgggttgg	gttcgacaca		540
accccgttca	tgtacaatgc	catggcgggt	gcctaccct	catactcgac	aaactgggca		600
gatgagcagg	tactgaaggc	taagaacata	ggattatgtt	caacagacct	gacggaagg		660
agacgaggca	agttgtctat	tatgagaggg	aaaaagctaa	aaccgtgcga	ccgtgtgctg		720
ttctcagtag	ggtcaacgct	ctaccggaa	agccgcaagc	tacttaagag	ctggcacctg		780
ccatcggtgt	tccatttaaa	gggcaaactc	agcttcacat	gccgctgtga	tacagtgggt		840
tcgtgtgagg	gctacgtcgt	taagagaata	acgatgagcc	caggccttta	tggaataacc		900
acaggggatg	cggtaaccca	ccacgcagac	ggattcctga	tgtgcaagac	taccgacacg		960
gttgacggcg	aaagagtgtc	attctcggtg	tgacatac	tgccggcgac	catttgtgat		1020
caaatgaccg	gcaccttgc	tacagaagtc	acgccggagg	atgcacagaa	gctgttggtg		1080
gggctgaacc	agagaatagt	ggttaacggc	agaacgcaac	ggaatatgaa	caccatgaaa		1140



## Sequence listing-CHK-II

aattatctgc	ttcccggtgt	cgcccaagcc	ttcagtaagt	gggcaaagga	gtgccgga	1200
gacatggaag	atgaaaaact	cctgggggtc	agagaaagaa	cactgacctg	ctgctgtcta	1260
tgggcattca	agaagcagaa	aacacacacg	gtctacaaga	ggcctgatac	ccagtcaatt	1320
cagaagggtc	aggccgagtt	tgacagcttt	gtggtaccga	gtctgtggtc	gtccgggttg	1380
tcaatccctt	tgaggactag	aatcaaattg	ttgttaagca	aggtgccaaa	aaccgacctg	1440
atcccataca	gcggagacgc	ccgagaagcc	cgggacgcag	aaaaagaagc	agaggaagaa	1500
cgagaagcag	aactgactcg	cgaagcccta	ccacctctac	aggcagcaca	ggaagatggt	1560
caggtcga	tcgacgtgga	acagcttgag	gacagagcgg	gcgcaggaat	aatagagact	1620
ccgagaggag	ctatcaaagt	tactgcccaa	ccaacagacc	acgtcgtggg	agagtacctg	1680
gtactctccc	cgagaccgt	actacgtagc	cagaagctca	gtctgattca	cgctttggcg	1740
gagcaagtga	agacgtgcac	gcacaacgga	cgagcaggga	ggtatgcggt	cgaagcgta	1800
gacggccgag	tcctagtgcc	ctcaggctat	gcaatctcgc	ctgaagagtt	ccagagtcta	1860
agcgaaagcg	caacgatggt	gtataacgaa	agagagtctg	taaacagaaa	gctacaccat	1920
attgcatg	acggaccagc	cctgaacacc	gacgaagagt	cgtatgagct	ggtgagggca	1980
gagaggacag	aacacgagta	cgtctacgac	gtggatcaga	gaagatgctg	taagaaggaa	2040
gaagccgcag	gactggtact	ggtgggcgac	ttgactaatc	cgccctacca	cgaattcgca	2100
tatgaagggc	taaaaatccg	ccctgcctgc	ccatacaaaa	ttgcagtcac	aggagtcttc	2160
ggagtaccgg	gatctggcaa	gtcagctatt	atcaagaacc	tagttaccag	gcaggacctg	2220
gtgactagcg	gaaagaaaga	aaactgccaa	gaaatcacca	ccgacgtgat	gagacagaga	2280
ggtctagaga	tatctgcacg	tacggttgac	tcgctgctct	tgaatggatg	caacagacca	2340
gtcgacgtgt	tgtacgtaga	cgaggcggtt	gcgtgccact	ctggaacgct	acttgctttg	2400
atcgctttgg	tgagaccaag	gcagaaagtt	gtactttgtg	gtgaccgcaa	gcagtgcggc	2460
ttcttcaata	tgatccagat	gaaagtcaac	tataatcaca	acatctgcac	ccaagtgtac	2520
cacaaaagta	tttccagggc	gtgtacactg	cctgtgaccg	ccattgtgtc	atcgttgcat	2580
tacgaaggca	aaatgcgcac	tacgaatgag	tacaacaagc	cgattgtagt	ggacactaca	2640
ggctcaacaa	aacttgaccc	tggagacctc	gtgttaacgt	gcttcagagg	gtgggttaaa	2700
caactgcaaa	ttgactatcg	tggatacgag	gtcatgacag	cagccgcac	ccaaggggta	2760
accagaaaag	gagtttacgc	agttagacaa	aaagttaatg	aaaacccgct	ctatgcatca	2820
acgtcagagc	acgtcaacgt	actcctaacg	cgtaaggga	gtaaaactgg	atggaagaca	2880
ctttccggcg	acccgtggat	aaagacgctg	cagaaccac	cgaaaggaaa	cttcaaagca	2940
actattaagg	agtgggaggt	ggagcatgca	tcaataatgg	cgggcatctg	cagtcaccaa	3000
atgaccttcg	atacattcca	aaataaagcc	aacgtttgtt	gggctaagag	cttggtcctt	3060

## Sequence listing-CHK-II

atcctcgaaa	cagcggggat	aaaactaaat	gataggcagt	ggtctcagat	aattcaagcc	3120
ttcaaagaag	acaagcata	ctcacctgaa	gtagccctga	atgaaatatg	tacgcgcatg	3180
tatggggtgg	atctagacag	cgggctattt	tctaaaccgt	tggtgtctgt	gtattacgcy	3240
gataaccact	gggataatag	gcctggaggg	aaaatgttcg	gatttaaccc	cgaggcagca	3300
tccattctag	aaagaaagta	tccattcaca	aaagggaggt	ggaacatcaa	caagcagatc	3360
tgcgtgacta	ccaggaggat	agaagacttt	aaccctacca	ccaacatcat	accggccaac	3420
aggagactac	cacactcatt	agtggcggaa	caccgcccag	taaaagggga	aagaatggaa	3480
tggtcgttta	acaagataaa	cggccaccac	gtgctcctgg	tcagtggcta	taaccttgca	3540
ctgcctacta	agagagtcac	ttgggtagcg	ccgttaggtg	tccgcggagc	ggactacaca	3600
tacaacctag	agttgggtct	gccagcaacg	cttggtaggt	atgaccttgt	ggtcataaac	3660
atccacacac	cttttcgcat	acaccattac	caacagtgcg	tcgaccacgc	aatgaaactg	3720
caaatgctcg	ggggtgactc	attgagactg	ctcaaaccgg	gcggctctct	attgatcaga	3780
gcatatggtt	acgcagatag	aaccagtga	cgagtcattt	gcgtattggg	acgcaagttt	3840
agatcgtcta	gagcgttgaa	accaccatgt	gtcaccagca	acactgagat	gtttttccta	3900
ttcagcaact	ttgacaatgg	cagaaggaat	ttcacaactc	atgtcatgaa	caatcaactg	3960
aatgcagcct	tcgtaggaca	ggtcaccgga	gcaggatgtg	caccgtcgta	ccgggtaaaa	4020
cgcatggaca	tcgcgaagaa	cgatgaagag	tgcgtagtca	acgccgctaa	ccctcgcggg	4080
ttaccaggtg	acggtgtttg	caaggcagta	tacaaaaaat	ggccggagtc	ctttaagaac	4140
agtgcacaac	cagtgggaac	cgcaaaaaca	gttatgtgcg	gtacgtatcc	agtaatccac	4200
gctgttggtg	caaactttct	taattattcg	gagtcctgaag	gggaccggga	attggcagct	4260
gcctatcgag	aagtcgcaaa	ggaagtaact	aggctgggag	taaatagtgt	agctatacct	4320
ctcctcteca	cagggtgtata	ctcaggaggg	aaagacaggc	tgaccagtc	actgaaccac	4380
ctctttacag	ccatggactc	gacggatgca	gacgtgggtc	tctactgccg	cgacaaagaa	4440
tgggagaaga	aaatatctga	ggccatacag	atgcggaccc	aagtagagct	gctggatgag	4500
cacatctcca	tagactggga	tattgttcgc	gtgcaccctg	acagcagctt	ggcaggcaga	4560
aaaggataca	gaaccacgga	aggcgcactg	tactcatatc	tagaaggggac	ccgttttcat	4620
cagacggctg	tggatatggc	ggagatacat	actatgtggc	caaagcaaac	agaggccaat	4680
gagcaagtct	gcctatatgc	cctgggggaa	agtattgaat	caatcaggca	gaaatgcccg	4740
gtggatgatg	cagacgcac	atctccccc	aaaactgtcc	cgtgcctttg	ccgttacgct	4800
atgactccag	aacgcgtcac	ccggcttcgc	atgaaccacg	tcacaagcat	aattgtgtgt	4860
tcttcgttct	ccctcccaaa	gtacaaaata	gaaggagtgc	aaaaagtcaa	atgctctaag	4920



## Sequence listing-CHK-II

gtaatgctat	ttgaccacaa	cgtgccatcg	cgcgtaagtc	caaggggaata	tagatcttcc	4980
caggagtctg	cacaggaggc	gagtacaatc	acgtcactga	cgcatagtca	attcgacctt	5040
agcgttgatg	gcgagatact	gcccgtcccg	tcagacctgg	atgctgacgc	cccagcccta	5100
gaaccagcac	tagacgacgg	ggcgacacac	acgtgccat	ccacaaccgg	aaaccttgcg	5160
gccgtgtctg	actgggtaat	gagcaactga	cctgtcgcgc	cgcccagaag	aaggcgaggg	5220
agaaacctga	ctgtgacatg	tgacgagaga	gaaggaaata	taacacccat	ggctagcgct	5280
cgattcttta	gggcagagct	gtgtccggtc	gtacaagaaa	cagcggagac	gcgtgacaca	5340
gcaatgtctc	ttcaggcacc	accgagtacc	gccacggaac	cgaatcatcc	gccgatctcc	5400
ttcggagcat	caagcgagac	gttccccatt	acatttgggg	acttcaacga	aggagaaatc	5460
gaaagcttgt	cttctgagct	actaactttc	ggagacttct	taccaggaga	agtggatgac	5520
ttgacagaca	gcgactggtc	cacgtgctca	gacacggacg	acgagttatg	actagacagg	5580
gcagggtgggt	atatattctc	gtcggacacc	gggccaggtc	atttacaaca	gaagtcagta	5640
cgccagtcag	tgctgccggt	gaacaccctg	gaggaaagtc	acgaggagaa	gtgttaccca	5700
cctaagctgg	atgaagcaaa	ggagcaacta	ttacttaaga	aactccagga	gagtgcattc	5760
atggccaaca	gaagcaggta	tcagtcgcgc	aaagtagaaa	acatgaaagc	agcaatcatc	5820
cagagactaa	agagaggctg	tagactatac	ttaatgtcag	agaccccaaa	agtccctact	5880
taccggacta	catatccggc	gcctgtgtac	tcgcctccga	tcaacgtccg	attgtccaat	5940
cccaggtccg	cagtggcagc	atgcaatgag	ttcttagcta	gaaactatcc	aactgtctca	6000
tcataccaaa	ttaccgacga	gtatgatgca	tatctagaca	tggtggacgg	gtcggagagt	6060
tgcttggaac	gagcgacatt	caatccgtca	aaactcagga	gctacccgaa	acagcacgct	6120
taccacgcgc	cctccatcag	aagcgtgta	ccgtcccat	tccagaacac	actacagaat	6180
gtactggcag	cagccacgaa	aagaaactgc	aacgtcacac	agatgaggga	attacccact	6240
ttggactcag	cagtattcaa	cgtggagtgt	ttcaaaaaat	tcgcatgcaa	ccaagaatac	6300
tggaagaagt	ttgctgcag	ccctattagg	ataacaactg	agaatttagc	aacctatgtt	6360
actaaactaa	aagggccaaa	agcagcagcg	ctattcgcaa	aaaccataa	tctactgcca	6420
ctacaggaag	taccaatgga	taggttcaca	gtagatatga	aaagggacgt	gaaggtgact	6480
cctggtataa	agcatacaga	ggaaagacct	aagggtcagg	ttatacaggc	ggctgaaccc	6540
ttggcgacag	catacctatg	tgggattcac	agagagctgg	ttaggaggct	gaacgccgtc	6600
ctcctaccea	atgtacatac	actatttgac	atgtctgccg	aggatttcga	tgccatcata	6660
gccgcacact	ttaaagccagg	agacactgtt	ttggaaacgg	acatagcctc	ctttgataag	6720
agccaagatg	attcacttgc	gcttactgct	ttgatgctgt	tagaggattt	aggggtggat	6780
cactccctgc	tggacttgat	agaggctgct	ttcggagaga	tttccagctg	tcacctaccg	6840

## Sequence Listing-CHK-II

acaggtacgc	gcttcaagtt	cggcgccatg	atgaaatcag	gtatgttcct	aactctgttc	6900
gtcaacacat	tgtaaacaat	caccatcgcc	agccgagtgc	tggaagatcg	tctgacaaaa	6960
tccgcgtgcg	cggccttcat	cggcgacgac	aacataatac	atggagtcgt	ctccgatgaa	7020
ttgatggcag	ccagatgtgc	cacttggatg	aacatggaag	tgaagatcat	agatgcagtt	7080
gtatccttga	aagccccctta	cttttgtgga	gggtttatac	tgcacgatac	tgtgacagga	7140
acagcttgca	gagtggcaga	cccgctaaaa	aggcttttta	aactgggcaa	accgctagcg	7200
gcaggtgacg	aacaagatga	agatagaaga	cgagcgctgg	ctgacgaagt	gatcagatgg	7260
caacgaacag	ggctaattga	tgagctggag	aaagcggtat	actctaggta	cgaagtgcag	7320
ggatatatcag	ttgtggtaat	gtccatggcc	acctttgcaa	gctccagatc	caacttcgag	7380
aagctcagag	gacccgctcat	aactttgtac	ggcggctcta	aataggtagc	cactacagct	7440
acctattttg	cagaagccga	cagcaagtat	ctaaacacta	atcagctaca	atggagttca	7500
tcccaaccca	aacttttttac	aataggaggt	accagcctcg	accctggact	ccgcgctcta	7560
ctatccaaat	catcaggccc	agaccgcgcc	ctcagaggca	agctgggcaa	cttgcccagc	7620
tgatctcagc	agttaataaa	ctgacaatgc	gcgcggtacc	ccaacagaag	ccacgcagga	7680
atcgaagaa	taagaagcaa	aagcaaaaac	aacaggcgcc	acaaaacaac	acaaatcaaa	7740
agaagcagcc	acctaaaaag	aaaccggctc	aaaagaaaaa	gaagccgggc	cgcagagaga	7800
ggatgtgcat	gaaaatcgaa	aatgattgta	ttttcgaagt	caagcacgaa	ggtaaggtaa	7860
caggttaacg	gtgcctgggtg	ggggacaaaag	taatgaaacc	agcacacgta	aaggggacca	7920
tcgataacgc	ggacctggcc	aaactggcct	ttaagcggtc	atctaagtat	gaccttgaat	7980
gcgcgcagat	acccgtgcac	atgaagtccg	acgcttcgaa	gttcacccat	gagaaaccgg	8040
aggggtacta	caactggcac	cacggagcag	tacaatactc	aggaggccgg	ttcaccatcc	8100
ctacaggtgc	tggcaaacca	ggggacagcg	gcagacctat	cttcgacaac	aagggaacgcg	8160
tggtggccat	agtcttagga	ggagctaattg	aaggagccccg	tacagccctc	tcggtggtga	8220
cctggaataa	agacattgtc	actaaaatca	cccccgaggg	ggccgaagag	tggagtcttg	8280
ccatcccagt	tatgtgcctg	ttggcaaaac	ccacgttccc	ctgctcccag	cccccttgca	8340
cgccctgctg	ctacgaaaag	gaaccggagg	aaaccctacg	catgcttgag	gacaacgtca	8400
tgagacctgg	gtactatcag	ctgctacaag	catccttaac	atgttctccc	caccgccagc	8460
gacgcagcac	caaggacaac	ttcaatgtct	ataaagccac	aagaccatac	ttagctcact	8520
gtcccgaactg	tggagaaggg	cactcgtgcc	atagtcctcg	agcactagaa	cgcacagaaa	8580
atgaagcgac	agacgggacg	ctgaaaatcc	aggtctcctt	gcaaatcaga	ataaagacgg	8640
atgacagcca	cgattggacc	aagctgcgtt	atatggacaa	ccacatgcca	gcagacgcag	8700



## Sequence listing-CHK-II

agagggcggg	gctatttcta	agaacatcag	caccgtgtac	gattactgga	acaatgggac	8760
acttcatcct	ggcccgatgt	ccaaaagggg	aaactctgac	ggtgggattc	actgacagta	8820
ggaagattag	tcattcatgt	acgcacccat	ttcaccacga	ccctcctgtg	ataggctcggg	8880
aaaaattcca	ttcccgaaccg	cagcacggta	aagagctacc	ttgcagcacg	tacgtgcaga	8940
gcaccgccgc	aactaccgag	gagatagagg	tacacatgcc	cccagacacc	cctgatcgca	9000
cattaatgtc	acaacagtcc	ggcaacgtaa	agatcacagt	caatggccag	acggtgcggt	9060
acaagtgtaa	ttgcgggtggc	tcaaatgaag	gactaacaac	tacagacaaa	gtgattaata	9120
actgcaaggt	tgatcaatgt	catgccgcgg	tcaccaatca	caaaaagtgg	cagtataact	9180
cccctctggt	cccgcgtaat	gctgaacttg	gggaccgaaa	aggaaaaatt	cacatcccgt	9240
ttccgctggc	aaatgtaaca	tcaggggtgc	ctaaagcaag	gaacccccacc	gtgacgtacg	9300
ggaaaaacca	agtcattcatg	ctactgtatc	ctgaccaccc	aacactcctg	tcctaccgga	9360
atatggggaga	agaaccaaac	tatcaagaag	agtgggtgat	gcataagaag	gaagtcgtgc	9420
taaccgtgcc	gactgaaggg	ctcgaggtca	cgtggggcaa	caacgagccg	tataagtatt	9480
ggccgcagtt	atctacaaac	ggtacagccc	atggccaccc	gcatgagata	attctgtatt	9540
attatgagct	gtaccctact	atgactgtag	tagttgtgtc	agtggccacg	ttcatactcc	9600
tgctgatggt	gggtatggca	gcggggatgt	gcatgtgtgc	acgacgcaga	tgcatcacac	9660
cgtatgaact	gacaccagga	gctaccgtcc	ctttcctgct	tagcctaata	tgctgcatca	9720
gaacagctaa	agcggccaca	taccaagagg	ctgcgatata	cctgtggaac	gagcagcaac	9780
ctttgttttg	gctacaagcc	cttattccgc	tggcagccct	gattgttcta	tgcaactgtc	9840
tgagactctt	accatgctgc	tgtaaacgt	tggctttttt	agccgtaatg	agcgctcggg	9900
cccacactgt	gagcgcgtac	gaacacgtaa	cagtgatccc	gaacacgggtg	ggagtaccgt	9960
ataagactct	agtcaataga	cctggctaca	gccccatggt	attggagatg	gaactactgt	10020
cagtcacttt	ggagccaaca	ctatcgcttg	attacatcac	gtgcgagtac	aaaaccgtca	10080
tcccgtctct	gtacgtgaag	tgctgcggta	cagcagagtg	caaggacaaa	aacctacctg	10140
actacagctg	taaggctctc	accggcgtct	acccatttat	gtggggcggc	gcctactgct	10200
tctgcgacgc	tgaaaacacg	cagttgagcg	aagcacatgt	ggagaagtcc	gaatcatgca	10260
aaacagaatt	tgatcagca	tacagggtc	ataccgcac	tgatcagct	aagctccgcg	10320
tcctttacca	aggaaataac	atcactgtaa	ctgcctatgc	aaacggcgac	catgccgtca	10380
cagttaagga	cgccaaattc	attgtggggc	caatgtcttc	agcctggaca	cctttcgaca	10440
acaaaattgt	ggtgtacaaa	ggtgacgtct	ataacatgga	ctacccgccc	tttggcgag	10500
gaagaccagg	acaatttggc	gatattcaaa	gtcgcacacc	tgagagtga	gacgtctatg	10560
ctaatacaca	actgggtactg	cagagaccgg	ctgcgggtac	ggtacacgtg	ccatactctc	10620

## Sequence listing-CHK-II

aggcaccatc	tggtttaag	tattggctaa	aagaacgcg	ggcgctactg	cagcacacag	10680
caccatttgg	ctgccaaata	gcaacaaacc	cggttaagagc	ggtgaactgc	gccgtaggga	10740
acatgcccac	ctccatcgac	ataccggaag	cggccttcac	tagggtcgtc	gacgcgccct	10800
ctttaacgga	catgtcgtgc	gaggtaccag	cctgcacca	ttcctcagac	tttgggggcg	10860
tcgccattat	taaatatgca	gccagcaaga	aaggcaagtg	tcggtgcat	tcgatgacta	10920
acgccgtcac	tattcgggaa	gctgagatag	aagttgaagg	gaattctcag	ctgcaaattct	10980
ctttctcgac	ggccttagcc	agcgccgaat	tccgcgtaca	agtctgttct	acacaagtac	11040
actgtgcagc	tgagtgccac	ccccgaagg	accacatagt	caactaccgc	gcgtcacata	11100
ccacctcgg	ggtccaggac	atctccgcta	cggcgatgtc	atgggtgcag	aagatcacgg	11160
gaggtgtggg	actggttgtt	gctgttgccg	cactgattct	aatcgtggtg	ctatgcgtgt	11220
cgttcagcag	gcac					11234